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Abstract
Changes in environmental factors, diet, and genetics all influence metabolism, which is frequently
dysregulated at the cellular and organismal levels in diseases such as metabolic syndrome, cancer, and
inborn errors of metabolism. These maladies are often intertwined; for example, metabolic diseases such
as obesity and inborn errors of metabolism such as fumarate hydratase deficiency can both increase the
risk for developing certain cancers. One metabolic pathway frequently altered in disease is de novo
lipogenesis (DNL). Aberrant DNL is believed to play a critical role in pathogenesis of cancer and nonalcoholic fatty liver disease (NAFLD), a manifestation of metabolic syndrome in the liver. DNL requires the
metabolite, acetyl-CoA, which is predominantly synthesized in the cytosol and nucleus from the cleavage
of citrate through the action of ATP-citrate lyase (ACLY). Consistent with its role in DNL, elevated levels or
activity of ACLY is frequently observed in cancer and NAFLD. Therefore, I utilized a genetic loss-offunction approach coupled with metabolomic methods to investigate how abrogating ACLY impacts
metabolism in proliferating cells and the liver. Unexpectedly, impairment of ACLY leads to metabolic
compensation through ACSS2-dependent acetate usage at the cellular and tissue levels. Moreover, by
depleting ACLY, we identify a link between dietary carbohydrate and microbiome-derived acetate in
supporting hepatic DNL. These findings have revised our understanding of acetyl-CoA metabolism in
cells, and how nutritional sources feed into this pathway in disease contexts.
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ABSTRACT
FROM SUGAR TO ACETATE – THE ORIGINS OF ACETYL-COA DICTATE ITS USE
IN CELLS AND IN MICE.
Steven Zhao
Dr. Kathryn Wellen
Changes in environmental factors, diet, and genetics all influence metabolism,
which is frequently dysregulated at the cellular and organismal levels in diseases such
as metabolic syndrome, cancer, and inborn errors of metabolism. These maladies are
often intertwined; for example, metabolic diseases such as obesity and inborn errors of
metabolism such as fumarate hydratase deficiency can both increase the risk for
developing certain cancers. One metabolic pathway frequently altered in disease is de
novo lipogenesis (DNL). Aberrant DNL is believed to play a critical role in pathogenesis
of cancer and non-alcoholic fatty liver disease (NAFLD), a manifestation of metabolic
syndrome in the liver. DNL requires the metabolite, acetyl-CoA, which is predominantly
synthesized in the cytosol and nucleus from the cleavage of citrate through the action of
ATP-citrate lyase (ACLY). Consistent with its role in DNL, elevated levels or activity of
ACLY is frequently observed in cancer and NAFLD. Therefore, I utilized a genetic lossof-function approach coupled with metabolomic methods to investigate how abrogating
ACLY impacts metabolism in proliferating cells and the liver. Unexpectedly, impairment
of ACLY leads to metabolic compensation through ACSS2-dependent acetate usage at
the cellular and tissue levels. Moreover, by depleting ACLY, we identify a link between
dietary carbohydrate and microbiome-derived acetate in supporting hepatic DNL. These
findings have revised our understanding of acetyl-CoA metabolism in cells, and how
nutritional sources feed into this pathway in disease context
vi
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CHAPTER 1: ACETYL-CoA METABOLISM IN DISEASE
Acetyl-CoA production links catabolic and anabolic metabolism in cells.

Acetyl-coenzyme A (Acetyl-CoA) is a metabolite that links nutrient breakdown for energy
and the synthesis of more complex metabolites. Due to this positioning within cellular
metabolism, acetyl-CoA production and abundance is tightly regulated in response to
nutritional availability and other signals such as oncogenic activation1. However, the
mechanisms that govern this regulation are still not entirely understood. Adding to the
complexity, acetyl-CoA can be synthesized in various cellular compartments and from
different substrates. Discussed below are the sources and locations of acetyl-CoA
production at the time of this work.

Pyruvate:
Glucose is taken into cells via the SLC2/GLUT family of transporters, which are
expressed in a tissue-specific manner2. Following uptake, glucose is phosphorylated by
hexokinase to glucose-6-phosphate and trapped within the cell. Glucose-6-phosphate is
shunted into glycolysis, resulting in the production of pyruvate in the cytosol. Pyruvate is
imported into the mitochondria by the mitochondrial pyruvate carrier (MPC), which is
converted into acetyl-CoA within the mitochondria by the pyruvate dehydrogenase
complex (PDC). Mitochondrial acetyl-CoA is condensed with oxaloacetate to form
citrate, which can enter the citric acid cycle to fuel the generation of ATP, NADH, and
FADH2 or be exported from the mitochondria to the cytosol in exchange for malate via
the transporter SLC25A13 (Figure 1.1). In addition to the mitochondria, the PDC has
been reported to also function within the nucleus to generate nuclear acetyl-CoA4.
1

Citrate:
In addition to glucose, catabolism of other nutrients such as fatty acids and amino acids
within the mitochondria can also yield citrate (Figure 1.1). Once exported out of the
mitochondria, nuclear-cytosolic citrate is cleaved into acetyl-CoA by the enzyme ATPcitrate lyase (ACLY) in an ATP-dependent manner, regenerating oxaloacetate as a byproduct. Given the high concentrations of circulating glucose (~5 mM) and abundance of
other nutritional sources, this is believed to be the major route of nuclear-cytosolic
acetyl-CoA production in vivo. Consistent with this, congenital deletion of Acly in mice
fails to produce viable offspring, displaying early embryonic lethality around E8.55. Like
the PDC, ACLY has also been found to localize to the nucleus6, although its nuclear
regulation and functions remains largely unknown.

Acetate:
In addition to citrate, another major route of acetyl-CoA synthesis is utilizing the shortchain fatty acid (SCFA) acetate. In vivo, levels of circulating acetate are relatively low
(~100 M), as compared to glucose (~5 mM), but can reach much higher levels in
certain parts of circulation such as the portal vein that connects the intestine to the liver7.
This is because the majority of acetate is produced in the large intestine by the gut
microbiome, which ferment undigestible nutrients into SCFAs such as butyrate,
propionate, and acetate. However, despite its lower circulating levels, turnover of acetate
in vivo is very high8, suggesting that it is avidly used by cells within the body. Acetate is
taken up by mammalian cells through the proton-coupled monocarboxylate transporters
such as MCT1 and MCT47, and directly ligated to free CoA in an ATP-dependent
manner by the Acyl-CoA Synthetase Short Chain family of enzymes (ACSS1, ACSS2,
ACSS3)9. Of these, ACSS1/3 are found in the mitochondria, whereas ACSS2 is found in
the cytosol and nucleus like ACLY.
2

Figure 1.1 | Acetyl-CoA metabolism in mammalian cells.
Acetyl-CoA is synthesized using multiple substrates and in various cellular compartments.
Mitochondrial acetyl-CoA is synthesized from pyruvate via glucose by the PDC, or acetate by
ACSS1/3. Cytosolic acetyl-CoA is synthesized from citrate and acetate, by ACLY and ACSS2
respectively. Acetyl-CoA can diffuse from the cytosol to the nucleus, yet the PDC, ACLY and
ACSS2 all localize to the nucleus. Acetyl-CoA is used for histone acetylation to regulate the
epigenome, as well as for synthesis of lipids such as cholesterol and fatty acids.

3

Acetyl-CoA metabolism in cancer
In order for a cell to divide, it must effectively double its cellular contents, including
nucleic acids, proteins, and lipids. As a disease of unrestrained proliferation, cancer cells
must overcome this metabolic barrier and either acquire or generate enough molecular
building blocks to divide frequently. To accomplish this, cancer cells rewire their
metabolism to favor uptake of nutrients such as glucose and perform glycolysis even in
the presence of oxygen, also known as the Warburg effect10. In addition, cancer cells will
increase usage of anapleurotic metabolites such as glutamine11, and even scavenge for
macromolecules to break down into metabolic building blocks12. Discussed below are
two prominent ways that acetyl-CoA metabolism promotes cancer growth: epigenetic
regulation and lipid metabolism (Figure 1.1).

Metabolic Control of Epigenetics in Cancer13
Abstract
Alterations in the epigenome and metabolism both affect molecular rewiring in cancer
cells and facilitate cancer development and progression. However, recent evidence
suggests the existence of important bidirectional regulatory mechanisms between
metabolic remodeling and the epigenome (specifically methylation and acetylation of
histones) in cancer. Most chromatin-modifying enzymes require substrates or cofactors
that are intermediates of cell metabolism. Such metabolites, and often the enzymes that
produce them, can transfer into the nucleus, directly linking metabolism to nuclear
transcription. We discuss how metabolic remodeling can contribute to tumour epigenetic
alterations, thereby affecting cancer cell differentiation, proliferation and/or apoptosis, as
well as therapeutic responses.
4

Introduction
Epigenetic plasticity in cancer facilitates the acquisition of its hallmark characteristics14,15.
The metabolic traits of tumour cells are also crucial for adjusting to changes in the
availability of oxygen and nutrients (carbohydrates, lipids and amino acids) in the tumour
microenvironment, to sustain proliferation and resist mitochondria-dependent
apoptosis10,16,17. Cellular metabolism and the epigenome interact with one another and
with the genetic and molecular drivers of cancer, in a bidirectional manner. An
integrative understanding of the interplay between the molecular, metabolic and
epigenetic rewiring in cancer is far from complete, but conceptual themes are beginning
to emerge. Further elucidation of these links is likely to lead to more effective cancer
therapies.
Most post-translational modifications (PTMs), such as phosphorylation, acetylation and
other acyl modifications, methylation and O-linked N-acetylglucosamine modification (OGlcNAcylation), require metabolites as substrates (FIG. 1.2). In the nucleus, these
metabolites are used for chromatin modifications, including acetyl-CoA for histone
acetylation and S-adenosylmethionine (SAM) for histone and DNA methylation. The
histone code hypothesis is based on writers, erasers and readers of chromatin marks6.
This assumes that the ‘ink’ in this process is never limiting; however, based on a growing
body of evidence that the availability of metabolites to the writers has an impact on
chromatin modifications, we believe that it may be time to add a fourth parameter in this
code: the metabolite-producing enzymes, which provide the ink for histone modification
(FIG. 1.2). In this Review, we discuss how metabolic control of the epigenome is
emerging as a crucial mechanism by which cancer cells can adapt to a changing
environment.
5

Basic biochemistry of acetylation
More than 8,000 unique acetylation sites in proteins have been detected in mammalian
cells18–20. Within the nucleus, histones comprise the bulk of acetylation loci. The
chromatin of mammalian cells contains at least 10 billion potential acetylation sites,
meaning that a global change in histone acetylation may lead to a substantial reduction
in cellular or nuclear acetyl-CoA levels. Given the high amounts of energy stored in a
molecule of acetyl-CoA, this may represent a potential energy sink21.
Each histone octamer subunit (as well as the linker histone, H1) contains multiple lysine
residues, which are positively charged in the nucleoplasmic environment, leading to
attraction of the negatively charged DNA. More than 60 of these lysine residues are
known to be acetylated in mammals (H1 has 16 sites, H2A has 10 sites, H2B has 16
sites, H3 has 13 sites and H4 has 9 sites)22,23. Acetylation neutralizes the positive charge
of lysine, loosening the interaction between the histone and the negatively charged DNA
and leading to a more open chromatin configuration (euchromatin) that is permissive for
transcription. Histone deacetylation is usually associated with condensed, compacted
chromatin (heterochromatin) and transcriptional repression.
Protein acetylation occurs both cotranslationally onto the N-terminal residue of a protein,
catalysed by Nα acetyl transferases, and post-translationally onto the Nε amino group of
lysine residues. Lysine acetylation is catalysed by multiple families of lysine
acetyltransferases (KATs) and reversed by lysine deacetylases (KDACs). Nα affects
approximately 85% of human proteins and is important for their stability, localization and
function24,25. Nε acetylation can alter protein function by altering its catalytic activity,
interactions with other factors, subcellular localization and stability26. These effects can
originate directly from changes in charge, from binding of proteins that contain acetyl6

lysine recognition bromodomains27,28 or from prevention of other post-translational lysine
modifications (including ubiquitylation, methylation and formylation)26. Nε acetylation can
also occur through a non-enzymatic mechanism throughout the cell, and this is
promoted in alkaline environments such as the mitochondrial matrix29,30. Thus, pH
gradients, such as the one that occurs across the inner mitochondrial membrane (that is,
mitochondrial membrane potential, which is increased in most tumours31,32), may directly
influence acetylation reactions33. Conversely, acetylation of histones in the nucleus may
influence intracellular pH (pHi) because acetate export from the cell is proton coupled34.
Hence, in low-pHi conditions global deacetylation of histones generates acetate to be
exported as a mechanism to extrude protons to neutralize pHi34.
Owing to the very large amounts of acetate stored on his- tones, histone acetylation has
been proposed to function as a pHi buffer34. Histone acetylation is variable within
tumours, probably reflecting differences in the tumour microenvironment and cellular
diversity. Attempts have been made to correlate clinical outcomes with histone
acetylation levels in tumour specimens that, perhaps not surprisingly, have led to
conflicting results35–40. As discussed, there are also many non-histone acetylation
targets, a complexity that is very difficult to address in clinical specimens. Acetyl-CoA is
the sole donor of acetyl groups for acetylation in eukaryotic cells26. This central
metabolite comprises an acetyl moiety (CH3CO) bound through a high-energy thioester
bond to CoA, which is a derivative of vitamin B5, ATP and cysteine21. Hydrolysis of the
energy-rich thioester bond results in the release of 31.4 kJ mol–1 of energy. To put this in
perspective, the energy released by the hydrolysis of ATP to ADP + Pi is 30.5 kJ mol–1
41,42

. This makes acetyl-CoA a very unstable molecule, suggesting that acetylation must

occur very close to the site where acetyl-CoA is produced. Along with the fact that
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acetyl-CoA cannot easily cross cellular membranes, this underlies the importance of
acetyl-CoA compartmentalization in the regulation of acetylation reactions.

Basic biochemistry of methylation
Methylation is different from acetylation and other PTMs in that both proteins and DNA
can be methylated. In human DNA, cytosines are typically methylated in the context of
CpG dinucleotides. Overall, methylation of CpG islands in promoter regions typically
inhibits transcription. Cancers frequently display global DNA hypomethylation compared
with their healthy tissue counterparts, although at the same time, exhibiting
hypermethylation of CpG islands in genomic regions responsible for the expression of
tumour suppressor genes such as von Hippel–Lindau tumour suppressor (VHL), BRCA1
or retinoblastoma 1 (RB1)43–46.

Histone methylation can occur on lysine or arginine
residues, ranging from mono- to trimethylation. These histone methyl marks can either
activate or repress gene expression depending on which residue is modified and the
number of methyl groups incorporated. DNA methylation tends to be a more stable
modification than histone methylation, but much of tumour suppressor gene silencing is
driven by histone modification, before DNA methylation occurs47. Nearly half of the
known histone methyltransferases (HMTs) have been associated with cancer48. The first
histone demethylase (HDM), that is, lysine-specific histone demethylase 1 (LSD1; also
known as KDM1A), was discovered only in 200449, but since then several classes of
demethylase, which we discuss below, have shown remarkable links to metabolism and
cancer, including the Jumonji-C (JMJC) domain-containing HDMs (JHDMs), which can
remove mono-, di- and trimethylation groups, and the TET enzymes, which are
responsible for initiating the demethylation of DNA by hydroxylating 5-methylcytosine.
8

Similar to acetylation, methylation uses the energy stored in a sulfur bond to facilitate the
reaction. SAM is the primary methyl group donor and is generated

in the methionine

cycle from methionine and ATP. The methionine cycle begins with the conversion of
methionine into SAM, which is catalysed by a methionine adenosyltransferase. After
donating its methyl group, SAM becomes S-adenosylhomocysteine (SAH). SAdenosylhomocysteine hydrolase (SAHH) deadenylates SAH to make homocysteine.
The cycle is completed when homocysteine accepts a methyl group from the folate cycle
to regenerate methionine50,51.

Metabolic control of epigenetics
The relationship between epigenetic regulation and metabolism is complex, with
overarching themes but also context-specific mechanisms. We first discuss the role of
metabolites as regulators of enzymatic activity, followed by the choreography of
subcellular compart- mentalization of metabolic pathways as they relate to epigenetic
modifications, focusing on acetyl-CoA producers as an example. We then describe the
impact of oncogenic metabolic rewiring on acetyl-CoA production and histone acetylation
in cancer cells.

Metabolites promote and inhibit enzyme activity.
In phosphorylation (which is the most thoroughly studied mechanism in signalling),
kinases use an important intracellular metabolite, ATP, as a substrate. However, kinases
typically have high affinity for ATP, and thus are regulated by other types of signalling
cue but generally not by ATP availability. A notable exception is AMP-activated protein
kinase (AMPK), which evolved to sense energy changes and becomes activated when
the AMP/ATP ratio rises in the cell52. In contrast, many chromatin-modifying enzymes
not only use metabolic intermediates as cofactors or substrates but are also regulated by
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their availability. Thus the levels of these metabolites can influence the capacity of the
cell to write or erase chromatin marks, pointing to an intimate relationship between
metabolic and epigenetic regulation.
As described above, DNA and HMTs use SAM as a methyl donor, while the product
SAH inhibits methyl- transferase activity50 (FIG. 1.2). Similarly, the Krebs cycle (also
known as the tricarboxylic acid (TCA) cycle) inter- mediate α-ketoglutarate (α-KG) is a
required co-substrate for JHDMs and TET methylcytosine dioxygenases, which
participate in a multi-step DNA demethylation process; whereas structurally related
metabolites such as succinate, fumarate and 2-hydroxyglutarate (2-HG) are competitive
inhibitors of these α-KG-dependent dioxygenase enzymes53–56.
Acetylation is similarly promoted by the acetyl group donor acetyl-CoA and inhibited by
its product, CoA1,57,58 (FIG. 1.2). Adding complexity, recent evidence suggests that other
acyl-CoAs, notably palmitoyl-CoA59, can also act as inhibitors of KAT reactions.
Crotonyl-CoA, conversely, is used as an alternative substrate by the acetyltransferase
p300 (crotonylation)60. Deacetylation reactions are also metabolically responsive. Sirtuin
deacetylases, in both mitochondria and nuclei, use NAD+ as a cofactor, and energydepleted conditions that promote AMPK activation increase NAD+ levels and promote
sirtuin-mediated deacetylation61 (FIG. 1.2). Whereas deacetylation reactions are
energetically favourable, sirtuins are intriguing as they catalyse the reaction in a
seemingly wasteful way: one NAD+ molecule is hydrolysed to produce NADH and Oacetyl-ADP-ribose. In order to understand the importance of these reactions, factors
beyond deacetylation need to be considered; for example, the anabolic fate of O-acetylADP-ribose in cancer cells or interactions with ‘nearby’ acetyl-CoA producers that also
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regulate and are regulated by the NAD+/NADH ratio, like the pyruvate dehydrogenase
complex (PDC; which we discuss below). In addition to metabolic regulation of sirtuin
deacetylases, metabolic products, including the glycolytic product lactate and the ketone
body β-hydroxybutyrate, have been identified as endogenous inhibitors of KDACs62,63.
With numerous metabolites potentially affecting each histone modification,
understanding the true influences of metabolism on chromatin might seem hopelessly
com- plex. Towards reducing this complexity, a recent metabolomics study in cancer
cells analysed the relationship of global histone acetylation with levels of various
metabolites, including acetyl-CoA, CoA, NAD+ and β-hydroxy- butyrate, upon dosedependent glycolytic inhibition, and found that the level of acetyl-CoA was the best
predictor of histone acetylation levels in this context64.

The spatial choreography of metabolism in subcellular compartments.
Acetyl-CoA is present in the mammalian cell in multiple, distinct pools: mitochondrial,
cytosolic, nuclear, peroxisomal and in the endoplasmic reticulum (ER). Acetyl-CoA
cannot readily cross organelle membranes and thus these pools are physically
separated. In addition, owing to its inherent instability, it is likely that acetyl-CoA is
synthesized locally according to its intended use in the cell. Thus, localized sub-pools of
acetyl-CoA may be locally produced and used in specific functions.
The largest and best understood pools of acetyl-CoA in the cell are the mitochondrial,
cytosolic and nuclear pools. Mitochondrial acetyl-CoA has key roles in the Krebs cycle
and mitochondrial ATP production, whereas the cytosolic pool supplies fatty acid,
cholesterol and hexosamine biosynthesis pathways. Mitochondria are the major site of
acetyl-CoA production from nutrient catabolism. Acetyl-CoA is produced in mitochondria
from glycolysis-derived pyruvate through the glucose oxidation gate-keeping enzyme
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PDC; catabolism of branched chain amino acids and β-oxidation of fatty acids also
contribute to the mitochondrial acetyl-CoA pool depending on cell type and
conditions21,65. Acetyl- CoA condenses with oxaloacetate inside mitochondria to
generate citrate, which is oxidized within the Krebs cycle to produce the electron donors
NADH and FADH2 or citrate is exported to the cytoplasm. After export from the
mitochondria, citrate is cleaved into oxaloacetate and acetyl-CoA by the enzyme ATPcitrate lyase (ACLY) in an ATP-dependent manner. This pathway is a major route for
extramitochondrial acetyl-CoA production in mammalian systems under nutrient-replete
conditions66. However, under stressed conditions, such as low nutrient availability or
hypoxia, citrate can be generated through reductive carboxylation of glutamine in the
cytoplasm through isocitrate dehydrogenase 1 (IDH1), in addition to the mitochondrial
pathway, which involves IDH267–69. Acetate can also be activated upon ligation to CoA to
produce acetyl-CoA in an ATP-dependent reaction by acyl-CoA synthetase short-chain
family member 2 (ACSS2). Although not normally a fuel in most mammalian cells,
acetate uptake and use increases in tumours70,71, particularly under hypoxic conditions in
which acetate has been shown to contribute a significant fraction of the lipogenic acetylCoA pool72,73. Under hypoxic conditions, acetate also promotes histone acetylation
globally and at the promoters of lipogenic genes, promoting their expression74 (FIG. 1).
Global levels of nuclear histone acetylation are sensitive to overall acetyl-CoA levels;
however, it is attractive to speculate that localized production of acetyl-CoA by spatial
regulation of acetyl-CoA producers could confer specificity to metabolic regulation of
acetylation. Presently, it is known that several acetyl-CoA-producing enzymes are
localized to the nucleus, in addition to other cellular compartments. ACLY and ACSS2
have been known for several years to be present in the nucleus in addition to the
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cytoplasm, and to participate in the regulation of overall histone acetylation levels66,75.
ACSS2 has recently been described as predominantly nuclear in some tumours76, and
exposure to exogenous acetate promotes its nuclear localization76. Additionally, the PDC
was recently shown to dynamically translocate from mitochondria to nuclei following
serum stimulation, epidermal growth factor (EGF) signalling or mitochondrial stress,
where it produces acetyl-CoA to promote histone acetylation4. These data, as well as
other evidence of acetyl-CoA producers localizing to the nucleus in disease states such
as cancer73,76,77, suggest that acetyl-CoA production may be spatially controlled,
potentially conferring specificity to the effects of metabolism on acetylation (FIG. 1.3).
It is unclear whether nuclear ACLY, ACSS2 and PDC are redundant or fulfil distinct roles
in the nucleus. Studies have pinpointed a metabolic role for nuclear ACSS2 in stress
responses, whereby acetylation of hypoxia-inducible factor 2α (HIF2α) by the
acetyltransferase CREB-binding protein (CBP; also known as CREBBP) is dependent on
nuclear translocation of ACSS2 to supply acetyl-CoA76,77. Similarly, as discussed,
mitochondrial stress was shown to promote PDC translocation to the nucleus to increase
histone acetylation involved in cell cycle progression4. Additionally, the presence of a
functional Krebs cycle was shown to be important for maintaining overall levels of
histone acetylation, regardless of the availability of exogenous acetate68. Parsing out
the relative contributions and mechanisms of compensation between each of these
enzymes in different contexts will be important for both understanding the physiological
control mechanisms for acetylation and identifying opportunities for targeting these
pathways. Moreover, the mechanisms governing their nuclear localization remain
elusive, as none has a reported nuclear localization sequence. It is likely that the
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mechanism by which each of the acetyl-CoA-producing enzymes are brought into the
nucleus has a substantial impact on their function within the organelle.

Oncogene rewiring of acetyl-CoA metabolism.
The importance of acetyl-CoA in several pathways and multiple cellular compartments
implicates it as a chief target of the metabolic remodelling and molecular rewiring in
cancer. Indeed, evidence that frequent primary molecular changes or driver mutations in
cancer can directly affect acetyl-CoA homeostasis suggests an intimate link between
molecular and metabolic signalling. MYC and AKT both fulfil prominent roles in
stimulating nutrient uptake and rewiring cellular metabolism in cancer cells78–80. Among
their metabolic roles, both have been shown to promote acetyl-CoA production through
ACLY. MYC regulates acetyl-CoA production for use in lipid synthesis and histone
acetylation81, and MYC- deficient cells maintain lower acetyl-CoA levels, despite
evidence of compensatory mechanisms82,83. AKT directly phosphorylates and activates
ACLY84,85, thus enabling cells to maintain histone acetylation even when glucose
availability is limited1. Conversely, AKT inhibition decreases cellular acetyl-CoA and
histone acetylation levels. Notably, overall histone acetylation levels in human prostate
tumours and gliomas correlate significantly with phosphorylated Ser473 on AKT 1. Thus,
AKT activation in cancer cells may enable them to sustain a high nuclear level of acetylCoA, preventing histone acetylation from fluctuating with microenvironmental nutrient
availability. Such a mechanism could conceivably enable cells to maintain proproliferative gene expression programmes in a harsh microenvironment, enabling them
to respond more rapidly when adequate nutrients for growth become available.
Tyrosine kinases can phosphorylate pyruvate dehydrogenase kinase (PDK) and activate
it, thus indirectly inhibiting PDC86; they can also directly phosphorylate and inhibit
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PDC87,88. The net result is a decrease in PDC activity and thus a net decrease in
mitochondrial acetyl-CoA pro- duction and Krebs cycle activity, with all its downstream
effects, including reduced α-KG, citrate and NADH levels. EGF can promote PDC
translocation in the nucleus, where it can remain constitutively active, producing acetylCoA, because PDK, which tonically inhibits PDC in mitochondria, is absent from the
nucleus, at least in some cancers4. Although it is becoming increasingly clear that
oncogenic alterations in acetyl-CoA homeostasis facilitate tumorigenesis and
progression, delineating the effects on metabolism and molecular signalling has
remained elusive. Below, we propose three models of how metabolic rewiring can lead
to remodelling of the epigenome landscape in tumours as part of a greater bidirectional
feedback mechanism between molecular signalling and metabolism in cancer.

Potential models of coordination
As the body of literature on metabolic control of the epigenome has grown, it has
become clear that a single mode of regulation does not apply universally to all scenarios
in which metabolism influences chromatin marks. Therefore, in delineating the
relationship between cellular metabolism and epigenetic modification, we propose three
models that we believe encapsulate the types of regulation that have been observed
thus far (FIG. 1.4). These models provide a framework within which to understand the
diverse roles for metabolism in epigenetic control in cancer biology and how the
molecular and metabolic rewiring may influence these processes, although raising
questions that remain to be addressed.
Model 1: inhibitor metabolite production and chromatin regulation. Some chromatinmodifying enzymes use metabolites as substrates, but these metabolites are not
normally regulatory for the function of the enzyme, except in the presence of inhibitor
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metabolites. For example, α-KG is a co-substrate required for the activity of some
histone and DNA demethylases, as discussed above (FIG. 1.2). Metabolites that
interfere with the use of α-KG by these enzymes, including 2-HG, succinate and
fumarate, which are structurally similar to α-KG, can inhibit some demethylases when
their levels are elevated. The discovery of mutations in IDH1 and IDH2, through genomic
studies of gliomas and other cancers, led to the identification of the first oncometabolite,
(R)-2-hydroxyglutarate (R-2HG), produced by the mutant IDH enzymes89–93. Tumours
harbouring IDH1 or IDH2 mutations exhibit increased histone and DNA methylation and
more poorly differentiated gene expression profiles93–96 (FIG. 1.4). For in-depth
discussion on the biology of IDH mutations and R-2HG, see recent review articles56,97.
Interestingly, the other enantiomer, S-2HG, is produced by lactate dehydrogenase (LDH)
under hypoxic conditions, in which it also affects histone methylation and hypoxic
transcriptional responses98,99. Accumulation of succinate or fumarate, which occurs in
tumours deficient for succinate dehydrogenase (SDH) or fumarate hydratase (FH),
similarly inhibit α-KG- dependent enzymes, resulting in hypermethylation54,55,100.
Conversely, embryonic stem cells (ESCs) maintain an elevated α-KG/succinate ratio that
is crucial for maintaining histone and DNA demethylation and pluripotency101. Thus,
production of inhibitor metabolites in both physiological and pathological conditions can
alter the activity of chromatin-modifying enzymes.
Model 2: nutrient sensing and regulation of chromatin. Chromatin modifications can also
occur in direct response to physiological changes in nutrient availability. Such
mechanisms may enable cells to optimize crucial short- and long-term adaptation
mechanisms in conditions of limited fuel supply, such as those commonly found in many
tumours. A canonical example of metabolite sensing is that of AMPK, which responds to
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AMP and/or ADP availability52. As cells conduct work, ATP is consumed and ADP
produced. The adenylate kinase reaction buffers cellular ATP concentrations, converting
two ADP molecules into ATP and AMP. Hence, rising AMP levels convey energetic
stress to the cell, doing so by binding to the γ-subunit of the AMPK heterotrimer,
facilitating a conformational change that promotes phosphorylation of AMPKα-Thr172 by
liver kinase B1 (LKB1; also known as STK11). AMPK has been described as regulating
numerous activities in the cell52,102, generally serving to restore energy balance by
inhibiting energy consuming pathways and activating mechanisms that promote ATP
production. Recent evidence implicates AMPK in stress-induced histone
phosphorylation103, suggesting that insults to the energy status of the cell can be
translated into functional outputs in part through histone modification and gene
regulation (FIG. 1.4).
Another example of how the overall supply of nutrients can be sensed and can affect
epigenetic mechanisms comes from the dependence of methylation reactions on dietderived essential amino acids (BOX 1). Owing to dependence on the essential amino
acid methionine (up to 50% of the daily intake of methionine is converted into SAM104)
and folate to propagate the methionine cycle, the serum levels of SAM and SAH in
patients, as well as the degree of methylation in tumours, change with diet105,106. For
example, dietary folate supplementation increases global DNA methylation of rectal
mucosa107 and colonic polyps108. Furthermore, tumour samples from patients with colon
cancer who consumed more than 400 μg folate per day seem to have more global DNA
methylation than tumour samples from patients consuming less than 200μg folate per
day109. This may have direct effects on tumorigenesis, as consuming a methyl donordeficient diet has been shown to reduce spontaneous tumour formation in animals
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predisposed to intestinal tumours110. Moreover, methylation of specific histone residues
(H4K3-trimethyl (me3)) is directly related to the availability of dietary methionine and
intracellular production of SAM, further linking metabolism to epigenetic regulation111.
Finally, nuclear and cytosolic acetyl-CoA levels may be sensed by the cell, enabling it to
gauge its metabolic health. Acetyl-CoA levels are dynamic and parallel growth and
proliferation, as well as histone acetylation, in both yeast and mammalian cells. This
suggests that cells may sense acetyl-CoA to optimize the metabolic needs of
proliferation with nutrient supply1,112–114. The evidence for acetyl-CoA availability affecting
acetylation levels first emerged from an elegant study conducted in yeast75. Unlike
mammalian cells, Saccharomyces cerevisiae relies on a single enzyme outside
mitochondria to produce acetyl-CoA, Acs2p, the orthologue of mammalian ACSS2.
Deletion of ACS2 resulted in a rapid drop in overall histone acetylation levels, and
reconstitution with either a nucleus- or cytosol-confined enzyme, but not with a
mitochondria-confined enzyme, restored histone acetylation. This study demonstrated
the need for continuous production of acetyl-CoA in the nucleus or cytoplasm to sustain
histone acetylation levels, and additionally provided experimental evidence for the
separation of the mitochondrial and nuclear–cytosolic acetyl-CoA pools. Importantly,
acetyl-CoA availability is also crucial for sustaining histone acetylation levels in
mammalian cells, mediated largely through ACLY1,66.
If acetyl-CoA levels are indeed ‘sensed’, this implies that one or more acetyltransferases
are potential sensors, mediating acetylation reactions in a nutrient-responsive manner.
According to a nutrient-sensing model, bulk cellular acetyl-CoA levels fluctuate with
nutrient availability or metabolic state to influence histone acetylation. Acetyl-CoA
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concentrations in yeast oscillate during metabolic cycles, over a range of approximately
3–30 μM, corresponding to periods of growth112; increased acetyl- CoA coincides with
rising levels of histone acetylation both globally and locally at the promoters of growthassociated genes112. This regulation occurs in a manner dependent on the SAGA
acetyltransferase complex112, as yeast Gcn5 has a high KD for acetyl-CoA
(approximately 8.5 μM) and can therefore be affected by acetyl-CoA oscillations. In
addition to requiring acetyl-CoA for their activity, KATs are also subject to inhibition by
their product, that is, CoA. Thus, it has been hypothesized that it may be the acetylCoA/CoA ratio that regulates KAT activity and histone acetylation in mammalian
cells57,58. Moreover, the acetyl-CoA/CoA ratio not only influences the enzymatic activity
of KATs, but also alters their specificity115,116. Glucose restriction or inhibition of signal
transduction through the PI3K–AKT pathway results in a decline in both total acetyl-CoA
levels and the acetyl-CoA/CoA ratio, corresponding to reduction in histone acetylation1.
Experiments in isolated nuclei further showed that bulk histone acetylation can indeed
be regulated by the acetyl-CoA/CoA ratio1. The acetyl-CoA/CoA ratio is also affected in
liver by fasting and refeeding, suggesting its relevance to nutritional responses in whole
organisms117. Conversely, glycolysis inhibition with 2-deoxy-D-glucose (2-DG) caused
acetyl-CoA levels to fall, but acetyl-CoA/CoA ratio to rise, suggesting that these effects
may be driven by alternative mechanisms in addition to feedback inhibition64. Such
apparent differences may also be reflective of measuring whole-cell instead of nuclear
levels of these metabolites, as necessitated by current mass spectrometry methods.
Collectively, these findings suggest that acetyl-CoA levels and/or the acetyl-CoA/CoA
ratio is a major indicator of the metabolic status of a cell, and that this should perhaps
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now be added to the AMP/ATP and NAD+/NADH ratios, which have already been
established as crucial rheostats in metabolic sensing (FIG. 1.5).
Model 3: localized metabolite production and chromatin regulation. We discussed how
nuclear acetyl-CoA- producing enzymes (ACLY, ACSS2 and PDC) provide the ink in an
expanded definition of the histone code and can regulate global histone acetylation and
global acetyl-CoA homeostasis. There is now emerging evidence that direct recruitment
of metabolic enzymes to specific sites on chromatin can facilitate site-specific cofactor or
substrate production and histone modification (FIGS 1.3,1.4). Such regulation could
participate in altered gene regulation in cancer and contribute to diverse cancer
phenotypes.
One of the first examples of local production of a metabolite through recruitment of a
metabolic enzyme into a transcription factor complex was described for Sadenosylmethionine synthase isoform type 2 (MAT2A), which is recruited through a
direct protein–protein interaction to the DNA binding sites of the transcription factor
MAFK118. There, MAT2A locally synthesizes SAM118, which can then be used for
localized histone methylation through interactions with HMTs such as SETDB1119 (FIG.
1.4).
Very recently, two additional complexes containing acetyl-CoA-producing enzymes were
described. The aryl hydrocarbon receptor (AHR), a transcription factor associated with
xenobiotic metabolism, forms a complex on chromatin with pyruvate kinase M2 (PKM2),
PDC and the acetyltransferase p300120. This complex results in acetylation of H3K9 at
the enhancer of CYP1A1, an AHR target gene, enhancing its transcription120. In this
complex, PKM2 uses phosphoenolpyruvate to produce pyruvate and ATP, as it does in
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the cytoplasm. The pyruvate is then used by PDC to produce acetyl-CoA, which is
provided to p300 for histone acetylation. The PDC, which despite its very large size is
translocated as an intact complex and remains functional in the nucleus4, can efficiently
use this locally produced metabolite to produce acetyl-CoA and acetylate the target
histone lysine through p300, as all the enzymes and the transcription factor form a
complex (FIG. 1.3). This beautiful example of a targeted local acetylation system in the
nucleus raises the intriguing possibility that such mechanisms may be commonly used to
regulate transcription.
Additionally, recent evidence in yeast has shown that the yeast PKM2 orthologue, Pyk1,
forms a large complex with serine biosynthesis and methionine cycle enzymes, as well
as Acs2p. The existence of this complex, coined serine-responsive SAM-containing
metabolic enzyme (SESAME), is another example of metabolic enzymes acting in
concert to regulate epigenetic marks. The SESAME complex interacts with the Set1
methyltransferase complex, providing the necessary SAM for H3K4 methylation at target
genes121. Moreover, serine produced by members of the SESAME complex is proposed
to activate Pyk1 kinase activity, increasing H3T11 phosphorylation at sites where the
SESAME complex is recruited by Set1121. It remains to be determined whether an
analogous SESAME complex exists in mammalian cells.
Local metabolite production may also influence chromatin-dependent processes beyond
transcription, such as the repair of DNA damage. Consistent with this possibility, a
recent study implicated nuclear FH in non-homologous end-joining DNA double-strand
break repair122. Recruitment of FH facilitates localized production of fumarate, which
inhibits the activity of the α-KG-dependent lysine-specific demethylase 2B (KDM2B),
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resulting in elevated histone H3K36 methylation and DNA repair protein recruitment to
double-strand DNA break sites.
By considering these three models, it is clear that metabolic influences on the cancer
epigenome can occur through multiple mechanisms. These mechanisms are not
mutually exclusive and tumours probably engage all three modes of regulation. The first
model (inhibitor metabolite production), is probably the best understood mechanism of
regulation in the context of cancer biology at present, owing to intense investigation of
the mechanisms through which IDH1 and IDH2 mutations contribute to tumorigenesis.
The second model (nutrient sensing-mediated regulation of chromatin) clearly occurs
and is altered in tumours, although a mechanistic understanding of how it regulates
specific biological processes is lacking. Much more work is needed in this area to
elucidate both the sensing mechanisms and how they mediate specific responses. The
third model (localized metabolite production) is just beginning to gain attention, as
demonstrated by several very recent studies and it seems likely that additional examples
of this type of regulation will emerge. As new examples of metabolic regulation of
chromatin are studied, considering them in the framework of these three models may
help in elucidating the logic and biological functions of such regulation.

Impact on major cell decisions
Despite the evidence that the overall availability of acetyl-CoA levels (or the acetylCoA/CoA ratio) can regulate histone acetylation, at this point it may be premature to
conclude that this can also directly regulate major cell decisions in a coordinated
manner, affecting all cellular compartments. For example, does an increase in this
rheostat of metabolism promote cell proliferation, cell death or differentiation? If so, this
would imply that drugs that would ultimately increase or decrease acetyl-CoA levels may
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regulate such cell decisions that form the foundation of many diseases such as cancer
or degenerative diseases. Evidence has emerged that an increase in nuclear acetylation
is associated with cell cycle progression and proliferation (FIG. 1.6). As discussed,
increased acetyl-CoA levels are associated with increased histone acetylation,
proliferation and growth, and a large proportion of acetyl-CoA-responsive genes are
involved in cell growth and cell cycle progression1,112. Indeed, nuclear acetylation may
promote the expression of proliferation genes at the expense of differentiation, at least in
certain contexts4,123. For example, mouse ESCs have very high levels of acetyl-CoA,
which, upon induction of the differentiation process, decrease significantly124. A similar
fluctuation of acetyl-CoA during differentiation has also been observed recently in human
ESCs, which produce acetyl-CoA through glucose metabolism but rapidly suppress this
function during differentiation. Loss of pluripotency is associated with decreased
glycolytic activity, lowered acetyl-CoA levels and histone deacetylation123. In contrast,
when acetyl-CoA levels are preserved through exogenous supply of acetate, preserved
histone acetylation delays stem cell differentiation123.
Cell survival and death decisions are also affected by acetyl-CoA availability. Autophagy,
a catabolic process that is crucial for organelle quality control and cell survival during
metabolic stress, is suppressed by high acetyl-CoA availability. In the nucleus, acetylCoA induces histone acetylation and repression of pro- autophagic genes125.
Additionally, high cytoplasmic levels of acetyl-CoA suppress autophagy in a p300dependent manner126 (FIG. 1.6). Furthermore, organelle-specific depletion of acetyl-CoA
owing to loss of function of the transporter responsible for the import of acetyl-CoA into
the ER, which is crucial for lysine acetylation of proteins in the ER, induces
autophagy127. Interestingly, low levels of acetyl-CoA are also associated with protection
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against pro-apoptotic stimuli. The anti-apoptotic protein BCL-XL (also known as
BCL2L1) suppresses acetyl-CoA levels and N-terminal acetylation of caspase 2,
promoting cell survival21,128. Alterations in metabolite availability for chromatin
modification during ageing may also have a role in modulating the survival of whole
organisms. At mid-life, flies (Drosophila melanogaster) were found to exhibit increased
ATP-citrate lyase (termed ATPCL in flies) activity, acetyl-CoA levels and levels of
acetylation on several histone lysines compared with young flies. Interfering with ATPCL
or the acetyltransferase Chameau extended lifespan129. The evidence is mounting that
acetyl-CoA levels are important regulators of major cellular decisions, spanning the fate
of individual stem cells to the life expectancy of an entire organism.
The global effects of methylation are more difficult to interpret given the interplay
between histone and DNA methylation, that is, overall hypomethylation in cancer, but
increased methylation of CpG islands. In ESCs, maintaining an elevated α-KG/succinate
ratio decreases suppressive methylation marks on DNA and histones, which promotes
pluripotency101. Methionine metabolism and the availability of SAM also regulate stem
cell differentiation and the transition from naive to primed ESCs130–132. Tumours
exhibiting hypermethylation, including those with IDH and SDH mutations, are
associated with poorly differentiated gene expression profiles93,94,96,100,133,134 (FIG. 1.6).
Moreover, interfering with either 2-HG production or DNA methylation promotes
differentiation in the context of IDH mutation134–138. It has recently emerged that
disruption of demethylation also promotes carcinogenesis at least in part through
regulation of chromatin structure. In IDH-mutant glioma, hypermethylation of CCCTC
binding factor (CTCF) binding sites was shown to result in the loss of CTCF binding and
interaction between previously insulated topologically associating domains (TADs). This
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enabled a constitutive enhancer to aberrantly interact with and upregulate the oncogene
platelet-derived growth factor receptor-α (PDGFRA)139. Consistent with recent evidence
that conserved CTCF binding sites are frequently mutated in cancer and can affect
differentiation and tumorigenesis140–142, mutations of IDH genes may promote tumour
growth by disrupting chromatin structure in addition to methylation patterns in genes and
regulatory elements. Thus, metabolic control of demethylation through α-KG participates
in maintaining chromatin organization and regulating differentiation processes, both of
which are disrupted by the production of inhibitory metabolites such as 2-HG.

Acetylation promotes metabolic rewiring
In addition to histones, acetylation can directly regulate the function or intracellular
localization of many proteins that are crucial to carcinogenesis (FIG. 1.7). For example,
acetylation seems to directly promote mitochondrial suppression and glycolysis
upregulation. Hyperacetylation of mitochondrial enzymes owing to loss of sirtuin 3
(SIRT3) has been shown to predispose rodents to cancer as well as other proliferative
diseases in animals and humans, such as pulmonary arterial hypertension143–145.
Acetylation can suppress mitochondrial function by several mechanisms: inhibition of the
production of acetyl-CoA-producing pathways such as PDC87 and β-oxidation146,147;
inhibition of the activity of Krebs cycle enzymes like IDH2148 and SDH149,150; suppression
of complex I of the electron transport chain151 and dismutation of superoxide by
mitochondrial super-oxide dismutase (MnSOD; also known as SOD2)152; and increase in
the nuclear transcriptional activity of the HIF1α–aryl hydrocarbon receptor nuclear
translocator (ARNT) complex153, which subsequently suppresses mitochondria by
several mechanisms including upregulation of PDK154. As acetylation inhibits PDC by
promoting the recruitment of PDK, and PDK is not found in the nuclear fraction of PDC,
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this may be an escape mechanism by which PDC is able to produce acetyl-CoA in the
nucleus without inhibiting itself. However, mitochondrial suppression may be offset by
competing mitogenic transcription factors, as acetylation inhibits peroxisome proliferatoractivated receptor-γ co-activator 1α (PGC1α) but activates nuclear respiratory factor 1
(NRF1) and NRF2 (also known as NFE2L2)155,156. Similarly, acetylation has opposing
effects on HIF1 and HIF2 (activating HIF1 and inhibiting HIF2). These transcription
factors are known to have different roles in the cell, with HIF1 pre- dominantly mediating
the effect of hypoxic signalling on tumour metabolism157. Thus, the overall effect of
acetylation is likely to be cell type specific or context specific.
Acetylation in the cytoplasm also promotes the trans- location of several glycolytic
enzymes to the nucleus where they are proposed to ‘moonlight’ as transcriptional
regulators in proliferative states, for example, glyceraldehyde 3-phosphate
dehydrogenase (GAPDH)158,159 and PKM2160, as well as the nuclear accumulation or
increased activity of pro-proliferative transcription factors such as MYC161–163 and signal
transducer and activator of transcription 3 (STAT3)164. The mTOR complex 2 (mTORC2)
member, rapamycin-insensitive companion of mTOR (RICTOR) can also be acetylated
in a metabolically responsive manner, promoting resistance to cancer therapies165.
Acetylation in the cytoplasm may also redirect carbon sources towards biomass
generation by increasing the production of nucleosides by the pentose phosphate
pathway (PPP) through stimulation of the activity of 6-phosphogluconate dehydrogenase
(PGD)166,167.
Importantly, ACLY itself can be acetylated in a glucose-sensitive manner, promoting its
stability168. This increase in ACLY activity increases generation of lipogenic acetyl-CoA
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in tumour cells from citrate derived from either the Krebs cycle or the reductive glutamine
pathway, which is upregulated in cancer68,69. Conversely, ACSS2 is deacetylated and
activated by SIRT1, potentially providing a compensatory source of cytosolic acetyl-CoA
under low-nutrient conditions169.
Conversely, acetylation of p53 in response to DNA damage and tubulin acetylation are
insensitive to silencing of ACLY or PDC, suggesting that modulating nuclear–cytosolic
acetyl-CoA availability alone does not have a global impact on all cytoplasmic protein
acetylation4,66. Identifying nuclear and cytoplasmic proteins that are acetylated in an
acetyl-CoA-dependent manner will be a considerable step towards understanding how
many cellular and molecular events respond to changes in nutrient availability.

Translational implications
Although cancer metabolism and epigenetic mechanisms, particularly histone
acetylation, have independently been the focus of intensive efforts for drug development,
many of which are in clinical trials, the presence of a metabolism–epigenome axis may
have several important translational implications. For example, the effects of inhibitors
that target metabolic pathways may reach epigenetic mechanisms and alter the levels of
many gene products, beyond what their direct metabolic effects would have predicted.
Thus the interpretation of their effects now needs to consider epigenetic mechanisms.
Drug specificity may be increased by considering the targeting of histone modifications
in a condition-specific manner. For example, loss of the 9p21 tumour suppressor locus,
one of the most common deletion events in cancer, has recently been shown to cause
deregulated methionine metabolism owing to deletion of the gene encoding the enzyme
methylthioadenosine phosphorylase (MTAP)170–172. Importantly, these MTAP-deficient
cancer cells are now sensitized to inhibition of the protein arginine N-methyltransferase 5
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(PRMT5), opening a new therapeutic opportunity based on this interaction of methionine
metabolism and the epigenome170–172.
Given the direct effects of the nuclear acetyl-CoA producers on histone acetylation,
inhibitors of ACLY, ACSS2 and PDC may now be seen as perhaps a new class of drugs
that target the metabolism–epigenome axis, compared with their current approach as
metabolic modulators. Several of these drugs under development (previously or
currently) include the ACLY inhibitors SB-204990 (pre- clinical)173,174, BMS-303141
(preclinical)175, ETC-1002 (phase II clinical trial)176–178, and hydroxycitrate (phase IV
clinical trial)179,180 and the ACSS2 inhibitor, N-(2,3-di-2-thienyl-6-quinoxalinyl)-Nʹ-(2methoxyethyl)urea (pre-clinical)70. Following preclinical studies, the PDC activator
dichloroacetate (DCA) which activates PDC by inhibiting PDK20, has entered clinical
development in phase I clinical trials in cancer181–183. By increasing the activity of the
Krebs cycle, DCA can increase acetyl-CoA production in the mitochondria and
cytoplasm. However, at least in some cancers, PDK, despite forming a complex with
PDC in mitochondria, does not follow the translocation of PDC to the nucleus4,
suggesting that nuclear PDC may be constitutively active or ‘immune’ to DCA. In
contrast, as PDC is directly inhibited by tyrosine kinases (TKs), TK inhibitors may
activate both mitochondrial and nuclear PDC86,88,184.
The conflicting results in the efficacy of KDAC inhibitors in cancer treatment may be
because many of these inhibitors target multiple KDACs instead of a single target and
histone remodelling is heterogeneous depending on context, tissue and cancer type185–
187

. Moreover, the large number of acetylated proteins in addition to histones adds to the

complexity of responses to KDAC inhibition. Further investigation is needed to clarify
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contexts for effective use of existing KDAC inhibitors, as well as for development of more
effective and specific drugs.
The consideration of a metabolism–epigenome axis may alter the way we approach
biomarker studies in cancer (BOX 1). For example, metabolomic studies should be
considered in parallel with transcriptomic studies under the same experimental
conditions. Several parameters that take into account dietary intake are controlled in
metabolomic studies, but currently this is not typically done in transcriptomic studies
from human specimens, potentially influencing the accuracy and variability in these
studies. Notably, it has been shown that serum methionine levels in humans are variable
between individuals over a range that could affect histone methylation; moreover,
approximately 30% of the variation in methionine concentration is explained by dietary
factors111.
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Box 1 | The metabolism–epigenetics axis and its systemic effects on multiorgan organisms in vivo
Most of the discussion in this Review is focused on the regulation of the metabolism–
epigenome axis in a single cell. In complex organisms, additional levels of complexity are
likely to be activated to optimize and synchronize energy use with growth, perhaps via the
circadian rhythm machinery and peripheral clocks, which are closely linked to metabolism and
acetylation353,354. Starvation reduces acetyl-CoA and protein acetylation levels in several
organs, including the heart and muscle. This is prevented by strategies that promote acetylCoA production: for example, the pyruvate dehydrogenase complex (PDC) activator
dichloroacetate (DCA)126. However, starvation does not affect acetyl-CoA levels in the brain126
although it increases acetyl-CoA and protein acetylation levels in the liver355. Circulating
ketone bodies produced by one organ, for example, the liver under starvation, may regulate
acetylation mechanisms in other organs and may be involved in the explanation of these
organ-specific effects. For example, β-hydroxybutyrate can inhibit several lysine deacetylases
(KDACs)63. In addition, alternative sources of acetyl-CoA exist in specific cell types such as
neurons, which can generate acetyl-CoA through β-hydroxybutyrate356, or hepatocytes, which
can generate acetyl-CoA from ethanol357. These data underlie the importance of recognizing
that often acetyl-CoA homeostasis mechanisms can be context, cell type or organ specific.
This needs to be considered in the studies of cancers arising from different organs or in the
interpretation of the global effects of cancer therapies or metabolic modulators on the
metabolism–epigenetic axis in the whole organism. Similarly, dysregulation of metabolic
homeostasis is likely to prove important in our understanding of cancer cachexia.

.

Conclusions and perspectives
Although considerable progress has been made in understanding the link between
metabolism and epigenetics, several outstanding questions remain. The list of metabolic
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enzymes present in the nucleus has grown extensively in recent years. As more
metabolic enzymes are identified in the nucleus, understanding their role in this
compartment will be crucial in elucidating the links between metabolism and epigenetic
regulation. Of particular importance, many of these nuclear metabolic enzymes function
in complex with one or multiple other proteins. Thus, uncovering interacting partners of
metabolic enzymes in the nucleus will be telling with regard to their function. Additionally,
although we have focused here on metabolic enzymes that use their metabolic activity to
produce substrates for chromatin modification, several metabolic enzymes have been
reported to use alternative, non-metabolic functions in the nucleus; distinguishing
metabolic and other moonlighting functions of these enzymes is crucial to understanding
their biological roles in the nucleus. Lastly, although many metabolic enzymes have now
been found in the nucleus, how they arrive there remains unclear, as many lack a
canonical nuclear localization sequence.
Metabolic rewiring in cancer affects the epigenome in a manner that facilitates tumour
development and/or progression. Furthering our understanding of the roles of metabolic
enzymes in affecting epigenetics and cell fate decisions has great potential to lead to
novel strategies to battle cancer.
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Figure 1.2 | Histone code writers require metabolites as ink to write
epigenetic marks.
N-Acetylglucosamination (GlcNAcylation) by O-GlcNAc transferase (OGT) uses the metabolite
UDP-glucosamine (UDP-GlcNAc) synthesized by the hexosamine biosynthetic pathway from
inputs such as glucose and glutamine (top left). Acetylation uses the metabolite acetyl-CoA,
which is synthesized in the cytoplasm and nucleus from acetate, citrate or pyruvate by acyl-CoA
synthetase short-chain family member 2 (ACSS2), ATP-citrate lyase (ACLY) and pyruvate
dehydrogenase complex (PDC), respectively. The lysine acetyltransferase (KAT) reaction
releases CoA-SH, a product that can inhibit these enzymes. Certain fatty acyl-CoAs have also
been shown to inhibit KAT enzymes (top right). Lactate, a glycolytic product, and β‑
hydroxybutyrate, a ketone body, have been identified as endogenous lysine deacetylase (KDAC)
inhibitors. S-Adenosylmethionine (SAM), synthesized from the essential amino acid methionine
and ATP by methionine adenosyltransferase (MAT) enzymes, is the substrate for histone
methyltransferases (HMTs) and DNA methyltransferases (DNMTs), resulting in the production of
S-adenosylhomocysteine (SAH), which in turn can inhibit HMTs and DNMTs. Other metabolites,
such as fumarate, succinate and 2-hydroxyglutarate (2-HG), have been identified as inhibitors of
Jumonji-C (JMJC) domain-containing histone demethylases (JHDMs) and TET demethylases,
which rely on the structurally similar metabolite α‑ketoglutarate (α-KG) as a co-substrate (bottom
right). Energetic stress can also affect epigenetic regulation by activating AMP-activated protein
kinase (AMPK), leading to stress-induced histone phosphorylation (bottom left). SIRT, sirtuin.
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Figure 1.3 | Histone acetylation may be mediated by global or local
production of acetyl-CoA.
a, Nuclear acetyl-CoA producers ATP-citrate lyase (ACLY), acyl-CoA synthetase short-chain
family member 2 (ACSS2) and pyruvate dehydrogenase complex (PDC) create pools of acetylCoA that can be accessed non-specifically by lysine acetyltransferases (KATs) in the nuclear
domain.
b, Acetyl-CoA is generated locally in a subnuclear domain by a complex of proteins that directly
link production of acetyl-CoA (that is, pyruvate kinase M2 (PKM2)) with acetyl-CoA production
(that is, PDC) with a KAT to locally acetylate specific histone targets. Ac, acetylation; PEP,
phosphoenolpyruvate.
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Figure 1.4 | Models of coordination between metabolism and the
epigenome.
a, Model 1: inhibitor metabolite production and chromatin regulation. The production of inhibitor
metabolites such as R-2-hydroxyglutarate (R-2HG) and S-2HG by mutant isocitrate
dehydrogenase (IDH) and promiscuous lactate dehydrogenase (LDH) activity, respectively,
increases histone and DNA methylation by competitively inhibiting the α‑ketoglutarate (α-KG)dependent Jumonji-C (JMJC) domain-containing histone demethylases (JHDMs) and TET
demethylases.
b, Model 2: nutrient sensing and chromatin regulation. The availability of metabolites used as the
ink for histone writers fluctuates based on the energy status of the cell. For example, a nutrientpoor cell may have activation of AMP-activated protein kinase (AMPK) and a reduction in
methionine and acetyl-CoA levels, leading to altered expression of adaptive response genes
owing to changes in the phosphorylation (P), methylation (Me) and acetylation (Ac) of chromatin.
c, Model 3: localized metabolite production and chromatin regulation. Direct recruitment of
metabolic enzymes to specific sites on chromatin facilitates site-specific substrate production and
histone modification. For example, S-adenosylmethionine (SAM) synthase isoform type 2
(MAT2A) locally produces SAM for histone methylation (Me) at specific sites. Similarly, nuclear
ATP-citrate lyase (ACLY), acyl-CoA synthetase short-chain family member 2 (ACSS2) and
pyruvate dehydrogenase complex (PDC) locally generate acetyl-CoA to be used by lysine
acetyltransferases (KATs) to acetylate (Ac) histones, resulting in regulation of specific genes. MT,
methyltransferase; TF, transcription factor.
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Figure 1.5 | Metabolites as rheostats of cellular nutritional state.
Metabolic state can be conveyed to chromatin through fluctuations in concentrations of several
metabolites that are substrates or regulators of chromatin modifiers. Levels of Sadenosylmethionine (SAM) and acetyl-CoA increase in high-nutrient conditions (abundant
methionine or glucose, respectively), favouring increased histone methylation and acetylation
(top). Under low-nutrient conditions (bottom), AMP levels rise, activating AMP-activated protein
kinase (AMPK) and inducing targeted histone phosphorylation. NAD+ levels also rise under lownutrient conditions, leading to the activation of sirtuin deacetylases. Furthermore, levels of
product metabolites S-adenosylhomocysteine (SAH) and CoA may increase with nutrient
limitation in a context-dependent manner, feeding back to inhibit methyltransferases and
acetyltransferases, respectively. These feedback mechanisms enable cells to dynamically
modulate their chromatin modification landscape in response to metabolic conditions. Ac,
acetylation; DNMT, DNA methyltransferase; HMT, histone methyltransferase; KAT, lysine
acetyltransferase; Me, methylation; P, phosphorylation.
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Figure 1.6 | The metabolic–epigenome axis regulates major cell decisions.
a, A high acetyl-CoA/CoA-SH ratio promotes the acetylation (Ac) of histones and transcription
factors involved in proliferation. Conversely, reduction in the acetyl-CoA/CoA-SH ratio and thus
histone deacetylation signals a change from proliferation to differentiation. Depletion of acetylCoA favours the deacetylated, active versions of proteins involved in autophagy (autophagyrelated genes (ATGs)), and an AMP-activated protein kinase (AMPK)-dependent inhibition of
mTOR complex 1 (mTORC1), causing activation of several enzymes crucial for the biogenesis of
autophagosomes.
b, Increased histone and DNA methylation (Me) due to inhibition of histone and DNA
demethylases by fumarate, succinate and 2-hydroxyglutarate (2-HG) (from loss-of-function (LoF)
or mutant isocitrate dehydrogenase (IDH), fumarate hydratase (FH) and succinate
dehydrogenase (SDH)) promotes proliferation over differentiation. Conversely, histone and DNA
demethylation stimulated by production of the demethylase reaction cofactor α‑ketoglutarate (αKG) promotes pluripotency. JHDM, Jumonji-C domain-containing histone demethylases.
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Figure 1.7 | Acetylation promotes molecular and metabolic rewiring in
cancer.
Acetylation (Ac) of proteins may activate, inhibit or promote their translocation to a different
subcellular compartment. Mitochondrial suppression: acetylation globally suppresses
mitochondria by inhibiting the Krebs cycle enzymes isocitrate dehydrogenase 2 (IDH2) and
succinate dehydrogenase (SDH) as well as complex I (I) in the electron transport chain and
mitochondrial superoxide dismutase (MnSOD). Furthermore, acetylation prevents the entry of
acetyl-CoA into the Krebs cycle by inhibiting β‑oxidation (inhibition of long-chain acyl-CoA
dehydrogenase (LCAD)) and glucose oxidation (inhibition of pyruvate dehydrogenase complex
(PDC)), which is potentiated by the upregulation of PDC inhibitor pyruvate dehydrogenase kinase
(PDK) secondary to activating acetylation of hypoxia-inducible factor 1α (HIF1α) in the nucleus.
Proliferation: acetylation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pyruvate
kinase M2 (PKM2) promotes the nuclear translocation and moonlighting of these glycolytic
enzymes, whereby they join MYC and signal transducer and activator of transcription 3 (STAT3)
(each activated by acetylation in the nucleus) to promote proliferation. Biomass generation: in the
cytoplasm, acetylation activates ATP-citrate lyase (ACLY) to generate lipogenic acetyl-CoA from
citrate derived from both the Krebs cycle and the reductive glutamine pathway, while reducing
acetyl-CoA derived from acetate by inhibiting acyl-CoA synthetase short-chain family member 2
(ACSS2). Also in the cytoplasm, acetylation activates 6-phosphogluconate dehydrogenase (PGD)
in the anabolic pentose phosphate pathway (PPP) to produce NADPH and nucleoside
precursors. Thus, a global increase in acetylation is associated with suppression of mitochondria
and a proliferative phenotype, a fact that may be applicable to other proliferative diseases,
beyond cancer. ACO2, aconitase 2; α-KG, α‑ketoglutarate; CS, citrate synthase; FFA, free fatty
acid; FH, fumarate hydratase; MDH, malate dehydrogenase; OGDC, oxoglutarate
dehydrogenase complex; SCS, succinyl-CoA synthetase.
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Acetyl-CoA production provides the substrate for de novo
lipogenesis.
In addition to its role as a substrate for histone and non-histone protein acetylation,
acetyl-CoA is also the substrate for de novo lipogenesis (DNL), which is the intracellular
synthesis of lipids such as fatty acids and sterols (Figure 1.1, Figure 1.8).

Figure 1.8 | Nuclear-cytosolic acetyl-CoA is required for de novo
lipogenesis.
ACLY and ACSS2 synthesize nuclear-cytosolic acetyl-CoA, which is further metabolized into
malonyl-CoA by acetyl-CoA carboxylase (ACC). Fatty acid synthase (FASN) utilizes acetyl-CoA
and multiple malonyl-CoA molecules to synthesize nascent fatty acids, such as palmitic acid.
Acetyl-CoA can also be metabolized into HMG-CoA, which is converted into mevalonate for sterol
synthesis. Inhibitors of these reactions that have been used in human patients are indicated.
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During fatty acid synthesis, nutrients such as carbohydrates or amino acids are broken
down into acetyl-CoA, and following export from the mitochondria, acetyl-CoA is
metabolized into malonyl-CoA by Acetyl-CoA Carboxylase (ACC) at the rate-limiting step
of fatty acid synthesis188. Subsequently, Fatty Acid Synthase (FASN) utilizes acetyl-CoA
and multiple molecules of malonyl-CoA to produce nascent fatty acids. These fatty acids
can be further modified into more complex lipids, which often play structural roles within
cellular membranes189. At the organismal level, fatty acid synthesis is thought to be an
energy storage process, whereby excess nutrients are broken down and converted into
fatty acids for storage as triglycerides in lipid droplets190. As such, many nutrients
activate molecular signals that promote production of lipogenic acetyl-CoA and
downstream lipid products. These signals can be at the transcriptional or posttranslational levels. For instance, the transcription factor Sterol Regulatory Element
Binding Protein 1 (SREBP-1) is activated downstream of insulin signaling following
carbohydrate consumption191. SREBP-1 promotes the transcription of lipogenic enzymes
such as ACLY, ACC, and FASN, among others192. At the post-translational level,
production of lipogenic acetyl-CoA and malonyl-CoA are tightly regulated. For instance,
ACLY is phosphorylated downstream of insulin action by the kinase AKT, resulting in a
several-fold induction of activity84,85,193. Additionally, ACLY has been reported to be
phosphorylated by the Branch Chain Ketoacid Dehydrogenase Kinase (BCKDK)194,
which also regulates amino acid catabolism, thereby linking the two processes.
Conversely, ACC is negatively regulated by phosphorylation downstream of the energy
stress sensor, AMPK195,196. Importantly, malonyl-CoA is itself a negative regulator of fatty
acid catabolism through its interaction with Carnitine Palmitoyltransferase 1 (CPT1)197.
Thus, the balance between nutrient catabolism for energy production and anabolism for
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energy storage can be tightly regulated. When this balance is disrupted, lipid
accumulation in adipose tissue, as well as ectopic lipid deposition, can occur, resulting in
obesity, insulin resistance, and other metabolic diseases198. In many cancers, DNL is
markedly elevated, a phenomenon believed to support biogenesis of cellular membrane
for rapid cell division199,200. As such, inhibitors of ACC and FASN are being investigated
as therapeutic target for treatment of cancer and metabolic diseases, and have reached
various stages of clinical trials201–204.
In addition to fatty acids, sterols comprise another major lipid fate of acetyl-CoA. Sterols
are a product of the mevalonate pathway, a multistep process in which acetyl-CoA is
converted into 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMG-CoA is then
metabolized into mevalonate by the enzyme HMG-CoA Reductase (HMGCR) in what is
considered the rate-limiting step of the mevalonate pathway, and is also the mechanistic
target of the statin class of drugs (Figure 1.8). Like fatty acids and their derivatives,
sterols are also an important component of intracellular lipid pools due to their role in
maintaining fluidity of cellular membranes189. As such, cholesterol synthesis is also
frequently deregulated in diseases such as cancer205. This can be achieved through
activation of the transcription factor SREBP-2, which controls the expression of
cholesterol biosynthetic and uptake genes192. Unlike SREBP-1 which is stimulated by
nutrient availability, SREBP-2 is regulated by a sterol feedback mechanism in which high
levels of cholesterol prevent its activation, thereby ensuring its activation when
cholesterol is in demand206.
Among tissues in mammals, the liver and adipose tissues display the highest levels of
DNL207. At normal levels in these tissues, DNL helps to maintain lipid homeostasis in
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tissues and circulation. However, improperly regulated DNL serves an important role in
promoting both cancer and metabolic diseases, particularly in the liver, as discussed
below.

Role of de novo lipogenesis and ACLY in hepatic maladies.
Liver cancer is now the fifth most common cancer worldwide with over half a million new
cases diagnosed each year208. Hepatocellular carcinoma (HCC) is the most common
cancerous malignancy of the liver, accounting for up to 90% of all primary liver
cancers209. HCC incidence in the United States has increased over 3-fold since the
1970s208,210, and is one of the fastest rising causes of cancer deaths in the United States,
owing to a poor 5-year survival rate of 17%211. This is largely due to the fact that most
HCC patients are diagnosed at advanced stages of disease when treatment options are
limited. Moreover, HCC does not present with a predominant oncogenic driver in
patients, which is an obstacle towards developing targeted therapies212,213. This lack of a
defined oncogenic driver reflects the multitude of causes linked to HCC. In many
countries, fibrosis resulting from hepatitis B and C virus infection remains the most
significant identifiable cause of HCC209. However, epidemiological evidence from the
United States and many other Western countries estimates that up to 40% of HCC
cases present without viral origins214,215, highlighting the need to identify and understand
non-viral causes of HCC. One such cause linked to HCC is the growing epidemic of
metabolic syndrome.

Metabolic syndrome is an umbrella term for a collection of metabolic diseases including
obesity, diabetes, and dyslipidemia. Over one third of the United States population fits
the criteria for metabolic syndrome, and over two thirds are considered overweight or
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obese216,217, underscoring the significant public health challenge presented by these
diseases. Obesity has been implicated in increasing the risk of death from multiple
cancer types, including liver cancer218,219. In addition to obesity, type-2 diabetes mellitus
(DM) has also been implicated in increasing cancer risk. Two recent meta-analyses
examining the association between DM and HCC from multiple case-control and cohort
studies concluded that DM increases the risk of developing HCC and HCC-associated
mortality rate by 2 to 2.5-fold220,221. In the liver, metabolic syndrome manifests as nonalcoholic fatty liver disease (NAFLD). NAFLD is characterized by excess lipid
accumulation in the liver, termed steatosis, and when combined with inflammation
eventually progresses to non-alcoholic steatohepatitis (NASH). NASH can progress to
fibrosis and cirrhosis, which ultimately gives rise to HCC (Figure 1.9). Patient studies in
the United States and other Western countries have linked NAFLD with causing
HCC222,223, and it is projected that NAFLD will soon become the predominant cause of
HCC as a result of the obesity epidemic224. In light of this, multiple recent studies have
shown that high-fat diet-induced obesity can promote HCC development in mice225–228.
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Figure 1.9 | Stage-wise progression of hepatic disease.
Progression from healthy liver to NAFLD is associated with an increase in DNL, followed by
inflammatory responses that promotes progression to NASH, fibrosis and ultimately cirrhosis.
Hepatocellular carcinomas frequently develop in cirrhotic livers, and there is growing evidence for
increased HCC incidence in patients who have not progressed beyond NAFLD or NASH.

De novo lipogenesis links non-alcoholic fatty liver disease and
hepatocellular carcinoma
A common molecular feature to NAFLD and HCC is de novo lipogenesis of both fatty
acids229,230 and cholesterol231. Notably, DNL accounts for roughly a quarter of liver lipid
content, and that DNL contributes over two-fold more to liver lipid content in obese
patients with severe steatosis than in those with mild steatosis, implicating hepatic DNL
as a key contributor to NAFLD development229,230. DNL also plays a prominent role in
HCC, where it has been shown that expression of lipogenic genes is high compared to
healthy liver tissue232. High-carbohydrate diets promote DNL by inducing expression of
lipogenic genes, and fructose is an even stronger inducer of DNL compared to other
carbohydrate sources such as glucose233,234. In contrast, high-fat diets actually suppress
expression of lipogenic genes235,236. Thus, while high-fat diets and high-fructose diets
both promote development of NAFLD, the mechanisms by which they do so likely differ.
This is supported by studies demonstrating that a high-fructose and fat diet promotes
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more liver lipid accumulation than a high-fructose or high-fat diet alone237.
Epidemiological data shows that between the 1970s and 1990s, consumption of fructose
increased by 1000% due to the increased usage of high fructose corn syrup as a food
sweetener238,239. Fructose has been shown to be a potent promoter of hepatic lipid
accumulation and inflammation in rodent and human studies233,240–246. While limited in
number, studies on dietary fructose and HCC in rodents have shown a pro-tumorigenic
role247,248, though the exact mechanisms behind this require further investigation. Given
the growing disease burden spurred by dietary obesity, uncovering the mechanisms by
which modern dietary factors promote HCC development will be crucial for effective
diagnosis and treatment of this disease.

ACLY levels are dysregulated in metabolic disease of the liver and
HCC.
ACLY is highly expressed in metabolic organs such as adipose, pancreas, and liver249.
ACLY levels in the liver are sensitive to diet and the whole-body metabolic state; high-fat
feeding suppresses ACLY levels in the liver and fat tissues235,236. In contrast, a highcarbohydrate diet elevates ACLY expression in the liver, but this effect is blunted in
diabetic animals250. Furthermore, leptin receptor-deficient (db/db) mice, an established
model for studying obesity and diabetes, display elevated ACLY expression specifically
in the liver and not adipose tissues251. RNA interference-mediated silencing of Acly in
livers of (db/db) mice suppressed DNL and protected against hepatic lipid accumulation.
These data suggest that hepatic ACLY is an important regulator of metabolic function in
the liver. Moreover, studies have identified that ACLY is upregulated or activated in
HCC252,253. Thus, ACLY may be a promising therapeutic target for the treatment and
prevention of NAFLD and HCC.
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ACLY has been envisioned as a therapeutic target for decades, beginning with
the competitive citrate analogue hydroxycitrate254–258. ACLY inhibitors decrease serum
fatty acid and cholesterol levels in humans, dogs, and rodents174,176,178,259. These studies
have contributed to the development of a hepatotropic ACLY inhibitor, ETC-1002, that is
currently in clinical trials for treatment of dyslipidemia as a statin alternative, and appears
to be safe and well-tolerated176–178,259–261. However, the use of ETC-1002 as an anticancer therapeutic has not been clinically tested to date. A significant hurdle in
combating HCC has been identifying effective targeted therapies, with Sorafenib
remaining the stand-alone targeted therapy used as a standard of care212,262. A key point
to note is that the average age of diagnosis for HCC is 65263, whereas obesity, diabetes
and NAFLD are diagnosed throughout adulthood. This suggests that progression to
HCC is a prolonged process, which presents a window for therapeutic intervention.
Unfortunately, efforts to further understand how ACLY loss affects development of
NAFLD, HCC and other hepatic maladies have been hampered because the Acly
knockout mouse is early embryonic lethal5. Thus, whether targeting ACLY is beneficial in
treatment of hepatic diseases has remained largely unexplored, and is the question that
the following work in this dissertation addresses.
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CHAPTER 2: ATP-Citrate Lyase Controls a Glucose-to-Acetate
Metabolic Switch264.
SUMMARY
Mechanisms of metabolic flexibility enable cells to survive under stressful conditions and
can thwart therapeutic responses. Acetyl-coenzyme A (CoA) plays central roles in
energy production, lipid metabolism, and epigenomic modifications. Here, we show that,
upon genetic deletion of Acly, the gene coding for ATP-citrate lyase (ACLY), cells remain
viable and proliferate, although at an impaired rate. In the absence of ACLY, cells
upregulate ACSS2 and utilize exogenous acetate to provide acetyl-CoA for de novo
lipogenesis (DNL) and histone acetylation. A physiological level of acetate is sufficient
for cell viability and abundant acetyl-CoA production, although histone acetylation levels
remain low in ACLY-deficient cells unless supplemented with high levels of acetate.
ACLY-deficient adipocytes accumulate lipid in vivo, exhibit increased acetyl-CoA and
malonyl-CoA production from acetate, and display some differences in fatty acid content and synthesis. Together, these data indicate that engagement of acetate
metabolism is a crucial, although partial, mechanism of compensation for ACLY
deficiency.

INTRODUCTION
Acetyl-coenzyme A (CoA) is a central molecule in cell metabolism, signaling, and
epigenetics. It serves crucial roles in energy production, macromolecular biosynthesis,
and protein modification21,265. Within mitochondria, acetyl-CoA is generated from
pyruvate by the pyruvate dehydrogenase complex (PDC), as well as from catabolism of
fatty acids and amino acids. To enter the tricarboxylic acid (TCA) cycle, acetyl-CoA
condenses with oxaloacetate, producing citrate, a reaction catalyzed by citrate synthase.
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Transfer of acetyl-CoA from mitochondria to the cytosol and nucleus involves the export
of citrate and its subsequent cleavage by ATP-citrate lyase (ACLY), generating acetylCoA and oxaloacetate. This acetyl-CoA is used for a number of important metabolic
functions, including synthesis of fatty acids, cholesterol, and nucleotide sugars such as
UDP-N-acetylglucosamine. Acetyl-CoA also serves as the acetyl-group donor for both
lysine and N-terminal acetylation21,265. ACLY plays an important role in regulating histone
acetylation levels in diverse mammalian cell types1,6,113,266.
In addition to ACLY, nuclear-cytosolic acetyl-CoA is produced from acetate by acyl-CoA
synthetase short chain family member 2 (ACSS2)9. Recent studies have revealed an
important role for this enzyme in hypoxia and in some cancers7,70–74,267. Acetate can be
produced intracellularly by histone deacetylase reactions or can be imported from the
environment265. Levels of acetate in circulating blood are rather low, ranging from 50 to
200 M in humans, although acetate concentrations can increase substantially in
certain conditions, such as following alcohol consumption, high-fat feeding, or infection,
or in specific locations such as the portal vein268–274. Acetate is also exported by cells
under certain conditions, such as low intracellular pH34, and thus could potentially be
made available for uptake by other cells in the immediate microenvironment. Two
additional acetyl-CoA-producing enzymes, the PDC and carnitine acetyltransferase
(CrAT), have been reported to be present in the nucleus and to contribute acetyl-CoA for
histone acetylation4,275. The PDC was shown to translocate from mitochondria to the
nucleus under certain conditions, such as growth factor stimulation; within the nucleus,
the complex is intact and retains the ability to convert pyruvate to acetyl-CoA4. The
relative contributions of each of these enzymes to the regulation of histone acetylation
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and lipid synthesis, as well as the mechanisms of metabolic flexibility between these
enzymes, are poorly understood.
Whole-body loss of ACLY is early embryonic lethal, indicating that it serves nonredundant roles during development5. Silencing or inhibition of ACLY suppresses the
proliferation of many cancer cell lines and impairs tumor growth173,276–280. Depending on
the context, ACLY silencing or inhibition can also promote senescence281, induce
differentiation173, or suppress cancer stemness282, further pointing to its potential as a
target for cancer therapy. Inhibition of ACLY in adult animals and humans is reasonably
well tolerated and produces blood lipid-lowering effects174,176,178. Thus, there may be a
therapeutic window for ACLY inhibition in treatment of cancer and/or metabolic diseases; although the extent to which cells could leverage other compensatory
mechanisms upon reduced ACLY function is not clear.
In this study, we aimed to elucidate two questions: first, does use of glucose-derived
carbon for fatty acid synthesis and histone acetylation require ACLY; and second, can
cells compensate for ACLY deficiency and, if so, by which mechanisms or pathways? To
address these questions, we generated a conditional mouse model of Acly deficiency
(Aclyf/f mice), as well as immortalized mouse embryonic fibroblast (MEF) cell lines (Aclyf/f
MEFs). As a complement to these models, we used CRISPR-Cas9 genome editing to
delete ACLY from human glioblastoma cells. ACLY deficiency in both MEFs and
glioblastoma cells potently impaired proliferation and suppressed histone acetylation
levels. Both lipid synthesis and histone acetylation from glucose-derived carbon were
severely impaired in ACLY-deficient MEFs. Cells partially compensated for the absence
of ACLY by upregulating ACSS2, and ACLY-deficient MEFs became dependent on
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exogenous acetate for viability. Acetate was used to supply acetyl-CoA for both lipid
synthesis and histone acetylation, although global histone acetylation levels remained
low unless cells were supplemented with high levels of acetate. ACSS2 upregulation in
the absence of ACLY was also observed in vivo upon deletion of Acly from adipocytes in
mice. AclyFAT-/- mice exhibited normal body weight and adipose tissue architecture, and
production of acetyl-CoA and malonyl-CoA from acetate was enhanced in ACLYdeficient adipocytes. Upon deuterated-water (D2O) labeling of wild-type (WT) and
AclyFAT-/- mice, we observed that de novo synthesized fatty acids were present in white
adipose tissue (WAT) in both genotypes, although some differences between depots
were apparent. Visceral (epididymal) WAT (VWAT) exhibited no significant differences
between WT and AclyFAT-/- mice in quantities of de novo synthesized fatty acids, while
synthesized saturated fatty acids were reduced in subcutaneous (inguinal) WAT (SWAT)
of AclyFAT-/- mice. Histone acetylation levels were also significantly altered in AclyFAT-/SWAT. Taken together, this study demonstrates that ACLY is required for glucosedependent fatty acid synthesis and histone acetylation and that a major, albeit partial,
compensatory mechanism for ACLY deficiency involves engagement of acetate
metabolism.

RESULTS
Genetic Deletion of Acly in Cells Is Consistent with Viability but Impairs
Proliferation
To facilitate investigation of the role of ACLY in vitro and in vivo, we generated a
conditional mouse model of Acly deficiency, using a conventional Cre-lox strategy (Aclyf/f
mice) (Figure S2.1A). MEFs from Aclyf/f mice were immortalized (Aclyf/f MEFs). Acly was
efficiently deleted from Aclyf/f MEFs upon administration of Cre recombinase (Figure
S2.1B). Acly∆/∆ MEFs continued to proliferate, although more slowly than parental cells
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(Figure S2.1C). However, over time, these cells regained ACLY expression, indicating
that deletion occurred in less than 100% of cells and that those that retained ACLY had
a growth advantage over Acly∆/∆ cells (Figure S2.1B). To address this, we generated
three clonal Acly knockout (KO) cell lines, designated PC7, PC8, and PC9 (Figure 2.1A).
ACSS2 was strikingly upregulated in these cell lines (Figure 2.1A). Proliferation in the
absence of ACLY was significantly slower in each of the KO cell lines than in the
parental Aclyf/f cells (Figure 2.1B). We also used CRISPR-Cas9 to delete ACLY from
LN229 glioblastoma cells (Figure 2.1C). ACSS2 levels were high at baseline in LN229
cells and only modestly increased with ACLY deletion (Figure 2.1C). However, similar to
the ACLY-deficient MEFs, ACLY-deficient LN229 clones exhibited a marked proliferative
impairment (Figure 2.1D). Two of the ACLY-KO clones, PC7 and PC9, were
reconstituted with wild-type ACLY (ACLY-WT) or a catalytically inactive ACLY mutant
(ACLY-H760A) (Figures 2.1E and S2.1D). ACLY-WT, but not ACLY-H760A, significantly
restored proliferation in the KO clones (Figures 2.1F and S2.1E). Of note, despite
comparable expression upon initial reconstitution (data not shown), ACLY-H760A failed
to stably express as highly as ACLY-WT (Figure S2.1D), further pointing to a strong
selective advantage for cells expressing catalytically active ACLY. ACSS2 levels were
elevated in both the nucleus and cytoplasm of ACLY-deficient cells, and this was
reversed upon reconstitution of ACLY-WT (Figure 2.1E). Next, we inquired whether
ACSS2 upregulation was induced by ACLY deletion or whether growing up ACLYdeficient clones selected for those that already had high ACSS2 expression. To test this,
we examined the timing of ACSS2 upregulation upon loss of ACLY function. In Aclyf/f
MEFs, ACSS2 was rapidly upregulated in parallel to loss of ACLY protein following Cre
administration (Figure 2.1G). Moreover, treatment of MEFs with an ACLY inhibitor (BMS50

303141) led to increased ACSS2 within 96 hr (Figure 2.1H). Thus, we conclude that the
loss of ACLY activity induces ACSS2 upregulation.

ACLY-Deficient MEFs Require Use of Exogenous Acetate for Viability
The amount of acetate in the serum used in these experiments was quantified by
nuclear magnetic resonance (NMR). Undiluted calf serum (CS) contained ~800–900 M
acetate, while acetate was undetectable in dialyzed fetal bovine serum (dFBS) (Figures
2A and S2A). Given that acetate was also undetectable in DMEM, our standard culture
conditions (DMEM + 10% CS) exposed cells to slightly less than 100M acetate. ACLYdeficient cells began to die when cultured in the absence of exogenous acetate (DMEM
+ 10% dFBS) (Figures 2.2B–2D), and adding 100 M acetate was sufficient to restore
viability (Figures 2.2C and 2.2E). No added proliferative benefit was gained by further
increasing the amount of acetate supplemented (Figure 2.2F). Additionally,
reconstitution of ACLY-WT, but not ACLY-H760A, restored the ability of KO cells to grow
in acetate-depleted conditions (Figures 2.2B and 2.2E). To test whether acetyl-CoA
production by ACSS2 was required for viability, we used CRISPR-Cas9 to delete Acss2
in Aclyf/f MEFs (Figure S2.2B). Little to no difference in the proliferation rate was
observed upon Acss2 deletion when Acly was intact (Figure S2.2C). However,
subsequent deletion of Acly resulted in extensive toxicity (Figures 2.2G and S2.2D),
which was not observed in cells expressing Acss2, confirming that cells rely on ACSS2
for survival in the absence of ACLY.

Physiological Levels of Acetate Support Lipid Synthesis in the Absence of
ACLY
ACLY deficiency did not alter rates of glucose or glutamine consumption, although
lactate and glutamate production were elevated (Figure 2.3A). To confirm the
requirement for ACLY for glucose-dependent fatty acid synthesis and test the use of
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acetate, we set up parallel stable isotope tracer experiments in which Aclyf/f, PC9, PC9ACLY-WT, and PC9-ACLY-H760A cells were incubated for 48 hr either with [UC]glucose (10 mM) and unlabeled acetate (100 M) or with [1,2-13C]acetate (100 M)
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and unlabeled glucose (10 mM) (Figure 2.3B). In ACLY-proficient cells, palmitate was
strongly labeled from glucose-derived carbon, as expected. In PC9 ACLY-KO cells,
labeling of palmitate from 13C-glucose was nearly abolished; this could be restored by
reconstitution of ACLY-WT but not ACLY-H760A (Figure 2.3C). Conversely, a marked
increase in use of acetate for fatty acid synthesis was observed in PC9 and PC9-ACLYH760A cells (Figure 2.3D). We also examined the use of glucose and acetate carbon for
synthesis of HMG (hydroxymethylglutaryl)-CoA, an intermediate in the mevalonate
pathway and ketone body synthesis. Again, parental and PC9-ACLY-WT cells used
glucose-derived carbon for HMG-CoA synthesis (Figure 2.3E). In the absence of ACLY,
glucose carbon use for HMG-CoA synthesis was extremely limited (Figure 2.3E);
instead, acetate was used (Figure 2.3F). Total levels of HMG-CoA trended slightly lower
in the PC9 cells, though this difference was not statistically significant (Figure 2.3G). The
data thus show that, in MEFs, glucose-dependent synthesis of fatty acids and HMG-CoA
is nearly completely dependent on ACLY, and a physiological level of acetate can at
least partially support lipid synthesis in its absence.

ACLY Is the Primary Supplier of Acetyl-CoA for Maintaining Global Histone
Acetylation
Histone acetylation is another major fate of nuclear-cytosolic acetyl-CoA. Consistent with
previous data using RNAi-mediated ACLY silencing1,66, global levels of histone
acetylation were strikingly reduced upon genetic deletion of Acly, despite increased
ACSS2. Moreover, although 100 M acetate was sufficient to restore survival in dFBScultured KO cells, it failed to rescue histone acetylation levels. However, incubating cells
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with a high level of acetate (1 mM) markedly increased histone acetylation levels in KO
cells (Figure 2.4A). Reciprocally, histone acetylation levels were low in WT MEFs when
cultured in 1 mM glucose and increased with greater glucose concentrations. In KO
cells, histone acetylation levels were low at all concentrations of glucose tested, up to 25
mM (Figure S2.3A). Reconstitution of PC9 cells with ACLY-WT but not, ACLY-H760A,
restored histone acetylation levels to those in the parental cells (Figure 2.4A).
To determine the respective use of glucose- and acetate- derived carbon for histone
acetylation in each of the MEF cell lines, we conducted stable isotope tracer
experiments under three conditions: (1) [U-13C]glucose (10 mM) and unlabeled acetate
(100 M), (2) physiological [1,2-13C]acetate (100 M) and unlabeled glucose (10 mM), or
(3) high [1,2-13C]acetate (1 mM) and unlabeled glucose (10 mM) (Figure S2.3B). In
condition 1, histone acetyl groups were strongly labeled from 13C-glucose in Aclyf/f and
PC9-ACLY-WT cells (Figures 2.4B, 2.4E, and S2.3C). In PC9 and PC9-ACLY-H760A
cells, labeling of histone acetyl groups from glucose carbon was severely compromised
(Figures 2.4B, 2.4E, and S2.3C). Moreover, aligning with western blot data, total levels
of histone acetylation were lower in cells lacking functional ACLY (Figure 2.4E). Thus,
the data indicate that ACLY is required for the majority of glucose-dependent histone
acetylation. In cells lacking functional ACLY (PC9 and PC9-ACLY-H760A), 100 M
acetate contributed carbon to histone acetylation with ~40%–60% of the acetyl groups
derived from acetate after 24-hr labeling (Figure 2.4C), but total acetylation remained
low (Figures 2.4F and S2.3D). In 1 mM 13C-acetate, total histone acetylation levels rose
(Figures 2.4G and S2.3E), consistent with western blot data, and acetate carbon
constituted the majority of histone acetyl groups (Figure 2.4D). These data indicate that
ACLY is the dominant supplier of acetyl-CoA for histone acetylation in standard, nutrient53

rich conditions and that, in its absence, cells can use acetate to supply acetyl-CoA for
histone acetylation, although high exogenous acetate availability is needed to bring
histone acetylation up to levels matching those of ACLY-proficient cells. Of note, high
acetate did not produce a corresponding rescue of proliferation (Figure 2.2F). Thus,
while ACLY-deficient cells exhibit both slower proliferation and lower histone acetylation
levels, histone acetylation can be raised with high acetate without restoration of normal
rates of proliferation, supporting the notion that metabolism regulates histone acetylation
at least partially independently of proliferation.
We previously defined acetyl-CoA-responsive gene sets in LN229 glioblastoma cells1.
Cell-cycle- and DNA-replication-related genes were enriched among those genes that
were suppressed in low glucose and increased by both glucose and acetate, although
only glucose impacted doubling time1. As observed in MEFs, ACLY deletion in LN229
cells abolished glucose-dependent regulation of global histone acetylation (Figure
S2.4A). Acetate supplementation increased histone acetylation in ACLY null LN229 cells
in a dose-dependent manner (Figure S2.4A). Consistently, the ability of glucose to
promote expression of proliferation-related genes (E2F2, MCM10, and SKP2) was
potently inhibited in ACLY-deficient cells. Expression of these genes exhibited dosedependent rescue by acetate (Figure S2.4B), correlating with global histone acetylation
levels, despite the lack of a proliferation rescue (Figure S2.4C). In addition, we were
surprised to find that whole-cell acetyl-CoA levels were minimally impacted in ACLY-KO
as compared to WT LN299 cells in high-glucose conditions (Figure S2.4D).

Acetyl-CoA Levels Are Maintained by Acetate in ACLY-Deficient Cells
In prior studies, global histone acetylation levels have tracked closely with cellular acetylCoA levels1,64,112. It was, therefore, unexpected to find these uncoupled in ACLY-KO
54

LN229 cells (Figure S2.4D). We further explored this in ACLY-KO MEFs and found that
acetyl-CoA levels were significantly higher in the KO cells than in the WT Aclyf/f cells
when cultured in 10 mM glucose and 100 M acetate (Figure 2.5A). These data
suggested either that mitochondrial acetyl-CoA, which is inaccessible for histone
acetylation75, is elevated in ACLY-KO cells or that ACSS2 compensation allows plentiful
nuclear-cytosolic acetyl-CoA production from acetate but that this acetate-derived acetylCoA is used less effectively than glucose-derived acetyl-CoA for histone acetylation. We
reasoned that mitochondrial and extra-mitochondrial acetyl-CoA pools in ACLY KO cells
could be distinguished based on whether whole-cell acetyl-CoA is derived from glucose
or from acetate (Figure 2.5B). This is because, in the absence of ACLY, glucose carbon
does not meaningfully contribute to nuclear-cytosolic acetyl-CoA, as determined by its
minimal use for either lipid synthesis or histone acetylation (Figures 2.3 and 2.4). Within
mitochondria, both glucose (via PDC) and acetate (via mitochondrial acetyl-CoA
synthetases) can be used to generate acetyl-CoA for citrate synthesis. However, as
assessed by enrichment of citrate and malate, acetate contributes minimally to
mitochondrial metabolism in both WT and KO cells, while glucose is oxidized in both cell
lines under these conditions (albeit to a somewhat lesser extent in KO cells) (Figures
2.5C, 2.5D, S2.5A, and S2.5B). These data suggest that, in ACLY-KO cells, any
glucose-derived acetyl-CoA is mitochondrial, whereas acetate-derived acetyl-CoA is
predominantly nuclear cytosolic (Figure 2.5B). Thus measuring the contribution of
glucose and acetate to whole-cell acetyl-CoA should allow us to distinguish whether the
increase in acetyl-CoA in ACLY-KO MEFs reflects elevated mitochondrial or extramitochondrial acetyl-CoA. Therefore, we incubated cells with [U-13C]glucose (10 mM)
and 100 M unlabeled acetate or, reciprocally, [1,2-13C]acetate (100 M) and 10 mM
55

unlabeled glucose. In WT (Aclyf/f) cells, as expected, acetyl-CoA, malonyl-CoA, and
succinyl-CoA were more strongly enriched from glucose than acetate (Figures 2.5E–
2.5G). Interestingly, despite minimal labeling of malonyl-CoA from acetate in WT cells
(consistent with palmitate enrichment in Figure 2.3D), 20% of the acetyl-CoA pool was
enriched from 13C-acetate (Figures 2.5E and 2.5F), further hinting at differential
partitioning of acetate- and glucose-derived acetyl-CoA. In contrast, in the PC9 ACLYKO cells, acetyl-CoA was minimally labeled from glucose, and ~80% of the acetyl-CoA
pool was labeled from acetate after 6 hr (Figure 2.5E). Malonyl-CoA, but not succinylCoA, was also strongly enriched from 13C-acetate in PC9 cells (Figures 2.5F and 2.5G).
In sum, these data indicate that acetate is the major source of acetyl-CoA in the absence
of ACLY, and it appears to predominantly supply the extra-mitochondrial pool.
A second implication of these data is that, at least in KO cells, the mitochondrial acetylCoA pool is likely quite low in comparison to the extra-mitochondrial pool, since acetylCoA is minimally labeled from glucose-derived carbon. A large difference in relative
acetyl-CoA pool size can explain the apparently paradoxical finding that, in KO cells,
citrate is labeled from glucose, despite minimal acetyl-CoA enrichment (Figures 2.5C
and 2.5E). This interpretation is consistent with findings from a recent study of the
mitochondrial metabolome, which found that matrix acetyl-CoA levels are very low
unless complex I is inhibited, which increases the NADH/NAD ratio, reducing the activity
of citrate synthase283. Notably, another implication of this result is that a much larger
nuclear-cytosolic acetyl-CoA pool in cultured cells would explain why whole-cell acetylCoA measurements in ACLY-proficient cells correlate closely with histone acetylation
levels1,64. Together, these data indicate that acetate carbon is used to supply acetyl-CoA
for nuclear and cytosolic processes in the absence of ACLY. Nevertheless, histone
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acetylation levels remain low in the absence of ACLY unless a high level of acetate is
supplied, and proliferation remains constrained even in the presence of high acetate.
Thus ACSS2 is a key, but partial, mechanism of compensation for ACLY deficiency.

ACSS2 Is Upregulated In Vivo upon Deletion of Acly from Adipocytes
Finally, we sought to determine whether ACSS2 is upregulated upon loss of ACLY in
vivo. Glucose uptake and glucose-dependent lipid synthesis in adipocytes are closely
associated with insulin sensitivity and systemic metabolic homeostasis284,285. Moreover,
our prior work implicated ACLY in regulating histone acetylation levels and expression of
key genes in glucose metabolism, such as Glut4, in 3T3-L1 adipocytes66. To interrogate
the role of adipocyte ACLY in vivo, we bred Aclyf/f mice to Adiponectin-Cre transgenic
mice, which express Cre specifically in adipocytes286. ACSS2 was upregulated in SWAT
and VWAT upon deletion of Acly (Figures 2.6A and 2.6B). In VWAT, ACSS2
upregulation was more apparent at the protein level than the mRNA level (Figures 2.6A
and 2.6B). Fatty acid synthase (FASN) protein levels were also elevated in the absence
of ACLY, particularly in SWAT (Figure 2.6A). Lipid droplets formed normally in AclyFAT-/adipocytes; in VWAT, adipocytes were larger than in WT mice, while in SWAT,
adipocyte lipid droplet size was comparable between genotypes (Figure 2.6C). Body
weight was indistinguishable between WT and AclyFAT-/- mice fed a regular chow diet
(Figure 2.6D). However, overall gene expression patterns were altered, with lower
expression of adipocyte genes such as Glut4 in the AclyFAT-/- mice (Figure 2.6E).

Adipocyte Acetyl-CoA and Lipid Metabolism Is Altered in the Absence of
ACLY
These data suggested that acetate metabolism might, at least partially, compensate for
ACLY deficiency in adipocytes in vivo. Similar to that observed in MEFs, acetyl-CoA
levels were higher in both VWAT and SWAT from AclyFAT-/- as compared to WT mice,
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while liver acetyl-CoA levels were slightly reduced (Figure 2.7A). To test whether AclyFAT/-

adipocytes supply acetyl-CoA and dependent biosynthetic processes using acetate, we

isolated primary visceral adipocytes and tested acetate uptake. Indeed, acetyl-CoA, as
well as malonyl-CoA and HMG-CoA, were more enriched from [1,2-13C]acetate in
primary adipocytes from AclyFAT-/- mice as compared to those from WT mice (Figures
2.7B–2.7D).
Next, we investigated the extent to which de novo synthesized fatty acids were present
in adipose tissue in the absence of ACLY. To capture rates of de novo lipogenesis (DNL)
in vivo, D2O was administered to mice via a bolus injection and subsequent addition to
drinking water for 3 weeks. At the conclusion of labeling VWAT, SWAT, and liver were
collected, and total (saponified) fatty acids from each were analyzed by gas
chromatography-mass spectrometry (GC-MS). Plasma D2O enrichment was confirmed
to be equivalent between genotypes (Figure S2.6A). In both VWAT and SWAT,
abundance of the saturated fatty acids palmitic acid (C16:0) and stearic acid (C18:0)
was significantly reduced (Figures S2.6B and S2.6C). Conversely, monounsaturated
fatty acids, oleic acid (C18:1n9), and palmitoleic acid (C16:1n7), as well as the essential
fatty acid linoleic acid (C18:2n6), were elevated in SWAT from AclyFAT-/- mice (Figure
S2.6B). A slight reduction in palmitic acid was also observed in liver (Figure S2.6D).
Fractional enrichment of fatty acids was not significantly different in VWAT between
genotypes, although SWAT exhibited a moderate reduction in palmitic acid fractional
synthesis (Figures S2.6E and S2.6F). Fractional synthesis was not different between
genotypes in the liver, except for a small reduction for palmitoleic acid (Figure S2.6G).
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The relative quantities of de novo synthesized fatty acids present in each tissue were
calculated using plasma D2O enrichment, fatty acid labeling, and abundance. Notably,
DNL-derived fatty acids present in WAT may be synthesized in adipocytes or produced
in the liver and transported to fat. In the SWAT of AclyFAT-/- mice, total de novo
synthesized palmitic acid and stearic acid were significantly reduced (Figure 2.7E). In
contrast, no significant differences in the quantities of DNL-generated fatty acids were
detected between AclyFAT-/- and Aclyf/f mice in VWAT (Figure 2.7F). Liver DNL was
largely unchanged by adipocyte ACLY deficiency, although a slight reduction in palmitic
acid synthesis was observed (Figure 2.7G). Since DNL-derived fatty acids were reduced
in SWAT of AclyFAT-/- mice, this depot may maintain lipid droplet size through greater
storage of diet-derived fatty acids, as suggested by elevated levels of linoleic acid
(Figure S2.6B).
Histone acetylation levels were also analyzed. Despite ACSS2 upregulation and
elevated acetyl-CoA levels, H3K9ac and H3K23ac were significantly lower, and
H3K18ac trended lower, in the SWAT of AclyFAT-/- mice (Figure 2.7H). Interestingly, this
difference was not observed in VWAT, suggesting that acetate compensation for ACLY
deficiency may be more complete in this depot or that other factors are dominant in
determining histone acetylation levels (Figure 2.7I). No differences in histone H3
acetylation were detected in the liver (Figure 2.7J). Altogether, the data suggest that, in
vivo, adipocytes lacking ACLY partially compensate by engaging acetate metabolism.

DISCUSSION
The findings of this study demonstrate that ACLY is required for the vast majority of
glucose-dependent fatty acid syntheses and histone acetylations under standard culture
conditions and that ACSS2 upregulation and use of acetate carbon is a major
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mechanism of compensation for ACLY deficiency. Additionally, despite ACSS2
upregulation and higher acetyl-CoA levels, ACLY deficiency results in lower overall
histone acetylation levels, slower proliferation, and altered gene expression patterns.
The data suggest that ACLY and ACSS2 likely play distinct roles in the regulation of
histone acetylation and gene expression but also indicate that the potential for metabolic
compensation from acetate should be considered if ACLY is pursued as a therapeutic
target. From a clinical perspective, prior study of PET (positron emission tomography)
imaging in human hepatocellular carcinoma patients using 11C-acetate and 18Ffluorodeoxyglucose (FDG) revealed a dichotomy between acetate and glucose uptake.
Patient tumors, or regions within tumors, with high 11C-acetate uptake demonstrated low
18

F-FDG uptake and vice versa. More- over, tumors with high 18F-FDG uptake were

more proliferative287. These data support the concept that mammalian cells – cancer
cells, in particular – possess an intrinsic flexibility in their ability to acquire acetyl-CoA
from different sources to adjust to changing metabolic environments in vivo. Further
elucidation of the mechanisms connecting ACLY and ACSS2, as well as the differential
phenotypes observed downstream of their activity, could point toward synthetic lethal
strategies for cancer therapy or improved tumor imaging protocols.
In considering the roles of these enzymes in normal physiology, given the importance of
GLUT4-dependent glucose uptake and glucose-dependent fatty acid synthesis for
systemic metabolic homeostasis284,285, deletion of Acly in adipocytes results in a
surprisingly mild phenotype, with no overt metabolic dysfunction observed for mixedbackground mice on a regular chow diet. Nevertheless, larger adipocytes and reduced
expression of genes, such as Glut4, observed in this model are also characteristic of
obesity and are associated with poorer metabolic function. This suggests that AclyFAT-/60

mice may be more susceptible to metabolic dysfunction when nutritionally stressed, for
example, with high fructose feeding. Another interesting question is whether these mice
will exhibit exacerbated metabolic phenotypes under conditions that alter acetate
availability in the blood- stream, such as ethanol consumption or antibiotic treatment.
The differential impact of ACLY on SWAT and VWAT also warrants further investigation.
It is not clear why SWAT, but not VWAT, exhibits reduced histone acetylation and de
novo fatty acid synthesis, despite evidence for compensatory mechanisms such as
FASN upregulation. One possible explanation relates to an overall greater fraction of
fatty acids that are de novo synthesized in SWAT, as compared to VWAT (Figures
S2.6E and S2.6F), placing a greater demand for acetyl-CoA. Potentially, in a tissue with
a lower DNL rate, acetate may be more readily able to compensate in both DNL and
histone acetylation. Distribution of fatty acids in AclyFAT-/- WAT depots is also altered;
SWAT, in particular, exhibits increased levels of monounsaturated and essential fatty
acids (Figure S2.6B). Palmitoleate, which has been implicated as an insulin-sensitizing
lipokine288, is elevated in ACLY-deficient SWAT, raising questions about how altered
levels of bioactive lipid species in the absence of ACLY may influence metabolic
phenotypes. More mechanistic work is also clearly needed to elucidate the relationship
between ACLY and gene regulation. The relationship between global histone acetylation
and gene expression is not entirely consistent between VWAT and SWAT, possibly
reflecting gene regulatory mechanisms that are specific to ACLY.
A noteworthy observation in this study is that acetyl-CoA and histone acetylation levels
appear to become uncoupled in the absence of ACLY, suggesting that acetate-derived
acetyl-CoA may not be efficiently used for histone acetylation. Several possible
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mechanisms could account for this. First, it may be that, in MEFs, an insufficient amount
of ACSS2 is present in the nucleus to efficiently drive histone acetylation. ACSS2 has
been found to localize prominently to the nucleus in some conditions70,76,77; thus,
investigation of whether acetate more readily contributes to overall histone acetylation
levels in these contexts will be informative. However, potentially arguing against this
possibility, hypoxia promotes ACSS2 nuclear localization77; yet, although acetate does
regulate histone acetylation in hypoxic cells, a high level of acetate (~2.5 mM) is
required74. A second possibility is that, within the nucleus, acetyl-CoA producing
enzymes are channeled, compartmentalized into niches, or sequestered with particular
binding partners. Through such a mechanism, acetylation of specific proteins may be
regulated not only by the relevant acetyltransferase but also by a specific acetyl-CoAproducing enzyme. Consistent with this possibility, acetylation of HIF2a was shown to be
exclusively dependent on ACSS2 as a source of acetyl-CoA76,77. A third possibility is that
ACLY-deficient conditions may result in altered lysine acetyltransferase (KAT) or HDAC
(histone deacetylase) activity. Finally, a fourth possibility is that lower use of acetyl-CoA
for histone acetylation could be a feature of slow proliferation in the absence of ACLY
(i.e., secondary to the proliferation defect). However, prior findings that histone
acetylation is sensitive to glucose availability over a range that did not impact
proliferation1 and that the TCA cycle (which supplies ACLY substrate citrate) and
mitochondrial membrane potential have distinct and separate roles in regulating histone
acetylation and proliferation, respectively289, as well as data in the present article
showing that histone acetylation can be boosted by high acetate without a corresponding
rescue of proliferation, argue against this as a sole explanation. Nevertheless,
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elucidation of the mechanisms that constrain proliferation in the absence of ACLY could
help to definitively address this.
Investigating these possibilities will illuminate whether cells possess mechanisms to
differentially detect ACLY-generated versus ACSS2-generated acetyl-CoA as well as
define the functional relationship between histone acetylation levels and cellular
functions and phenotypes. Given that ACLY dominates in nutrient- and oxygen-replete
conditions, whereas ACSS2 becomes important in nutrient- and oxygen-poor
conditions73,74, having mechanisms such as different acetylation substrates to distinguish
between acetyl-CoA produced by each enzyme could be advantageous to cells. For
example, such mechanisms could potentially cue cells to grow when ACLY serves as
the acetyl-CoA source and to mediate adaptive responses when ACSS2 is the primary
acetyl-CoA source. The roles of these enzymes in gene regulation appear to be
complex, and in-depth analysis of the respective roles of ACLY and ACSS2 in genomewide histone acetylation and acetylation of other protein substrates is needed to begin
addressing these questions.
Recent work has shown that the PDC is present in the nucleus and is able to convert
pyruvate to acetyl-CoA for use in histone acetylation4, raising the question of how the
findings of the present study can be aligned with the described role of nuclear PDC. We
suggest two potential models that are consistent both with our data and with a role for
nuclear PDC in histone acetylation. In the first model, ACLY is the primary acetyl-CoA
producer for regulation of global levels of histone acetylation, while PDC (and,
potentially, other nuclear acetyl-CoA sources such as CrAT) could participate in
mediating histone acetylation at specific target genes but not globally. A recent report
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that PDC forms a complex with PKM2, p300, and the arylhydrocarbon receptor (AhR) to
facilitate histone acetylation at AhR target genes is consistent with such a possibility120.
In the second model, the role of ACLY in glucose-dependent histone acetylation
regulation could be context dependent, with a larger role for PDC emerging in certain
conditions or cell types. This possibility is supported by observations that PDC nuclear
translocation is stimulated by conditions such as growth factor stimulation and
mitochondrial stress4. Further investigation will be needed to evaluate these models.
In sum, this study points to a crucial interplay between glucose and acetate metabolism
to supply the nuclear-cytosolic acetyl- CoA pool for fatty acid synthesis and histone
acetylation. At the same time, it shows that, despite compensatory mechanisms, ACLY
is required for optimal proliferation, and simply increasing nuclear-cytosolic acetyl-CoA
production is insufficient to fully replace ACLY. This could point to the importance of
ACLY’s other product, oxaloacetate; a build-up of ACLY’s substrate citrate; deficiencies
in anapleurosis and/or mitochondrial function upon loss of a major catapleurotic
pathway; or a signaling mechanism that is specific to ACLY. Clearly, more work is
needed both to understand the mechanisms through which ACLY facilitates cell
proliferation and to further define the ways that cells partition and use acetyl-CoA
produced by different enzymes. The findings of this study raise a number of important
questions for future investigation, as discussed earlier. They also clarify the importance
of ACLY in glucose-dependent acetyl-CoA production outside of mitochondria and
provide key insights into the mechanisms of metabolic flexibility used for production of
nuclear-cytosolic acetyl-CoA. Understanding these compensatory mechanisms will be
important to consider for therapeutic targeting of acetyl-CoA metabolic pathways.
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EXPERIMENTAL PROCEDURES
Generation of Aclyf/f and AclyFAT-/- Mice
A Knockout First targeting vector was obtained from the Knockout Mouse Project
(KOMP) that targets exon 9 of Acly (KOMP: 80097), predicted to result in a truncated
protein subject to nonsense-mediated decay. The Knockout First allele is initially null but
can be converted to a conditional floxed allele upon Flp recombination290. Recombinant
129/B6 hybrid embryonic stem cells (ESCs) were generated in Penn’s Gene Targeting
Core, and blastocysts were injected at Penn’s Transgenic and Chimeric Mouse Core.
Upon acquisition of the chimeric mice, animals were bred to obtain germline
transmission. Aclyf/+ progenies were selected through sequential breeding with wild-type
C57Bl/6J mice (purchased from Jackson Laboratory) and mice expressing Flp
recombinase (B6.Cg-Tg(ACTFLPe) 9205Dym/J, Jackson Laboratory). Finally, Aclyf/f
mice were generated by inter- breeding and selected by genotyping (see the
Supplemental Information). Immortalized Aclyf/f MEFs were generated from these mice
(see the Supple- mental Information). To produce AclyFAT-/- mice, Aclyf/f mice were bred to
adiponectin-Cre transgenic mice (stock no: 010803; B6;FVB-Tg(Adipoq-cre) 1Evdr/J,
Jackson Laboratory). The University of Pennsylvania’s Institutional Animal Care and Use
Committee (IACUC) approved all animal experiments.

In Vivo De Novo Lipogenesis
13-week-old male Aclyf/f (n = 6) and AclyFAT-/- (n = 7) mice (C57Bl/6 back-crossed) were
injected intraperitoneally (i.p.) with 0.035 mL/g of body weight of 0.9% NaCl D2O (SigmaAldrich). For 3 subsequent weeks, mice were provided water bottles containing 8% D2O.
At the end of 3 weeks, mice were fasted for 6 hr and sacrificed, and plasma, liver,
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VWAT, and SWAT were collected and snap frozen. Plasma from four additional mice
(two Aclyf/f and two AclyFAT-/- that were not given D2O was used as controls.

Cell Culture and Proliferation Assays
MEFs (generation described in the Supplemental Information) were cultured in DMEM
(GIBCO) supplemented with 10% Cosmic Calf Serum (CS) (HyClone, SH30087.03, lot
number AXA30096). LN229 cells were cultured in RPMI 1640 medium (GIBCO)
supplemented with 10% CS (HyClone SH30087.03, lot number AXA30096) and 2 mM Lglutamine. For experiments using dFBS, cells were cultured in glucose-free DMEM +
10% dFBS (GIBCO 26400044), with indicated concentrations of glucose and sodium
acetate added. For proliferation assays, cells were plated in triplicate at the indicated
density and allowed to adhere overnight. Culture medium was changed the following
day, and cells were allowed to proliferate until the indicated days following plating. Cells
were collected and counted on a hemocytometer. Cell lines used for viral production
included Phoenix E and HEK293T cells, which were purchased from ATCC. Cells were
cultured in DMEM + 10% CS and used at low passage. All cell lines were routinely
monitored and confirmed to be free of mycoplasma.

Acyl-CoA Quantification and Isotopologue Analysis
Acyl-CoA species were extracted in 1 mL 10% (w/v) trichloroacetic acid (Sigma-Aldrich,
catalog #T6399). Isotopologue enrichment analysis to quantify the incorporation of 10
mM [U-13C]glucose and 100 mM [1,2-13C]acetate into acyl-CoA thioesters was performed
by liquid chromatograpy-mass spectrometry/high-resolution mass spectrometry (LCMS/HRMS). For quan- titation, internal standards containing [13C315N1]-labeled acylCoAs generated in pan6-deficient yeast culture291 were added to each sample in equal
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amounts. Samples were analyzed by an Ultimate 3000 autosampler coupled to a
Thermo Q Exactive Plus instrument in positive electrospray ionization (ESI) mode using
the settings described previously292.

Statistics
Student’s two-tailed t tests (two-sample equal variance, two-tailed distribution) were
used for analyses directly comparing two datasets except tissue gene expression and
acyl-CoA datasets (Figures 6 and 7), for which Welch’s t test was used. Significance
was defined as follows: *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001.

Genotyping
Tail-snips from mice were placed in digestion buffer (10% SDS, 5M NaCl, EDTA,
Tris, H2O, proteinase K) for two hours while shaking at 56°C. Genomic DNA was
isolated and then used for genotyping using the following primer sets: Cre-Fw:
TGCCACGACCAAGTGACAGC; Cre-Rv: CCAGGTTACGGATATAGTTCATG; tm1c
(floxed allele)-Fw: AAGGCGCATAACGATACCAC; tm1c-Rv:
CCGCCTACTGCGACTATAGAGA; Acly wild-type allele: WT-Fw:
TGCAATGCTGCCTCCAATGAT; WT-Rv: GGAGCCAGAGGAGAAAAAGGC

Generation of Aclyf/f MEFs
For mouse embryonic fibroblast (MEF) generation, two homozygous fertile females
were placed on a dedicated mating cage with a homozygous fertile male. On day
15.5, pregnant females were sacrificed and the fetuses were surgically removed and
placed in a 10-cm dish, washed two timed with PBS. Head and liver were removed
from each fetus, the remaining part was trimmed, pooled in a 50- mL tube and
washed again with PBS. Tissue remnants were digested with 5mL of Trypsin 0.25%
at room temperature for 30 minutes. The digestion was stopped with DMEM+10%
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CS. Cells were pelleted and washed again with DMEM+10% CS. Finally cells were
seeded in a 25-cm flask and cultured in DMEM+10% CS + 0.1 mM βmercaptoethanol. Cells were immortalized by serial passaging (plated at 1:3 dilution
and passaged at confluency) and began recovering from proliferation crisis after 13
(line 1) and 20 (line 2) passages.

Acly deletion and reconstitution in MEFs
For acute analysis, Aclyf/f MEFs (line 2) were infected with adenoviral Cre
recombinase (University of Pennsylvania Vector Core). For generation of stable
lines PC7, PC8, and PC9, retroviral transduction of Aclyf/f MEFs (line 2) with Cre
recombinase was conducted as follows: A retroviral vector containing Cre
recombinase (pBabe-puro-Cre, gift of L. Busino, University of Pennsylvania) was
used to produce retrovirus in Phoenix E cells. MEFs were transduced with retrovirus
and selected with 3 µg/mL of puromycin for 48 hours
until mock infected MEFs displayed no viable cells. Following selection, single cell
clonal populations were generated by plating cells in a limiting dilution. Deletion of
Acly was confirmed by Western blot.
For reconstitution experiments, wild-type ACLY or catalytically inactive (H760A)
ACLY were cloned into pBabe-hygro retroviral vector. Retrovirus was produced in
Phoenix E cells. PC7 and PC9 cells were transduced with retrovirus and selected
with hygromycin (400 µg/mL) for 48 hours until mock infected MEFs displayed no
viable cells. Reconstitution was confirmed by immunoblotting for ACLY expression.

CRISPR-Cas9 genetic editing
Guide RNA sequences were generated using a CRISPR design tool
(www.crispr.mit.edu). The guide sequences used are as follows: mAcss2
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(GCTGCACCGGCGTTCTGTGG), hACLY (GACCAGCTGATCAAACGTCG). Guides
were cloned into the LentiCRISPRv2 plasmid293 followed by lentiviral production in
HEK-293T cells. Cells were infected and selected with puromycin until a separate
mock-infected plate displayed complete cell death. Single-cell clonal expansion of
the selected population was done to ensure complete loss of the target gene. Loss
of target gene was determined by immunoblotting for the target protein.

Analysis of AclyFAT-/- mice
From 4 weeks to 16 weeks of age, mixed background Aclyf/f and AclyFAT-/- were fed
normal chow and weighed weekly. At 16 weeks of age mice were sacrificed and
white fat [visceral (epididymal) and subcutaneous (inguinal)] depots were harvested.
Depots were dissected into thirds with a third of each being fixed in formalin for
histological evaluation, a third being digested in Trizol for RNA expression analysis
and the final third digested in protein lysis buffer for protein analysis. For analysis of
histone acetylation and acetyl-CoA levels, a separate cohort of AclyFAT-/- (n=6) and
WT (Aclyf/f ; n=7) mice, females aged 10 to 11 weeks, backcrossed onto a C57Bl/6
background, were used. Mice were fasted for 6 hours, sacrificed, and liver, VWAT
and SWAT were removed. Organs were split in half; half snap frozen for acyl CoA
analysis and the other processed fresh for histone extraction, as described below.
The University of Pennsylvania’s Institutional Animal Care and Use Committee
(IACUC) approved all animal experiments.

Immunoblotting
Protein was extracted from cells using NP-40 lysis buffer (150 mM NaCl, 1.0% NP40, 50 mM Tris-HCl pH 8.0) with protease inhibitors (Roche). Mouse tissue was
lysed in RIPA lysis buffer (1%NP-40, 0.5% Deoxycholate, 0.1% SDS, 150nM NaCl,
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50mM Tris plus protease and phosphatase inhibitors). Fat was chopped with
scissors on ice to fine pieces, followed by homogenization with TissueLyser (30 Hz
for 20s x 2). Samples were chilled on ice for 30 min, spun down, and infranatant
saved and then sonicated. Protein concentration was determined using the BCA
protein assay (ThermoScientific). Proteins were separated by SDS-PAGE and
transferred to a nitrocellulose membrane (GE Health Sciences). Membranes were
probed with the specified antibodies (see Antibodies and Reagents), and developed
on a LI-COR Odyssey CLx scanner.

Antibodies and reagents
Antibodies used for Western blotting: ACLY (previously described 6 (Wellen et al.,
2009)), ACSS2 (Cell Signaling Technologies #3658S), Tubulin (Sigma T6199),
FASN (Cell Signaling Technologies #3189S), Lamin A/C (Cell Signaling
Technologies #2032S), Parp (Cell Signaling Technologies #9542S), Cleaved Parp
(Cell Signaling Technologies #9544T), Cleaved Caspase 3 (Cell Signaling
Technologies #9661S), Acetyl-H3 (Upstate 06-599), Acetyl-H4 (Millipore 06-866),
H4K5Ac (Millipore 07-327), H3K14Ac (Cell Signaling #7627S), H3K18Ac (Cell
Signaling 9675P), H3K23Ac (Cell Signaling 9674S), H3K27Ac (Abcam ab4729).
Secondary antibodies were IRDye680RD Goat Anti-Mouse (LI-COR 926-68070) and
IRDye800CW Goat Anti-Rabbit (LI-COR 926-32211).
Reagents: ACLY inhibitor BMS-303141 (Tocris Bioscience)

Nuclear-cytoplasmic subcellular fractionation:
Fractionation was performed essentially as described6. Cells were harvested in cold
Buffer A (10 mM HEPES pH 7.4, 10 mM KCl, 1.5 mM MgCl 2, 0.5 mM EDTA, 0.5 mM
EGTA; Complete Mini (Roche) protease inhibitor (PIC) tablet and 0.1% NP-40
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added fresh). Cells were lysed on ice for 15 minutes until the plasma membrane
was broken (assessed by trypan blue staining). Cells were centrifuged at 1000 RCF
for 5 min at 4ºC. Supernatant (cytosol) was transferred to a new microfuge tube and
spun down again at high speed to clear debris. Pellet (nuclei) from initial spin was
washed once with Buffer A without NP-40, then resuspended in equal volumes of
cold Buffer B (10 mM HEPES pH 7.4, 0.42 M NaCl, 2.5% glycerol, 1.5 mM MgCl 2,
0.5 mM EDTA, 0.5 mM EGTA, 1 mM DTT; PIC added fresh). Samples were
incubated on ice for 30 minutes with occasional vortexing, centrifuged 10 minutes at
15,000 RCF to clear debris, and the supernatant transferred to new tube (nuclei).
Lamin A/C and FASN were used as nuclear and cytoplasmic markers, respectively.

Histone Acid Extraction for Immunoblotting
Acid extraction on isolated nuclei was performed as previously described (Lee et al.,
2014). Histones for immunoblotting were extracted from nuclei by lysing cells with
NIB-250 buffer (15 mM Tris-HCl (pH 7.5), 60 mM KCl, 15 mM NaCl, 5 mM MgCl 2, 1
mM CaCl2, 250 mM sucrose, 1 mM DTT, 10 mM sodium butyrate, 0.1% NP-40,
protease inhibitors) for 5 minutes on ice. Nuclei were pelleted by spinning lysate at
600 RCF for 5 minutes at 4oC. Nuclei were washed with NIB-250 buffer without NP40 twice. Histones were extracted from nuclei by resuspending the pellet in 0.4N
H2SO4 and rotating overnight at 4oC, insoluble nuclear debris was cleared by
spinning at 11,000 RCF for 10 minutes at 4oC. Histones were precipitated by adding
100% trichloroacetic acid (TCA) until final solution reached 20% TCA and allowed to
precipitate overnight at 4oC. Precipitated histones were spun down at 11,000 RCF
for 10 minutes at 4oC and washed with 1 mL acetone + 0.1% 12 N HCl followed by a

71

wash of 1 mL acetone. Histone pellet was air dried at room temperature for at least
30 minutes and resuspended in glass distilled H2O.

YSI metabolite analysis:
Culture medium (glucose-free DMEM (Gibco) supplemented with 10% dFBS
(Gibson), 10 mM glucose, and 100 µM acetate) was collected from cells after
culturing for 48 hours. Glucose, lactate, glutamine, and glutamate levels in culture
medium were measured using a YSI 2950 Bioanalyzer. Because of differences in
proliferation rate and cell volume between clones, measurements were normalized
to cell volume (cell number X mean cell volume) area under the curve. Metabolite
consumption was defined as v = V(xmedium

control

- xfinal)/A, where v is metabolite

consumption/ production, V is medium volume, x is metabolite concentration, and A
is total cell volume area under the curve. A was calculated as N(T)d/ln2(1-2-T/d),
where N(T) is the final cell count, d is doubling time, and T is time of experiment.
Cell counts and volume measurements were taken on a Coulter Counter (Beckman
Coulter), and final cell count N(T) was multiplied by mean cellular volume to obtain
total cellular volume per sample. Doubling time was calculated as d =
(T)[log(2)/log(Q2/Q1)], where Q1 is starting cell number and Q2 is final cell number.

Quantitative RT-PCR
Cells were lysed using Trizol reagent (Ambion), and RNA was isolated as per Trizol
extraction protocol. Adipose tissue were excised from animals and immediately
frozen in liquid nitrogen, placed in Trizol, and lysed using a tissue homogenizer
before RNA isolation as per Trizol extraction protocol. RNA was resuspended in
DEPC H2O and quantified on a Biotek Synergy HT Plate Reader. cDNA was
generated from isolated RNA using High Capacity RNA-to-cDNA Kit (Applied
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Biosystems), and diluted 1:20 in nuclease free water for quantitative RT-PCR
reactions (qRT-PCR). qRT-PCR was run using Power SYBR Green PCR Master Mix
(Applied Biosystems) for 40 cycles at standard reaction speed on a ViiA 7 Real-Time
PCR System (Applied Biosystems). Primer sequences listed in the table below.

qRT-PCR primer sequences
Gene
Acly (mouse) Forward
Acly (mouse) Reverse
Acss2 (mouse) Forward
Acss2 (mouse) Reverse
Glut4 (mouse) Forward
Glut4 (mouse) Reverse
FASN (mouse) Forward
FASN (mouse) Reverse
FABP4 (mouse) Forward
FABP4 (mouse) Reverse
PPARg1 (mouse) Forward
PPARg1 (mouse) Reverse
PPARg2 (mouse) Forward
PPARg2 (mouse) Reverse
AdipoQ (mouse) Forward
AdipoQ (mouse) Reverse
18S (mouse) Forward
18S (mouse) Reverse
E2F2 (human) Forward
E2F2 (human) Reverse
MCM10 (human) Forward
MCM10 (human) Reverse
SKP2 (human) Forward
SKP2 (human) Reverse

Primer Sequence
TTCGTCAAACAGCACTTCC
ATTTGGCTTCTTGGAGGTG
GCTTCTTTCCCATTCTTCGGT
CCCGGACTCATTCAGGATTG
GCCCGAAAGAGTCTAAAGC
CTTCCGTTTCTCATCCTTCAG
ATTGGTGGTGTGGACATGGTC
CCCAGCCTTCCATCTCCTG
ACAAAATGTGTGATGCCTTTGTGGGAAC
TCCGACTGACTATTGTAGTGTTTGATGCAA
TGAAAGAAGCGGTGAACCACTG
TGGCATCTCGTGTCAACCATG
TGGCATCTCTGTGTCAACCATG
GCATGGTGCCTTCGCTGA
GCACTGGCAAGTTCTACTGCAA
GTAGGTGAAGAGAACGGCCTTGT
AAATCAGTTATGGTTCCTTTGGTC
GCTCTAGAATTACCACAGTTATCCAA
TTTACCTCCTGAGCGAGTCA
AGCACGTTGGTGATGTCATAG
CGGAACAAACCTAGTGGGATAA
AGAAGGCTTCCACACAGATG
GTGTACAGCACATGGACCTAT
CCAGGCTTAGATTCTGCAACT

Gas Chromatography/Mass Spectrometry of Fatty Acid Methyl Esters
(GC/MS-FAME)
To measure glucose incorporation into lipids, 2x105 cells were plated and allowed to
adhere overnight. Culture medium was changed the following day to DMEM without
glucose (Gibco) supplemented with 10% dialyzed fetal bovine serum (dFBS) (Gibco
26400044, Lot. 1616514), 10 mM [U-13C]glucose (Cambridge Isotope Laboratories),
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and 100 µM sodium acetate, and incubated for 48 hours. To measure acetate
incorporation into lipids, DMEM without glucose was supplemented with 10% dFBS,
10 mM glucose, and 100 µM or 1 mM [1,2-13C]acetate (Cambridge Isotope
Laboratories). On day of harvest, cells were washed with 1x PBS, followed by 1x
PBS + fatty acid free BSA before detachment with trypsin. Cells were spun down,
and frozen at -80°C until day of extraction.
Fatty acids were extracted from cells by resuspending and sonicating cells in a
mixture of methanol, distilled H2O, and chloroform (2:1:2). Mixture was spun at
10,000 RCF for 10 minutes at 4oC to separate organic and aqueous phases. The
organic phase was evaporated under nitrogen to obtain a dry lipid fraction for
derivatization. Fatty acids were derivatized by adding 2 mL of IS solution (40 mL
MeOH, 10 mL toluene, 5 mg butylated hydroxytoluene) and 2 µL of acetylchloride
(Sigma) to the dried lipid fraction and heating at 95oC for 1 hour. Derivatized fatty
acid methyl esters were then extracted by adding 5 mL of 6% potassium carbonate
solution to separate hydrophobic and hydrophilic phases. The hydrophobic phase
containing fatty acid methyl esters was analyzed by GC/MS on an Agilent GC/MS
7890A/5975A with a DB-5 column. Enrichment of

13

C into palmitate was determined

using IsoCor294.

Gas Chromatography/Mass Spectrometry of TCA cycle metabolites
Measurements of citrate and malate were conducted essentially as described 278.
Briefly, 6x105 cells (for 6 hour labeling) or 4x105 cells (for 24 hour labeling) were
plated and allowed to adhere overnight. Culture medium was changed the following
day to DMEM without glucose (Gibco), supplemented with 10% dialyzed fetal bovine
serum (dFBS) (Gibco 26400044, Lot. 1616514), 10 mM [U-13C]glucose (Cambridge
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Isotope Laboratories), and 100 µM sodium acetate, and incubated for 6 or 24 hours.
To measure acetate incorporation into TCA cycle metabolites, DMEM without
glucose was supplemented with 10% dFBS, 10 mM glucose, and 100 µM [1,213

C]acetate (Cambridge Isotope Laboratories). At time of harvesting, media was

removed from cells and cells were quickly scraped into 1 mL of cold methanol and
collected into conical tubes. 0.3 mL of water was added to each sample, and
samples were then sonicated for 60 seconds. Samples were then centrifuged for 15
minutes at 8,500 RPM at 4oC. Following centrifugation, supernatant was transferred
to a 4 ml vial, and samples were heated under nitrogen to evaporate methanol. For
derivatization, pyridine and BSTFA-TCMS were added sequentially in a 1:1 ratio,
and allowed to react at 54oC for 30 minutes. Finally, samples were spun down for 10
minutes at 13,000 RPM at room temperature. Supernatants were transferred GCMS vials with pulled glass inserts and were analyzed by GC/MS on an Agilent
GC/MS 7890A/5975A with a DB-5 column. Enrichment of 13C into TCA cycle
intermediates was determined using IsoCor295.

Mass Spectrometry Analysis of Histone Acetylation
To measure glucose incorporation into histone acetyl-groups, 105 cells were plated
and allowed to adhere overnight. Culture medium was changed the following day to
glucose-free DMEM (Gibco) supplemented with 10% dFBS (Gibson), 10 mM [U13

C]glucose, and 100 µM acetate, and incubated for 24 hours. Measurement of

acetate incorporation into histone acetyl-groups was done in identical conditions, but
with 100 µM or 1mM [1,2-13C]acetate and 10 mM glucose. Histones were acid
extracted from cells using 0.4 N HCl. These samples were TCA precipitated,
acetone washed, and prepared for mass spectrometry analysis as previously
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described296. A Waters (Milford, MA) Acquity H-class UPLC system coupled to a
Thermo (Waltham, MA) TSQ Quantum Access triple-quadrupole (QqQ) mass
spectrometer was used to quantify modified histones. Selected reaction monitoring
was used to monitor the elution of the acetylated and propionylated tryptic peptides.
Transitions were created to distinguish between normal and heavy (13C) acetylation
marks on the histone H3 tail: histone H3 lysine 9 (H3K9), H3K14, H3K18, and
H3K23.

QqQ MS Data Analysis:
Each acetylated and/or propionylated peak was identified by retention time and
specific transitions. The resulting peak integration was conducted using Xcalibur
software (version 2.1, Thermo). The fraction of a specific peptide (Fp) is calculated
as Fp =Is /(∑Ip), where Is is the intensity of a specific peptide state and Ip is the
intensity of any state of that peptide.
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Determination of acetyl-CoA and

13C

incorporation into acyl-CoAs:

Internal standard generation:
[13C315N1]-labeled acyl-CoA internal standard was generated by culturing pan6deficient Saccharomyces cerevisiae with [13C315N1]- pantothenate (Isosciences, King
of Prussia, PA), as described previously291. A 500 ml culture at stationary phase was
resuspended in 100 ml of 10% (w/v) trichloroacetic acid (Sigma-Aldrich, St. Louis,
MO cat. #T6399). The cells were dismembranated in 10 ml aliquots by sonication
(60 0.5 s pulses) with a probe tip sonicator (Thermo Scientific) and centrifuged at
3000 g for 10 mins at 4°C. The cleared supernatant was stored at -80°C.

Cell treatment and harvest:
[U-13C]glucose and [U-13C]acetate incorporation into acyl-CoA thioesters were
analysed in cells incubated in the presence of 10 mM [U-13C]glucose (Cambridge
Isotope Laboratories CLM-1396-1) or 100 µM [U-13C]acetate (Cambridge Isotope
Laboratories CLM- 440-1) for 6 hours. For relative acetyl-CoA determination cells
were incubated in the same conditions in the absence of labeled substrate. Cells
were removed from culture dish by scraping on ice and resuspended directly in the
cell culture medium. Cell volume and concentration were determined by Coulter
counter (Beckman-Coulter). An appropriate volume of each cell sample was pelleted
by centrifugation (500 x g for 10 min at 4 °C) such that total cell volume in each cell
pellet was equal.

Short chain acyl-CoA extraction:
Frozen tissue samples were cut to ~ 50 mg on a super chilled ceramic tile on dry
ice. The weighed samples were added to 1 mL of thawed [13C315N1]-labeled acylCoA internal standard in 1.5 mL Eppendorf tubes on ice. Cell pellets were
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resuspended in 1 ml 10% (w/v) trichloroacetic acid. For relative acyl-CoA
quantitation, 100 µl of [13C315N1]-labeled acyl-CoA internal standard was added to
each sample. Internal standard was omitted for

13

C labeling experiments. Samples

were homogenized and dismembranated by 60 (for tissues) or 20 (for cell pellets)
0.5 s pulses with a probe tip sonicator (Thermo Scientific). The homogenised
samples were centrifuged at 13,000 × g for 10 min at 4 °C. Supernatants were
purified by solid-phase extraction using Oasis HLB 1cc (30 mg) SPE columns
(Waters). Columns were washed with 1 mL methanol, equilibrated with 1 mL water,
loaded with supernatant, desalted with 1 mL water, and eluted with 1 mL methanol
containing 25mM ammonium acetate. The purified extracts were evaporated to
dryness under nitrogen then resuspended in 55 µl 5% (w/v) 5-sulfosalicylic acid in
water.

Liquid chromatography:
Analytes were separated before introduction to the mass spectrometer using a
reversed-phase Phenomenex HPLC Luna C18 column with 5 mM ammonium
acetate in water as solvent A, 5 mM ammonium acetate in acetonitrile/water (95:5,
v/v) as solvent B, and acetonitrile/water/formic acid (80:20:0.1, v/v/v) as solvent C.
Gradient conditions were as follows: 2% B for 1.5 min, increased to 25% over 3.5
min, increased to 100% B in 0.5 min and held for 8.5 min, washed with 100% C for 5
min, before equilibration for 5 min. The flow rate was 200 µl/min. For determination
of [13C]acetate incorporation into acetyl-CoA in primary mature adipocytes an
alternative LC method was used, as described297.
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Mass-spectrometry:
For relative quantitation of acetyl-CoA levels in cells, samples were analyzed using
an API 4000 triple-quadrupole mass spectrometer (Applied Biosystems, Foster City,
CA, USA) in the positive ESI mode as described previously 291. Acetyl-CoA was
quantified by single reaction monitoring (SRM) of m/z 810.1/303.1 and the
[13C315N1]-labeled internal standard at m/z 814.1/307.1.
Samples (10 µl) were injected using a Leap CTC autosampler (CTC Analytics,
Switzerland) and data were analyzed with Analyst 1.4.1 software (Applied
Biosystems).
For [U-13C]glucose and [U-13C]acetate labeling and mouse tissue experiments,
samples were injected by an Ultimate 3000 autosampler and analytes were detected
using a Thermo Q Exactive instrument in positive ESI mode as described
elsewhere292. Briefly, scan parameters were alternating full scan from 760 to 1800
m/z at 140,000 resolution and data-independent acquisition (DIA) looped three times
with all fragment ions multiplexed at a normalized collision energy (NCE) of 20 at a
resolution of 280,000. An isolation width of 7 m/z with an offset of 3 m/z was used to
capture all relevant isotopologues for targeted acyl-CoA thioesters. Parent ion and
product ion m/z transitions detected are indicated in the table below.
Species

Isotopologue

Parent m/z

Acetyl-CoA

M0

810.1331

Product
m/z
303.1373

Acetyl-CoA

M1

811.1364

304.14066

Acetyl-CoA

M2

812.13976

305.14401

Acetyl-CoA

M3

814.14311

306.14737

Acetyl-CoA

M4

814.14647

307.15072

Acetyl-CoA

M5
[13C315N1]-internal standard

815.14982

308.15408

814.1402

307.1444

Acetyl-CoA
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Succinyl-CoA

M0

868.13853

361.14278

Succinyl-CoA

M1

869.14188

362.14614

Succinyl-CoA

M2

870.14524

363.14949

Succinyl-CoA

M3

871.14859

364.15285

Succinyl-CoA

M4

872.15195

365.1562

Succinyl-CoA

M5

873.1553

366.15956

Malonyl-CoA

M0

854.12288

347.12713

Malonyl-CoA

M1

855.12623

348.13049

Malonyl-CoA

M2

856.12959

349.13384

Malonyl-CoA

M3

857.13294

350.1372

Malonyl-CoA

M4

858.1363

351.14055

HMG-CoA

M0

912.16474

405.169

HMG-CoA

M1

913.1681

406.17235

HMG-CoA

M2

914.17145

407.17571

HMG-CoA

M3

915.17481

408.17906

HMG-CoA

M4

916.17816

409.18242

HMG-CoA

M5

917.18152

410.18577

HMG-CoA

M6

918.18487

411.18913

HMG-CoA

M7

919.18823

412.192482

For [13C]acetate incorporation into acetyl-CoA in primary mature adipocytes,
samples were injected by an Ultimate 3000 autosampler and analytes were detected
using a Thermo Q Exactive HF instrument with HESI in negative mode. Instrument
parameters were as follows, spray voltage 3000 V, capillary temperature 325 °C
sheath gas 40 arbitrary units, auxillary gas 10 arbitrary units, spare gas 2 arbitrary
units, S-lens RF level 55. Scan parameters were alternating full scan from 70 to 950
m/z at 120,000 resolution. Acetyl-CoA isotopologue ions were detected as listed in
the table below.

Species

Isotopologue

m/z

Acetyl-CoA

M0

808.1185

Acetyl-CoA

M1

809.12185
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Acetyl-CoA

M2

810.12521

Acetyl-CoA

M3

811.12856

Acetyl-CoA

M4

812.13192

Data were processed in Xcalibur, TraceFinder (Thermo), and isotopic enrichment
was calculated to compensate for the non-linearity of isotopic enrichment as outlined
and applied previously298,299. For acetyl-CoA determination in mouse tissues, the
parent ion peak for acetyl-CoA M0 and the [13C315N1]-acetyl-CoA internal standard
were integrated to determine relative abundance between samples.

In vivo de novo lipogenesis analysis
Plasma D2O enrichment:
The 2H labeling of water from samples or standards was determined via deuterium
acetone exchange300,301. 5 ls of sample or standard was reacted with 4 ls of 10N
NaOH and 4 ls of a 5% (v/v) solution of acetone in acetonitrile for 24 hours.
Acetone was extracted by the addition of 600 l chloroform and 0.5 g Na2SO4
followed by vigorous mixing. 100 ls of the chloroform was then transferred to a
GCMS vial. Acetone was measured using an Agilent DB-35MS column (30 m 3
0.25mm i.d. 3 0.25 mm, Agilent J&W Scientific) installed in an Agilent 7890A gas
chromatograph (GC) interfaced with an Agilent 5975C mass spectrometer (MS) with
the following temperature program: 60 °C initial, increase by 20 °C/min to 100 °C,
increase by 50 °C/min to 220 °C, and hold for 1 min. The split ratio was 40:1 with a
helium flow of 1 ml/min. Acetone eluted at approximately 1.5min. The mass
spectrometer was operated in the electron impact mode (70 eV). The mass ions 58
and 59 were integrated and the % M1 (m/z 59) calculated. Known standards were
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used to generate a standard curve and plasma % enrichment was determined from
this. All samples were analyzed in triplicate.
Total fatty acids were extracted from tissues and plasma using a Bligh and Dyer
based methanol/chloroform/water extraction with C16 D31 as an internal standard.
Briefly, 500 ls MeOH, 500 ls CHCL3, 200 ls H2O and 10 ls 10 mM C16 D31/ 10
mgs tissue were added to weighed pre-ground tissue. This was vortexed for 10
minutes followed by centrifugation at 10,000 g for 5 minutes. The lower chloroform
phase was dried and then derivitised to form fatty acid methyl esters via addition of
500 ls 2% H2SO4 and incubation at 50°C for 2 hours. FAMES were extracted via
addition of 100 ls saturated salt solution and 500 ls hexane and these were
analyzed using a Select FAME column (100m x 0.25mm i.d.) installed in an Aglient
7890A GC interfaced with an Agilent 5975C MS using the following temperature
program: : 80 °C initial, increase by 20 °C/min to 170 °C, increase by 1 °C/min to
204 °C, then 20 °C/min to 250 °C and hold for 10 min.

Calculations:
The % mass isotopomer distributions of each fatty acid was determined and
corrected for natural abundance using in-house algorithms adapted from Fernandez
et al.302. Calculation of the fraction of newly synthesized fatty acids (FNS) was based
on the method described by Lee et al.303, where FNS is described by the following
equation:
FNS=ME/(n x p)
Where ME is the average number of deuterium atoms incorporated per
molecule(ME =1 x m1 + 2 x m2 +3 x m3 ... ), p is the deuterium enrichment in water
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and n is the maximum number of hydrogen atoms from water incorporated per
molecule. N was determined using the equation:
m2/m1 = (N-1) /2 x p/q
As described by Lee et al.304 where q is the fraction of hydrogen atoms and p + q =
1. The molar amount of newly synthesized fatty acids was determined by:
MNS = FNS x total fatty acid amount (nmoles/mg tissue).

Acetate measurements:
Protein filtration from the samples:
200 ml of sample was filtered through 3 kDa cutoff nanosep centrifugation device
(Pall Inc. Port Washington, NY), and recovered volume of the filtrate noted.

Sample preparation for NMR spectroscopy:
180 µl of filtrate was added to 20 µl of DSS (4,4-Dimethyl-4-silapentane-1-sulfonic
acid, Cambridge Isotope Limited, Andover, MA) in D 2O to a final concentration of
0.16 mM.

Nuclear Magnetic Resonance (NMR) Spectroscopy:
All NMR spectra were acquired in Bruker Avance III HD NMR spectrometer
equipped with a triple resonance inverse (TXI) 3 mm probe (Bruker Biospin,
Billerica, MA) and a Bruker Samplejet for sample handling. One-dimensional NMR
spectra were acquired using the first transient of a 2 dimensional NOESY and
generally of the form RD-90-t-90-tm-90-ACQ305. Where RD = relaxation delay, t =
small time delay between pulses, tm = mixing time and ACQ = acquisition. The water
signal was saturated using continuous irradiation during RD and t m. The spectra
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were acquired using 76K data points and a 14 ppm spectral width over 384 scans
with a 1 second interscan (relaxation) delay and 0.1 second mixing time. The FIDs
were zero filled to 128K; 0.1 Hz of linear broadening was applied followed by Fourier
transformation, baseline and phase correction using an automated program
provided by Bruker Biospin.

Profiling of acetate signal from the NMR spectra:
The acetate signal was quantitatively profiled from the spectra using Chenomx v 8.0
(Edmonton, Canada)306 by quantifying the acetate peak at 1.90 ppm (Supplementary
Fig. 2A) relative to the DSS peak area. Proper care was taken to omit the effects of
the overlapping signals (for example, lysine and arginine overlapping with the 1.90
ppm acetate peak) using the Chenomx targeted spectral fitting algorithm 307.

Histology
For histology, subcutaneous and visceral white fat tissue was fixed in formalin
overnight, deyhydrated and submitted to the AFCRI Histology Core for paraffin
embedding, sectioning and hematoxylin and eosin staining.

Primary adipocyte

13C-acetate

uptake

Primary adipocyte isolation was conducted as previously described 308, with minor
modifications. Briefly, visceral white adipose tissues (VWAT) were removed from
mice ages 12-16 weeks and weighed. Isolation buffer (1X Krebs-Ringer- Phosphate
Buffer, 2% Hepes, 25 mg/mL BSA, 0.2 mM adenosine, 10 mM glucose, 100 µM
[1,2-13C]acetate, pH 7.5) and 1 mg/mL collagenase was prepared ahead of time and
added to VWAT at 2 mL per gram of tissue while on ice. VWAT fat pads were
chopped with scissors in the buffer for 5 minutes until no large chunks of tissue
remained, and then incubated at 37oC for 45 minutes while shaking to allow
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collagenase digestion to occur. Following collagenase digestion, tissue suspension
was passed through a 100 µm mesh filter and allowed to sit at room temperature
until primary adipocytes separated from infranatant. Infranatant was subsequently
removed and remaining adipocytes were washed 3x in isolation buffer without
collagenase. Following washes, primary adipocytes were re-suspended in 3x cell
volume of isolation buffer containing 100 µM [1,2-13C]acetate and incubated at 37oC
for 4 hours while shaking. Following incubation, suspension was allowed to sit at
room temperature until primary adipocytes separated from infranatant. Infranatant
was subsequently removed and the remaining primary adipocytes were resuspended in ice cold 10% tricholoroacetic acid, and frozen at -80oC until samples
could be analyzed for acyl-CoA species by mass spectrometry as described above.

FIGURES
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Figure 2.1 | Genetic Deletion of Acly Is Consistent with Cell Viability but
Impairs Proliferation
(A) Western blot of three clonal ACLY-deficient (KO) cell lines (PC7, PC8, and PC9) generated
from Aclyf/f MEFs.
(B) Proliferation curve of Aclyf/f and ACLY-KO MEFs over 5 days; mean ± SEM of triplicate wells,
statistical significance compared to Aclyf/f.
(C) Western blot verification of ACLY knockout by CRISPR-Cas9 in LN229 glioblastoma cells.
(D) Proliferation curve of LN229 and two ACLY-knockout clonal cell lines over 5 days; error bars
indicate mean ± SEM of triplicate wells, statistical significance compared to LN229.
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(E) Western blot of nuclear and cytoplasmic fractions of Aclyf/f, PC9, and reconstituted ACLY-WT
and ACLY-H760A PC9 cells. FASN and LMNA (lamin A/C) are cytoplasmic and nuclear markers,
respectively.
(F) Proliferation curve of Aclyf/f MEF and PC9 lines compared to PC9 reconstituted with ACLYWT or ACLY-H760A over 5 days; error bars indicate mean ± SEM of triplicate wells, statistical
significance compared to PC9.
(G) Western blot of ACLY and ACSS2 protein levels in Aclyf/f MEFs over 144 hr following
administration of Cre recombinase.
(H) Western blot of ACLY and ACSS2 protein levels in Aclyf/f MEFs over 144 hr with
pharmacological inhibition of ACLY (50 M BMS-303141).
For all panels: **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s., not significant. See also Figure S2.1.

88

Figure 2.2 | ACLY-Deficient MEFs Require Exogenous Acetate for Viability
(A) Acetate concentrations in DMEM, RPMI, 100% dialyzed fetal bovine serum (dFBS), and
100% calf serum (CS); error bars indicate mean ± SEM of triplicate aliquots. See Figure S2.2A for
spectrum. n.d., not detected.
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(B) Proliferation curve over 5 days of Aclyf/f, PC9, PC9-ACLY-WT, and PC9-ACLY-H760A cells in
acetate-free conditions (DMEM + 10% dFBS + 10 mM glucose); error bars indicate mean ± SEM
of triplicate wells.
(C) Image of ACLY-deficient PC9 cells cultured for 5 days in DMEM + 10% dFBS + 10 mM
glucose, without (left) or with (right) 100 M sodium acetate.
(D) Western blot of apoptotic markers cleaved poly(ADP-ribose) polymerase (PARP) and cleaved
caspase-3 (CASP3) in Aclyf/f and PC9 cells cultured in acetate- free conditions (DMEM + 10%
dFBS + 10 mM glucose) for 4 (D4) or 5 (D5) days.
(E) Cell numbers following 5 days in culture in DMEM + 10% dFBS + 10 mM glucose alone
(black) or supplemented with 100 M sodium acetate (red) in Aclyf/f, PC9, PC9-ACLY-WT, and
PC9-ACLY-H760A cells; error bars indicate mean ± SEM of triplicates. ***p < 0.001. Dotted line
represents cell number at plating.
(F) Proliferation of PC9 cells over 5 days cultured in DMEM + 10% dFBS + 10 mM glucose, with
100 M or 1 mM sodium acetate; error bars indicate mean ± SEM of triplicate wells.
(G) Parental Aclyf/f MEFs and two clones of ACSS2-deficient Aclyf/f MEFs were administered Cre
recombinase once (+) or twice (++) and proteins collected for western blot after 2 days (+) and 2
weeks (++). See Figure S2.2D for corresponding images.
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Figure 2.3 | Acetate Supports Lipid Synthesis in the Absence of ACLY
(A) Measurements of glucose consumption and lactate production (left) and glutamine
consumption and glutamate production (right), normalized to cell volume (cell number 3 mean cell
volume); error bars indicate mean ± SEM of triplicate wells; **p < 0.01; ***p < 0.001. Experiment
was performed in glucose-free DMEM + 10% dFBS + 10 mM glucose + 100 M sodium acetate.
(B) Experimental design for heavy isotope labeling of fatty acids using [U-13C]glucose, with
unlabeled acetate present (left) and [1,2-13C]acetate, with unlabeled glucose present (right).
(C) Isotopologue distribution of palmitate after 48-hr labeling in 10 mM [U-13C]glucose in Aclyf/f,
PC9, PC9-ACLY-WT, and PC9-ACLY-H760A MEFs (top). Expressed as percent enrichment of
palmitate (bottom); error bars indicate mean ± SD of triplicates. **p < 0.01; ***p < 0.001.
(D) Isotopologues of palmitate after 48-hr labeling in 100 M [1,2-13C]acetate in Aclyf/f, PC9, PC9ACLY-WT, PC9-Acly H760A MEFs (top). Expressed as percent enrichment of palmitate (bottom);
error bars indicate mean ± SD of triplicates. ***p < 0.001; ns, not significant.
(E) Isotopologues of HMG-CoA upon 6-hr labeling in 10 mM [U-13C]glucose (100 M unlabeled
acetate present) in Aclyf/f and PC9 MEFs; error bars indicate mean ± SD of triplicates.
(F) Isotopologues of HMG-CoA upon 6-hr labeling in 100 M [1,2-13C]acetate (10 mM unlabeled
glucose present) in Aclyf/f and PC9 MEFs; error bars indicate mean ± SD of triplicates.
(G) Total HMG-CoA quantitation in cells cultured in DMEM + 10% dFBS + 10 mM glucose + 100
M sodium acetate (unlabeled); error bars indicate mean ± SEM of triplicates. n.s., not significant.
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Figure 2.4 | ACLY Is Required for Sustaining Histone Acetylation Levels,
despite ACSS2 Compensation
(A) Western blot of acetylated histones extracted from Aclyf/f, PC9, PC9-ACLY-WT, and PC9ACLY-H760A MEFs cultured in complete medium (DMEM + 10% CS), dFBS medium (DMEM +
10% dFBS), +100 M acetate medium (DMEM + 10% dFBS + 100 M sodium acetate), and +1
mM acetate medium (DMEM + 10% dFBS + 1 mM sodium acetate) for 48 hr.
(B–D) Fractions of histone H3-K14, -K18, and -K23 acetylation (m+2) derived from 10 mM [U13C]glucose, with unlabeled 100 M acetate present (B); 100 M [1,2-13C]acetate, with 10 mM
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unlabeled glucose present (C); or 1 mM [1,2-13C]acetate, with 10 mM unlabeled glucose present
(D); error bars indicate mean ± SEM of triplicate samples. Labeling was for 24 hr (see also Figure
S2.3B for experimental design).
(E–G) Overall percentage of H3K23 acetylated in each cell line (y axis), as well as the relative
fraction of this acetylation incorporated from a labeled source (red): 10 mM [U-13C]glucose (E),
100 M [1,2-13C]acetate (F), and 1 mM [1,2-13C]acetate (G) or unlabeled sources (black); error
bars indicate mean ± SEM of triplicate samples. The same dataset is represented in parts (B–D)
and (E–G).
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Figure 2.5 | Acetyl-CoA Pools Are Sustained by Acetate in the Absence of
ACLY
(A) Relative whole-cell acetyl-CoA levels in Aclyf/f and PC9 MEFs cultured in glucose-free DMEM
+ 10% dFBS + 10 mM glucose + 100 M sodium acetate for 6 hr, normalized to cellular volume;
error bars indicate mean ± SD of triplicates.
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(B) Schematic of acetyl-CoA production from glucose and acetate with (top) or without (bottom)
ACLY.
(C) Isotopologue distribution of citrate after 6-hr incubation with 10 mM [U-13C]glucose, with 100
M unlabeled acetate present (black) or 100 M [1,2-13C]acetate with 10 mM unlabeled glucose
present (red), in Aclyf/f (top) or PC9 (bottom) MEFs; error bars indicate mean ± SEM of triplicates.
(D) Isotopologue distribution of malate in the same conditions as (C).
(E–G) m+2 acetyl-CoA (E), malonyl-CoA (F), or succinyl-CoA (G) following 6-hr labeling in 10 mM
[U-13C]glucose (with 100 M unlabeled acetate present) or 100 M [1,2-13C]acetate (with 10 mM
unlabeled glucose present); error bars indicate mean ± SEM of triplicates. For (E–G), all
statistical comparisons are to Aclyf/f using Holm-Sidak test. For all panels: *p < 0.05; **p < 0.01;
***p < 0.001.
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Figure 2.6 | ACSS2 Is Upregulated In Vivo upon Deletion of Acly from
Adipocytes
(A) Western blot of liver, SWAT, and VWAT from Aclyf/f and AclyFAT-/- mice.
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(B) mRNA expression of Acly and Acss2 in SWAT (left) and VWAT (right) from Aclyf/f and
AclyFAT-/- mice; error bars indicate mean ± SEM.
(C) Representative SWAT and VWAT histology from male 16-week-old Aclyf/f and AclyFAT-/- mice.
Scale bars, 100 m.
(D) Body weight of male Aclyf/f (n = 9) and AclyFAT-/- (n = 8) mice; error bars indicate mean ± SD.
(E) Expression of adipocyte genes in SWAT (left) and VWAT (right) from Aclyf/f (n = 8) and
AclyFAT-/- (n = 7) mice; error bars indicate mean ± SEM. For all panels: *p < 0.05; **p < 0.01.
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Figure 2.7 | ACLY-Deficient Adipose Tissue Exhibits Depot-Specific
Alterations in DNL and Histone Acetylation
(A) Acetyl-CoA abundance in SWAT, VWAT, and liver in 11-week-old Aclyf/f (n = 6) and AclyFAT-/(n = 7) mice.
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(B–D) Primary mature adipocytes were isolated from 12- to 16-week-old Aclyf/f (n = 5) and
AclyFAT-/- (n = 3) mice and labeled with 100 M [1,2-13C]acetate (with 5 mM unlabeled glucose
present). Acetyl-CoA (B), malonyl-CoA (C), and HMG-CoA (D) enrichment from acetate was
analyzed; error bars indicate mean ± SEM.
(E–G) Relative quantities of fatty acids synthesized de novo in SWAT (E), VWAT (F), and liver
(G) of Aclyf/f (n = 6) and AclyFAT-/- (n = 8) mice; error bars indicate mean ± SEM. The # sign
indicates not synthesized de novo.
(H–J) Overall histone H3 acetylation levels in 11-week-old SWAT (H), VWAT (I), and liver (J) of
Aclyf/f (n = 6) and AclyFAT-/- (n = 7) mice; error bars indicate mean ± SEM.
For all panels: *p < 0.05; **p < 0.01.
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Figure S2.1 | Deletion of Acly from mouse embryonic fibroblasts, related to
Fig. 2.1.
(A) Diagram of Acly locus in Aclyf/f mice, loxP sites flanking exon 9 are depicted.
(B) Western blot of ACLY and ACSS2 expression in Aclyf/f MEFs, +/- Cre treatment at the time of
initial deletion and one month later.
(C) Proliferation curve of Aclyf/f MEFs with or without Cre treatment over 6 days, mean +/- SEM of
triplicate wells.
(D) Western blot of ACLY and ACSS2 expression in Aclyf/f MEFs and PC7 and PC9 knockout
lines that have been reconstituted with wild type ACLY (+ACLY-WT) or catalytically dead ACLY
(+ACLY-H760A).
(E) Proliferation curve of Aclyf/f MEF and PC7 lines compared to PC7 with reconstituted ACLYWT or ACLY-H760A over 5 days, mean +/- SEM of triplicate wells, statistical significance
compared to PC7.
For all panels: **, p<0.01.
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Figure S2.2 | Acetate sustains viability in the absence of ACLY, related to
Fig. 2.2.
(A) NMR spectrum of undiluted calf serum.
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(B) Western blot verification of Acss2 knockout using CRISPR-Cas9 gene editing in Aclyf/f MEFs.
(C) Proliferation curve over 5 days of three ACSS2-deficient clonal cell lines as compared to
Aclyf/f MEFs, mean +/- SEM of triplicate wells.
(D) Representative images of Aclyf/f MEFs and sgAcss2 6.2 Aclyf/f MEFs, treated twice with
adenoviral Cre-recombinase at 4x zoom (left panels, bar represents 1000 µm) and 10x zoom
(right panels, bar represents 400 µm).
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Figure S2.3 | ACLY is required for sustaining histone acetylation levels,
related to Fig. 2.4.
(A) Histone acetylation in acid-extracted histones from Aclyf/f and PC9 MEFs cultured for 24 hours
in glucose-free DMEM supplemented with 10% dFBS and the indicated glucose concentrations.
(B) Experimental design of heavy isotope labeling of histone acetylation using 10 mM [U13C]glucose with 100 µM unlabeled acetate present (left), 100 µM [1,2-13C]acetate with 10 mM
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unlabeled glucose present (center), and 1 mM [1,2-13C]acetate with 10 mM unlabeled glucose
present (right).
(C-E) Percent of total acetylation of H3K14 (left) and H3K18 (right) from labeled (red) and
unlabeled (black) sources after labeling with 10 mM [U-13C]glucose (C), 100 µM [1,2-13C]acetate
(D), or 1 mM [1,2-13C]acetate (E), mean +/- SEM of triplicate samples.
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Figure S2.4 | Acetate regulates histone acetylation and gene expression in
ACLY-deficient glioblastoma cells, related to Fig. 2.4.
(A) Histone acetylation in acid-extracted histones from LN229 parental and ACLY KO clones
cultured for 24 hours in glucose-free RPMI + 10% dFBS + 1 or 10 mM glucose + 2 mM glutamine
+ 0, 0.1, or 1 mM acetate.
(B) Relative expression of E2F2, MCM10, and SKP2 in LN229 parental and ACLY KO clones
after 24 hours cultured in the same conditions as in panel A.
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(C) Cell number after 48 hours of culture in indicated conditions.
(D) Relative whole cell acetyl-CoA levels in LN229 parental and ACLY KO clones cultured in
glucose-free RPMI + 10% dFBS + 10 mM glucose + 100 µM acetate + 2 mM glutamine for 6
hours, normalized to cellular volume, mean +/- SEM of triplicate samples.
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Figure S2.5 | Acetate contributes minimally to mitochondrial metabolism in
the absence of ACLY, related to Figure 2.5.
(A,B) Isotopologue distribution of citrate (A) and malate (B) upon 24 hours labeling in 10 mM [U13C]glucose or 100 µM [1,2-13C]acetate in Aclyf/f (top) and PC9 (bottom) MEFs, mean +/- SEM of
triplicate samples.
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Figure S2.6 | Tissue fatty acid levels and enrichment after D2O labeling of
Aclyf/f and AclyFAT-/- mice, related to Fig. 2.7.
(A) Plasma D2O enrichment.
(B-D) Abundance of fatty acids in SWAT (B), VWAT (C), and liver (D).
(E-G) Fractions of fatty acids synthesized de novo present in SWAT (E), VWAT (F), and liver (G).
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CHAPTER 3: Dietary fructose feeds hepatic lipogenesis via
microbiome-derived acetate independent of citrate shuttling.
Abstract
Fructose consumption has risen dramatically in recent decades due to the use of sucrose
and high fructose corn syrup in beverages and processed foods238, contributing to rising
rates of obesity and non-alcoholic fatty liver disease (NAFLD)309–311. Fructose intake
triggers hepatic de novo lipogenesis (DNL)229,311,312, a multistep process that utilizes
acetyl-CoA as a substrate. ATP-citrate lyase (ACLY), the enzyme that cleaves cytosolic
citrate to generate acetyl-CoA, is potently upregulated upon carbohydrate consumption250.
Ongoing clinical trials are pursuing ACLY inhibition for treatment of metabolic diseases313.
The route from dietary fructose to hepatic acetyl-CoA and lipids, however, remains
unproven. Here we show that liver-specific Acly knockout (LAKO) mice are, unexpectedly,
not protected from fructose-induced DNL or fatty liver. In vivo isotope tracer studies using
13

C-fructose gavage show that fructose-derived carbons are used for DNL even in the

absence of ACLY. Dietary fructose is converted by the gut microbiome into acetate 314,
which supplies lipogenic acetyl-CoA independently of ACLY264. Depletion of the
microbiome or silencing of hepatic ACSS2, which generates acetyl-CoA from acetate,
potently suppresses fructose conversion into hepatic acetyl-CoA and fatty acids. Thus,
bolus fructose feeds hepatic acetyl-CoA pools indirectly via acetate, bypassing ACLY.
When fructose is consumed more gradually via drinking water to facilitate its absorption in
the small intestine, both ACLY and microbial acetate production contribute to lipogenesis.
The DNL transcriptional program, on the other hand, is induced in response to fructose
consumption in a manner that is both ACLY- and microbiome-independent, consistent with
a direct role for hepatic fructolysis in activating the carbohydrate-response element110

binding protein (ChREBP). These data reveal a two-pronged mechanism regulating
hepatic DNL, in which fructolysis within hepatocytes provides a signal to promote DNL,
while fructose metabolism by the gut microbiota provides the substrate to feed DNL.

Main Text
Since ACLY links carbohydrate and lipid metabolism (Fig. 3.1a), we hypothesized that
genetic deletion of Acly in hepatocytes would protect mice against fructose-induced lipid
accumulation. While whole body Acly knockout is embryonic lethal5, liver-specific Acly
knockout (LAKO) mice were grossly indistinguishable from wild-type (WT) littermate
controls, with similar body weights and organ sizes between genotypes when fed either
standard chow or a high-fructose (60%) diet (HFrD) (Extended Data Fig. 3.1a-b). Fructose
consumption triggered mild hepatic lipid accumulation in both WT and LAKO mice (Fig.
3.1b, Extended Data Fig. 3.1d). Neither fibrosis nor excess glycogen accumulation were
observed (Extended Data Fig. 3.1c), consistent with prior observations315. ACLY protein
was not detected within hepatocytes in LAKO livers (Extended Data Fig. 3.1e).
Metabolomic and lipidomic analyses revealed striking diet-dependent changes, and
relatively modest genotype-dependent differences (Extended Data Fig. 3.2a-b, 3.3a-c).
Consistent with loss of ACLY activity, LAKO-specific accumulation of citrate and its
downstream metabolite aconitate was observed (Extended Data Fig. 3.2c). Together,
these data demonstrate that ACLY deficiency neither dramatically impacts global hepatic
metabolite levels nor prevents fructose-induced accumulation of triglyceride.
To more specifically investigate the role of hepatic ACLY in fructose-induced steatosis
without altering the overall diet, we fed mice standard chow diets with either normal
drinking water (H2O) or drinking water containing a 1:1 mixture of fructose and glucose
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(15% each, Fruc:Gluc) (Extended Data Fig. 3.4a-c). Similar to HFrD, mice drinking
Fruc:Gluc for 4 weeks developed mild hepatic steatosis regardless of ACLY expression
(Extended Data Fig. 3.4d). Moreover, deuterated water (D2O) tracing revealed that
Fruc:Gluc consumption increases hepatic DNL to a similar extent in WT and LAKO mice
(Fig. 3.1c). Thus, deletion of Acly from liver does not prevent induction of DNL in response
to fructose consumption.
Given the unexpected result that hepatic ACLY is dispensable for fructose-induced DNL
(Fig. 3.1c), we directly tested the impact of ACLY deficiency on fructose conversion into
nascent fatty acids. WT and LAKO mice were gavaged with 1:1 fructose:glucose, with
either glucose or fructose

13

C-labeled (Fig. 3.1d). Strikingly, fructose carbons were

incorporated into fatty acids in LAKO and WT mice to a similar extent, while glucose
carbons were barely used (Fig. 3.1e, Extended Data Fig. 3.5a). These data indicate that,
in contrast with existing models of fructose metabolism, the use of fructose carbons for
hepatic DNL does not require ACLY.
We next investigated the mechanisms of how fructose carbons are used for fatty acid
synthesis in an ACLY-independent manner. It has been previously shown that the hepatic
DNL program is activated in response to carbohydrate consumption by ChREBP316,317.
Upon chronic high fructose consumption, livers of both WT and LAKO mice upregulated
the highly active ChREBP- isoform285, along with lipogenic genes (Acaca and Fasn) and
other ChREBP target genes, aldolase B (AldoB), and ketohexokinase (Khk)318 (Fig. 3.1f,
Extended Data Fig. 3.6a). WT mice also exhibited upregulation of Acly on HFrD (Fig. 3.1f).
The induction of the DNL program was also robust at the protein level (Fig. 3.1g, Extended
Data Fig. 3.6b). Acyl-CoA synthetase short chain family member 2 (ACSS2), which
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converts acetate into acetyl-CoA, was notably upregulated in fructose-consuming LAKO
mice (Fig. 3.1g, Extended Data Fig. 3.6a-b). Moreover, the Acss2 genomic locus showed
increased histone H3K27 acetylation, as well as ChREBP binding, after Fruc:Gluc
drinking, concurrent with induction of DNL transcriptional program (Extended Data Fig.
3.6c-e). We also confirmed ChREBP binding to the Acss2 locus in a published ChREBP
ChIP-Seq study dataset319 (Extended Data Fig. 3.6f). Acss2 is also a known target of
SREBP transcription factors, which are also activated in response to fructose
consumption9,320,321. These data suggest that Acss2 is component of the hepatic response
to fructose consumption.
Since acetate conversion to acetyl-CoA by ACSS2 can support de novo lipogenesis in the
absence of ACLY264, we hypothesized that acetate might be an important source of acetylCoA for hepatic DNL in the context of fructose feeding (Fig. 3.2a). Acetate can be
generated within mammalian cells through several mechanisms, including acetyl-CoA
hydrolysis, histone deacetylation, and pyruvate to acetate conversion322–324, prompting us
to investigate whether fructose is converted to acetate in a cell autonomous manner in
hepatocytes. In primary hepatocytes, high concentrations of glucose induce the DNL gene
program325. Incubation of wild-type murine hepatocytes with 25 mM 13C-fructose resulted
in considerable labeling of fructolytic intermediates (Fig. 3.2b). Surprisingly, however, 13Cfructose minimally labeled acetyl-CoA and malonyl-CoA, the core DNL substrates, in WT
hepatocytes (Fig. 3.2c). In contrast,

13

C-acetate, even at a much lower concentration,

labeled acetyl-CoA and malonyl-CoA, as well as HMG-CoA, an intermediate in the
mevalonate pathway downstream of acetyl-CoA (Fig. 3.2c). Therefore, even when ACLY
is intact, fructose catabolism may be uncoupled from DNL in primary hepatocytes, while
exogenous acetate can directly feed into lipogenic acetyl-CoA pools.
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These findings suggested the possibility that fructose may be converted to acetate by a
different cell type prior to reaching the liver, in order to feed hepatic DNL. To test this
possibility in vivo, we performed a

13

C-fructose tracing time course in mice. Orally

administered 13C-fructose quickly labeled fructose-1-phosphate (F1P) and pyruvate in the
liver with peaks between 15-30 min, indicative of rapid hepatic fructolysis (Fig. 3.2d).
Hepatic acetyl-CoA labeling was, however, much slower (peaking at 60-90 min) (Fig.
3.2d). The slower kinetic of acetyl-CoA labeling was closely aligned with the appearance
of labeled acetate in the portal circulation (Fig. 3.2d). Labeling of hepatic fatty acids follows
that of acetyl-CoA (peaking at 120-180 min) (Fig. 3.2d). These data suggest that fructose
may primarily feed hepatic acetyl-CoA and fatty acid production indirectly via acetate
generated from fructose.
We next sought to determine the source of fructose-derived acetate. While fructose is
mainly taken up by the small intestine, unabsorbed fructose reaches the colon where the
microbiome converts fructose into short chain fatty acids (SCFAs), including acetate314.
To test if the microbiome is important for hepatic DNL, we depleted it with an antibiotic
cocktail (Extended Data Fig. 3.7a-c, 3.8b). Antibiotic treatment did not suppress the levels
of labeled fructose and glucose in the portal vein following an oral administration of

13

C-

fructose (Extended Data Fig. 3.7d-e), indicative of intact small intestine fructose
absorption and metabolism. The induction of hepatic DNL genes following fructose
consumption

is

thought

to

be

dependent

on

fructolytic

and/or

glycolytic

intermediates316,326, and silencing of hepatic Khk suppresses fructose-induced
upregulation of DNL gene expression321. Consistent with normal passage of fructose from
the intestine to the liver, DNL gene expression upon fructose consumption remained intact
after antibiotic treatment (Extended Data Fig. 3.7f), as did labeling of F1P, pyruvate and
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citrate in the liver (Fig. 3.3a). In contrast, microbiome depletion dramatically reduced the
labeling of hepatic acetyl-CoA and palmitate, as well as fatty acids within circulating lipids,
from 13C-fructose (Fig. 3.3a,b, Extended Data Fig. 3.8a). This reduction was well matched
with depleted portal and cecal labeling of acetate, as well as other short-chain fatty acids
(Fig. 3.3a, Extended Data Fig. 3.7g-h). Antibiotic treatment also reduced total hepatic
triglycerides (Fig. 3.3c), which is consistent with prior observations240,327. Thus, depletion
of the microbiome suppresses hepatic DNL from

13

C-fructose, without impairing small

intestine or hepatic fructose metabolism or induction of DNL gene expression.
We next aimed to determine if acetate is a key microbial product supporting DNL. To
assess whether fructose intake led to an appreciable increase in portal acetate
concentrations, we measured acetate in portal and systemic blood after gavage. Portal
vein acetate concentrations increased approximately twofold over baseline (to > 1 mM) at
60-90 minutes after fructose gavage (Fig. 3.3d), corresponding with acetate labeling from
fructose (Fig. 3.2d). Strikingly, the rise in portal acetate was absent in antibiotic treated
animals (Fig. 3.3d). Acetate concentrations in systemic circulation were lower than that in
the portal vein and did not markedly fluctuate after fructose consumption, suggesting that
fructose-derived acetate is primarily cleared by the liver (Fig. 3.3d). Next, to assess
whether acetate supports DNL downstream of microbial metabolism, mice were gavaged
with 13C-acetate, along with 1:1 fructose:glucose. This showed that DNL from 13C-acetate,
in contrast to that from

13

C-fructose, is not impacted by antibiotic treatment (Fig. 3.3e).

Finally, to test if hepatic ACSS2 is required for fructose to feed DNL, ACSS2 in the liver
was silenced using an adeno-associated viral hairpin targeting Acss2328 (Extended Data
Fig. 3.8c-e). Depletion of hepatic ACSS2 strongly suppressed the labeling of circulating
lipids from

13

C-fructose (Fig. 3.3f). Altogether, these data point to a two-pronged
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mechanism of fructose-dependent DNL, with cell autonomous effects of fructose and/or
glucose in stimulating the hepatic DNL transcriptional program, but microbiomedependent acetate production serving as the major source of fructose-derived acetyl-CoA
for lipogenesis, via hepatic ACSS2, after consumption of a fructose bolus (Extended Data
Fig. 3.10a).
Microbiome-dependent acetate production from fructose occurs when rate of ingestion
exceeds small intestinal uptake capacity314. Thus, if fructose is consumed gradually, its
contribution to DNL might occur to a greater extent via ACLY, and to a lesser extent via
microbial acetate production. Still, upon providing Fruc:Gluc in the drinking water, DNL
was comparably stimulated in the presence or absence of ACLY (Fig. 3.1c). To explore
this further, mice were given 13C-labeled fructose or glucose in drinking water for 24 hours
(Fig. 3.4a). Fructose-derived carbons provided a substantial contribution to hepatic lipid
pools, with greater than 20% of total liver fatty acid carbons being labeled from
fructose after 24 hours of Fruc:Gluc drinking, while

13

C-

13

C-glucose contributed less (Fig.

3.4b). In this context of more gradual fructose intake, ACLY deficiency suppressed

13

C-

fructose and -glucose contribution to hepatic fatty acids (Fig. 3.4b). Nevertheless, total
DNL as measured by D2O labeling was not different between WT and LAKO mice (Fig.
3.4c), indicating sufficient availability of other two-carbon unit donors. One possibility is
assimilation of acetate from other sources (e.g. fiber fermentation). To test utilization
acetate for lipogenesis, we supplemented Fruc:Gluc drinking water with 13C-acetate upon
initial exposure (naïve) as well as after 2 weeks of Fruc:Gluc water (conditioned)
(Extended Data Fig. 3.9a). Fatty acid labeling from

13

C-acetate was higher in LAKO mice

at baseline (Fig. 3.4d). After fructose conditioning, acetate contribution to DNL increased
in WT animals, and this was further enhanced in LAKO mice (Fig. 3.4d), consistent with
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increased hepatic ACSS2 expression in LAKO mice following fructose feeding, which
preceded the onset of steatosis (Extended Data Fig. 3.9b-c). We next assessed the
contribution of microbiome-derived acetate from all dietary sources in the context of
sweetened water consumption. Antibiotic treatment suppressed total hepatic DNL in
LAKO mice (Fig. 3.4e, Extended Data Fig. 3.9d). ChREBP and DNL gene expression
were confirmed to be upregulated by Fruc:Gluc drinking in all groups (Fig. 3.4f). Finally,
we examined DNL in Fruc:Gluc-drinking mice following silencing of hepatic ACSS2,
finding that in the context of gradual fructose consumption via drinking water, loss of both
ACLY and ACSS2 is necessary to suppress DNL (Fig. 3.4g). These data indicate that
when fructose is consumed gradually to reduce its passage into the colon, the rate of DNL
is established by signaling mechanisms (i.e., sugar-driven ChREBP activation), and DNL
is suppressed only when acetyl-CoA production by both ACLY and ACSS2 is inhibited
(Extended Data Fig. 3.10b).
In this study, we demonstrate that bolus fructose consumption triggers hepatic DNL
independent of ACLY but dependent on fructose metabolism by gut microbiota. We found
that fructose feeds hepatic fatty acid synthesis through its microbial metabolism to acetate,
which reaches the liver via the portal vein. The induction of the DNL transcriptional
program in the liver, on the other hand, appears to be independent of both ACLY and the
microbiome, consistent with the notion that proximal fructolytic and/or glycolytic
metabolites are important for ChREBP activation. When consumed more gradually,
fructose can feed DNL in an ACLY-dependent manner. However, acetate from other
sources is also readily available to the liver, rendering ACLY dispensable for DNL even
when fructose is gradually consumed. The data also suggest that diet and microbiome
could potentially impact the efficacy of ACLY inhibitors, currently in clinical trials for
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hypercholesterolemia329. Prior studies using RNAi to silence hepatic ACLY have reported
that ACLY deficiency decreases hepatic lipid in db/db mice, but increases hepatic lipid in
mice fed a high fat diet251,330. In our own data, principal component analysis of hepatic
triglycerides separated LAKO mice from WT mice on HFrD but not on chow (Extended
Data Fig. 3.3c), supportive of the notion that ACLY may play distinct roles depending on
diet. Thus, further study of the impact of ACLY deficiency in different nutritional contexts
will be important to understand its physiological roles and to optimally leverage ACLY
inhibitors for the treatment of metabolic diseases.
Although hepatic fructose metabolism does not appear to directly supply substantial
amounts of lipogenic acetyl-CoA, fructolysis and/or glycolysis in hepatocytes remain
important for DNL induction at least in part to activate the DNL transcriptional program
(Extended Data Fig. 7f). This likely explains why KHK knockout mice are protected from
fructose-induced fatty liver331,332.

Thus, we propose a revised model of fructose-

dependent DNL induction, in which hepatic fructose metabolism provides a signal to
transcriptionally promote DNL while microbial fructose metabolism provides acetate to
feed DNL (Extended Data Fig. 10a). These dual mechanisms may also explain higher
lipogenic potential of fructose as compared to glucose333, at least in the context of high
dose sugar consumption, in that the small intestine rapidly absorbs even large loads of
glucose, whereas fructose spills over to the gut microbiome to generate acetate314. The
data also indicate that fructose-dependent activation of the DNL transcriptional program
can trigger enhanced DNL from other acetate sources (Extended Data Fig. 10b). Thus, it
will be important in the future to define how fructose interacts with other dietary sources
of acetate, such as ethanol and fermentable fibers. NAFLD currently afflicts ~30% of the
United States population and can be a precursor to non-alcoholic steatohepatitis and
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hepatocellular carcinoma334. Understanding the fundamental pathways involved in hepatic
DNL is important for the development of new therapeutic interventions for metabolic
diseases. The current data elucidate a previously unappreciated interplay between diet,
the gut microbiome, and host organ metabolism that contributes to fructose-induced
NAFLD.

Methods
Generation of Liver-specific ACLY Knockout (LAKO) mice:
Generation of Aclyf/f mice on a C57Bl6/J background was previously described264. To
generate hepatocyte-specific Acly knockouts, Aclyf/f mice were crossed to albumin-Cre
transgenic mice (B6.Cg-Tg(Alb-Cre)21Mgn/J, Jackson Laboratory)335.

Genoptying:
Genotyping of the recombined Acly allele was confirmed as previously described264.
Genotyping of the Albumin-Cre allele was confirmed with the following primer
sequences: AlbCre-5’F (CCTGCCAGCATGGATATAA), AlbCre-3’R
(GTTGTCCTTTGTGCTGCTGA), Alb-TSP3 (GAAGCAGAAGCTTAGGAAGATGG), and
the following cycling conditions: 1 cycle - 94o x 5 min. 35 cycles - 94o x 45 sec., 58o x 45
sec., 72o x 1 min. 1 cycle - 72o x 10 min, hold at 4oC.

Animal studies:
All animal protocols in this study were approved by the University of Pennsylvania's
Institutional Animal Care and Use Committee (IACUC) and Princeton University's
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IACUC. For diet studies, 4-week-old male mice were placed on either a regular chow
diet (Lab Diet 5010) or a high-fructose chow diet (Teklad TD.89247) for indicated lengths
of time. Weights of mice kept on each diet were taken weekly. For drinking water
studies, mice were provided with regular tap water (filtered through a 0.22 µm filter) or a
15% (w/v) fructose:15% (w/v) glucose (Sigma F3510, G8270) in tap water (filtered
through a 0.22 µm filter). To deplete the gut microbiome, mice were given a daily 10
µL/g body weight oral gavage consisting of 1 mg/mL ampicillin, 1 mg/mL gentamicin, 0.5
mg/mL vancomycin, 1 mg/mL neomycin, 1 mg/ml metronidazole in a 0.9% NaCl solution
for 7-10 days. Studies were controlled to mice given the same 0.9% NaCl solution
without antibiotics. To knockdown Acss2, 6-8 week-old male mice were injected via tail
vein with 2.0 x 1011 GC/mouse AAV8.U6.shAcss2.CMV.eGFP.SV40 (University of
Pennsylvania Vector Core) or AAV8.CMV.PI.eGFP.WPRE.bGH (Addgene) as control;
experiments were performed 1 week after injection.

Histology:
For H&E, Periodic Acid Shiff, Trichrome staining: tissues were fixed in formalin
overnight, dehydrated by titrating in ethanol (50%, 75%, 95%), and submitted to the
Molecular Pathology and Imaging Core at the University of Pennsylvania for paraffin
embedding, sectioning, and staining. For Oil Red O staining: tissues were fixed in
formalin overnight, dehydrated by titrating in sucrose (10%, 20%, 30%), and embedded
in Richard-Allan Scientific NEG-50 frozen section medium (ThermoFisher Scientific
6502) by freezing in 2-methylbutane that was cooled using dry ice. Tissues frozen in
NEG-50 were submitted to the Molecular Pathology and Imaging Core at the University
of Pennsylvania for cryosectioning and staining. Images were acquired on a Keyence
BZ-X710 microscope.
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Bacterial quantification:
Cecal contents were collected, snap frozen, and weighed before storage in -80C until
use. DNA was extracted from cecal contents using a Fecal DNA extraction kit (IBI
scientific IB47821) according to manufacturer instructions. Samples were diluted 1:1000
prior to use for RT-PCR. To establish a bacterial DNA standard, genomic DNA was
extracted from Stbl3 E. coli cells. A standard curve was generated using a 1:4 serial
dilution starting with 10 ng of E. coli DNA. RT-PCR was performed as described, using
previously published universal 16s primers (Forward: TCCTACGGGAGGCAGCAGT,
Reverse: GGACTACCAGGGTATCTAATCCTGTT)336. Relative bacterial load was
calculated by normalizing DNA content to initial cecal content weight.

Immunoblotting:
Protein extraction from tissue was performed by re-suspending frozen tissue in 0.5 mL of
RIPA buffer (1% NP-40, 0.5% Deoxycholate, 0.1% SDS, 150 mM NaCl, 50 mM Tris plus
protease and phosphatase inhibitors), and lysed using a tissue lyser (Qiagen) twice for
30 seconds at 20 Hz. Following lysis, samples were incubated on ice for 10 minutes,
then spun down at 15,000 RCF for 5 minutes in 4oC. Supernatant was collected and
stored in -80oC until immunoblotting. Antibodies used in this study: ATP-Citrate Lyase
(Proteintech 15421-1-AP), Acyl-CoA Synthetase Family Member 2 (Cell Signaling
Technology 3658S), Acetyl-CoA Carboxylase (Cell Signaling Technology 3676S), Fatty
Acid Synthase (Cell Signaling Technology 3189S), Catalase (Cell Signaling Technology
14097S), Ribosomal Protein S6 (Cell Signaling Technology 2217S), IRDye800CW Goat
Anti-Rabbit (LI-COR 926-32211). Immunoblots were developed using a LI-COR
Odyssey Clx.
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Quantitative RT-PCR:
RNA extraction from tissue was performed by re-suspending frozen tissue in 1 mL Trizol
(Life Technologies), and lysed using a tissue lyser (Qiagen) for 60 seconds at 30 Hz,
followed by manufacturer protocol for Trizol RNA extraction. cDNA was synthesized
using high-capacity RNA-to-cDNA master mix (Applied Biosystems 4368814), as per the
kit instructions. cDNA was diluted 1:20 and amplified using PowerUp SYBR Green
Master Mix (Applied Biosystems A25778) on the ViiA-7 Real-Time PCR system. Fold
change in expression was calculated using ΔCt, with 18S reference gene as an
endogenous control. Primer sequences for RT-qPCR are: Aldob (Forward:
GAAACCGCCTGCAAAGGATAA, Reverse: GAGGGTCTCGTGGAAAAGGAT), Khk
(Forward: ATGTGGTGGACAAATACCCAGA, Reverse:
CAAGCAAGGAAAGGACAGTGC), Acly (Forward: TTCGTCAAACAGCACTTCC,
Reverse: ATTTGGCTTCTTGGAGGTG), Acss2 (Forward:
GCTTCTTTCCCATTCTTCGGT, Reverse: CCCGGACTCATTCAGGATTG), Chrebpα
(Forward: CGACACTCACCCACCTCTTC, Reverse: TTGTTCAGCCGGATCTTGTC),
Chrebpβ (Forward: TCTGCAGATCGCGTGGAG, Reverse:
CTTGTCCCGGCATAGCAAC), Fasn (Forward: ATTGGTGGTGTGGACATGGTC,
Reverse: CCCAGCCTTCCATCTCCTG), Acc1 (Forward:
ACAGTGGAGCTAGAATTGGAC, Reverse: ACTTCCCGACCAAGGACTTTG).

Measurement of de novo lipogenesis using isotope tracers:
To assess total lipogenesis, mice were provided with 50% (v/v) deuterated water (Sigma
151882) mixed into 15% fructose:15% glucose drinking water for 24 hours. Systemic
blood was collected by cardiac puncture, allowed to coagulate on ice for 10 minutes, and
spun down at 15,000 x RCF for 10 minutes at 4oC to collect serum. To account for
differences in drinking water consumption, calculated deuterium enrichment labeling in
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serum water was used to normalize labeling into fatty acids. To assess lipogenesis from
dietary carbohydrates, on day of experiment, mice were weighed and fasted from 10
a.m. until 3 p.m., when they were given an oral gavage consisting of a 1:1 mixture of
glucose and fructose in a 0.9% NaCl saline. Doses used in this study ranged from
1.0g/kg of each sugar to 2.0g/kg of each hexose. [U-13C]-glucose (CLM-1396-1) or [U13

C]-fructose (CLM-1553-1) were provided with the corresponding unlabeled hexose. Six

hours following gavage, systemic blood was collected by tail bleeding the mice and
incubating the blood on ice for 15 minutes before spinning down at 15,000 x RCF for 10
minutes at 4oC to collect serum. Tissues were collected using a clamp pre-cooled with
liquid nitrogen. The frozen liver samples were ground at liquid nitrogen temperature with
a Cryomill (Retsch, Newtown, PA). Saponification of lipids and LC-MS analysis were
performed as previously described337. Briefly, serum (20 µL) or tissue powder (10 mg)
was incubated with 1 mL of 0.3 M KOH in 90% methanol at 80°C for 1 hour in a 2 mL
glass vial. Formic acid (0.1 mL) was then added for neutralization. The saponified fatty
acids were extracted by adding 0.5 mL of hexane, vortexing, and transferring the top
hexane layer to a new glass vial. Samples were then dried under a stream of N2 and
dissolved in 1 mL of isopropanol:methanol (1:1, v/v) solution for LC-MS analysis.
Separation was performed by reversed-phase ion-pairing chromatography on a C8
column coupled to negative-ion mode, full-scan LC-MS at 1-Hz scan time and 100,000
resolving power (stand-alone orbitrap; Thermo Fischer Scientific). Data analysis with
MAVEN software and natural isotope correction were performed as previously
described338.
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Primary Hepatocyte Isolation:
Hepatocytes were isolated using a two-step collagenase/DNAse digestion protocol339
and plated in M199 media containing 5 mM glucose, 10% FBS, 500 nM dexamethasone
and 1 nM insulin. Following attachment, cells were changed to M199 media containing 5
mM glucose, 500 nM dexamethasone and incubated overnight. Cells were switched to
M199 containing 5 mM glucose, 10% FBS, 500 nM dexamethasone, 100 nM insulin and
respective fructose and acetate supplementation for 6 hours on day of experiment.

Acyl-CoA measurements in primary hepatocytes:
Acyl-CoA measurements in primary hepatocytes were performed by liquid
chromatograpy-mass spectrometry/high-resolution mass spectrometry (LC-MS/HRMS)
as previously described292. Briefly, primary hepatocytes were isolated and cultured as
described above in 6-well plates. At harvest, culture media was completely aspirated
before harvesting cells in 0.5 mL ice-cold 10% trichloroacetic acid/well of a 6-well dish
using a cell lifter. Samples were then sonicated for 10 x 0.5 second pulses to completely
disrupt cellular membranes, and incubated on ice to precipitate proteins. Protein was
pelleted at 16,000 x RCF for 10 minutes at 4oC. Supernatant was collected and purified
by solid-phase extraction using Oasis HLB 1cc (30 mg) SPE columns (Waters). Eluate
was evaporated to dryness under nitrogen gas and re-suspended in 50 µL of 5% 5sulfosalicylic acid (w/v) for injection. Samples were analyzed by an Ultimate 3000
autosampler coupled to a Thermo Q-Exactive Plus instrument in positive electrospray
ionization (ESI) mode. For isotopic tracer analysis, isotopic enrichment from [U-13C]fructose (Cambridge Isotope Laboratories, CLM-1553) or [U-13C]-acetate (Cambridge
Isotope Laboratories, CLM-440-1) was calculated to compensate for the non-linearity of
isotopic enrichment using the FluxFix calculator340.
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Fructolyic measurements in primary hepatocytes:
For fructolytic intermediate measurements in primary hepatocytes, culture media was
completely aspirated before harvesting cells in 0.5 mL of cold 80:20 methanol:water/well
of a 6-well dish using a cell lifter. Samples were then sonicated for 10 x 0.5 second
pulses to completel disrupt cellular membranes, and incubated on ice. Samples were
then spun down at 16,000 x RCF for 10 minutes at 4oC. Supernatant was collected and
dried under nitrogen gas flow in preparation for water-soluble metabolomic analysis.

Chromatin Immunoprecipitation (ChIP) – PCR:
For H3K27ac-ChIP qPCR studies, male mice were provided with Fruc:Gluc drinking
water for 24 hours, and orally gavaged with 2.0 g/kg fructose + 2.0 g/kg glucose 1 hour
prior to sacrifice. For ChREBP-ChIP qPCR studies, female mice were provided with
Fruc:Gluc drinking water for 24 hours, and orally gavaged with 3.0 g/kg fructose + 3.0
g/kg glucose 1 hour prior to sacrifice. ChIP was performed as previously described341
with adjustments to start from liver tissue. Briefly, liver tissues were harvested from mice
90 minutes following gavage, and 100 mg of tissue was weighed out. Tissues were
homogenized by mincing briefly with razor blades followed by resuspension in 5 mL of
ice-cold 1X PBS and several passages through a 16 gauge syringe needle into 15 mL
conical tubes. Samples were crosslinked with 2% formaldehyde for 10 minutes at room
temperature. The reactions were quenched with 0.25 M glycine. The cells were then
washed with 1X PBS and resuspended in cell lysis buffer (10 mM Tris-HCl pH 8.1, 10
mM NaCl, 1.5 mM MgCl2, 0.5% NP-40), supplemented with protease inhibitors (Roche).
The cell pellet was resuspended in 0.5 mL of nuclear lysis buffer (50 mM Tris-HCl pH
8.1, 5 mM EDTA, 1% SDS) supplemented with protease inhibitors. The chromatin was
fragmented with a Diagenode Bioruptor Pico (12 cycles of 30 s on followed by 30 s off,
at 4°C). Samples were incubated with protein G magnetic beads (Millipore-Sigma 16125

662) and H3K27ac (Abcam ab4729), ChREBP (Novus Biologicals NB400-135), or
Normal Rabbit IgG (Cell Signalling Technology 2729S) antibody overnight at 4°C. The
next day, samples were washed 5 times with decreasingly stringent buffers. ChIP DNA
was eluted off the beads by incubating beads in 125 µL elution buffer for 10 minutes at
65°C. The combined supernatant was then incubated overnight at 65°C to reverse
crosslinks and proteinase K treated for 1 hour the next morning. Samples were purified
using Macherey-Nagel DNA purification kit, with NTB binding buffer. Samples were
diluted 1:5 in nuclease-free water prior to RT-qPCR reactions, which were performed as
described above with the following primers: Mlxipl p1 (Forward:
CGCACCCGGTCTACAGTTT, Reverse: GTGCCTCCTTCTCTCCTTAGC), Mlxipl p2
(Forward: GCCATCCACGTGCTAAGGA, Reverse: GGCTTTTAGACTGGGGTGTGG),
Mlxipl igc (Forward: CCCAACAATCACCCAGCTTC, Reverse:
GCGCCATCAGTACAAGCTCT), Pklr p1 (Forward: GGGAAGGATGCCCACTACAG,
Reverse: TGGAAGCCTTGTACACTGGG), Pklr p2 (Forward:
CCCAGTGTACAAGGCTTCCAT, Reverse: CTCTGCCTTTGTCAGTGGGA), Acss2 p1
(Forward: ATTGGATGCCTAGAGCACGG, Reverse: CGCATCAAGTTCCGAACACC),
Acss2 p2 (Forward: TCAGGACAGTTTAGGGTGCAA, Reverse:
TTACAAAGACCTGCCTCTGCC). Acss2 p3 (Forward: GAGACTCTGGCCTACCACCA,
Reverse: GGGCAGGATTTGTGGCTTGT), Acss2 igc (Forward:
GGCGAAAGAAGTTTCTGTTTTGG, Reverse: TTGCCTTTTCAGTGAGGCTGTC).

Triglyceride Measurements:
Triglyceride measurements were performed using a Triglyceride Colorimetric Assay Kit
(Cayman Chemical 10010303) as per manufacturer instructions.
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Metabolomics:
Water-soluble metabolite extraction was performed as previously described314. For
serum samples, 100 μL -20°C 40:40:20 methanol:acetonitrile:water (extraction solvent)
was added to 5 μL of serum sample and incubated on ice for 10 min, followed by
vortexing and centrifugation at 16,000 x g for 10 min at 4°C. The supernatant (first
extract) was transferred to a new tube. Then, 50 μL extraction solution was added to
resuspend the pellet, followed by vortexing and centrifugation at 16,000 x g for 10 min at
4°C. The supernatant (second extract) was combined with the first extract. Then, 3 μL of
the 150 μL extract was loaded to LC-MS. For tissue samples, frozen tissue samples
were ground at liquid nitrogen temperature with a Cryomill (Retsch, Newtown, PA). The
resulting tissue powder was weighed (∼20 mg). The extraction was then done by adding
-20°C extraction solvent to the powder and incubating in -20°C overnight, followed by
vortexing and centrifugation at 16,000 x g for 10 min at 4°C. The volume of the
extraction solution (μL) was 40 x the weight of tissue (mg) to make an extract of 25 mg
tissue per mL solvent. Serum and tissue extracts were analyzed by LC-MS, using two
different LC-MS methods chosen for optimal separation of glucose and fructose (in
serum) and of hexose phosphate species (from tissues). Serum extracts were analyzed
(without drying) using a quadrupole-orbitrap mass spectrometer (Q Exactive, Thermo
Fisher Scientific, San Jose, CA) operating in negative ion mode, coupled to hydrophilic
interaction chromatography via electrospray ionization and used to scan from m/z 70 to
1000 at 1 Hz and 75,000 resolution. LC separation was on a XBridge BEH Amide
column (2.1 mm x 150 mm, 2.5 μm particle size, 130 Å pore size) using a gradient of
solvent A (20 mM ammonium acetate, 20 mM ammonium hydroxide in 95:5 water:
acetonitrile, pH 9.45) and solvent B (acetonitrile). Flow rate was 150 μl/min. The LC
gradient was: 0 min, 85% B; 2 min, 85% B; 3 min, 80% B; 5 min, 80% B; 6 min, 75% B;
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7 min, 75% B; 8 min, 70% B; 9 min, 70% B; 10 min, 50% B; 12 min, 50% B; 13 min, 25%
B; 16 min, 25% B; 18 min, 0% B; 23 min, 0% B; 24 min, 85% B; 30 min, 85% B.
Autosampler temperature was 5°C, and injection volume was 3 μL. Tissue extracts were
dried under nitrogen gas flow and re-dissolved in LC-MS grade water. Metabolites were
analyzed via reverse-phase ion-pairing chromatography coupled to an Exactive Orbitrap
mass spectrometer (Thermo Fisher Scientific, San Jose, CA). The mass spectrometer
was operated in negative ion mode with resolving power of 100,000 at m/z 200 and scan
range of m/z 75-1000. The LC method was modified from an earlier method (Lu et al.,
2010), using an Atlantis T3 column (150 mm × 2.1 mm, 3 μm particle size, 100 Å pore
size), with a gradient of solvent A (97:3 water:methanol with 10 mM tributylamine and 15
mM acetic acid) and solvent B (methanol). The LC gradient was 0 min, 0% B, 200
μl/min; 2 min, 0% B, 200 μl/min; 4 min, 20% B, 200 μl/min; 13 min, 80% B, 200 μl/min;
17 min, 100% B, 200 μl/min; 17.5 min, 100% B, 300 μl/min; 20 min, 100% B, 300 μl/min;
20.5 min, 0% B, 300 μl/min; 24 min, 0% B, 300 μl/min; 25 min, 0% B, 200 μl/min. Other
LC parameters, common to both methods, were column temperature 25°C, autosampler
temperature 5°C, and injection volume 10 μL. Data analysis with MAVEN software and
natural isotope correction were performed as previously described338. Volcano plot and
principle component analysis of metabolomics data were generated using
Metaboanalyst342.

Acetate measurement:
Acetate was derivatized and measured by LC-MS. The derivatizing reagent was 12 mM
EDC, 15 mM 3-Nitrophenylhydrazine and pyridine (2% v/v) in methanol. Reaction was
stopped with quenching reagent consisting of 0.5 mM beta-mercaptoethanol and 0.1%
formic acid in water. Serum (5 µL) was mixed with derivatizing reagent (100 µL) and
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incubated for 1 hour at 4°C. Then, the samples were centrifuged at 16,000 x g for 10 min
at 4°C, and 20 µL of supernatant was mixed with 200 µL of the quenching reagent. After
centrifugation at 16,000 x g for 10 min at 4°C, supernatants were collected for LC-MS
analysis. A quadrupole-time of flight mass spectrometer (Q-TOF, Agilent, Santa Clara,
CA) operating in negative ion mode was coupled to C18 chromatography via
electrospray ionization and used to scan from m/z 100 to 300 at 1 Hz and 15,000
resolution. LC separation was on an Acquity UPLC BEH C18 column (2.1 mm x 100
mm, 1.7 5 µm particle size, 130 Å pore size; Waters, Milford, MA) using a gradient of
solvent A (0.01% formic acid in water) and solvent B (0.01% formic acid in isopropanol).
Flow rate was 400 µL/min, except that from 6 min to 8 min flow rate was increased to
700 µL/min. The LC gradient was: 0 min, 10% B; 2 min, 15% B; 5 min, 25% B; 6 min,
100% B; 8 min, 100% B; 8.6 min, 10% B; 10.5 min, 10% B. Autosampler temperature
was 5°C, and injection volume was 10 µL. Ion masses for derivatized acetate was 194.

Lipidomics:
Lipidomics was performed as previously described343, with some modifications on an
extraction step. Briefly, serum samples (10 μL) was dissolved in 100 μL of isopropanol.
After centrifugation at 14,000 g at 4°C for 10 min, supernatant was transferred to a glass
MS vial and injected into a 1290 Infinity UHPLC system coupled to Agilent 6550 iFunnel
Q-TOF mass spectrometer. To cover both the positive charged and negative charged
species, each sample was analyzed twice using the same LC gradient but with different
mass spectrometer ionization modes. The LC separation was performed on an Agilent
Poroshell 120 EC-C18 column (150 x 2.1 mm, 2.7 µm particle size) with a flow rate of
150 µL/min. Solvent A was 1 mM ammonium acetate + 0.2% acetic acid in
water/methanol (90:10). Solvent B was 1 mM ammonium acetate + 0.2% acetic acid in
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methanol/2-propanol (2:98). The solvent gradient in volume ratios was as follows: 02 min, 25% B; 2-4 min, 25 to 65% B; 4-16 min, 65 to 100% B; 16-20 min, 100% B; 2021 min, 100 to 25% B; 21-27 min, 25% B. Principle component analysis was generated
using Metaboanalyst342 (https://www.metaboanalyst.ca) and heatmap of lipidomics data
was generated using Morpheus (https://software.broadinstitute.org/morpheus).
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Figures

Figure 3.1 | Fructose-dependent fatty acid synthesis is ACLY-independent.
a, Schematic of fructolysis and glycolysis feeding into de novo lipogenesis. F1P = fructose-1phosphate, F-1,6-BP = fructose-1,6-bisphosphate, GA = glyceraldehyde, DHAP =
dihydroxyacetone phosphate, G3P = glyceraldehyde-3-phosphate.
b, H&E and Oil Red O histological stains of livers from WT or LAKO mice on chow (CD) or high
fructose diet (HFrD) for 4 or 18 weeks. Scale bars = 100 µm.
c, Relative deuterium labeling in palmitic acid (16:0) and stearic acid (18:0) after 24-hour D2O
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labeling of mice, normalized to percent plasma D2O labeling. D2O (n = 4/group) set to 1 and
compared to D2O Fruc:Gluc (n = 6/group) within each genotype, data are mean ± SEM.
d, Experimental design for data shown in e.
e, % total labeled carbons in fatty acids from 13C-glucose or 13C-fructose.
f, mRNA expression of ChREBP and its target genes in livers of WT or LAKO mice fed on CD or
HFrD (n = 4 mice/group), statistical comparisons WT-CD vs. WT-HFrD: ***P<0.001, LAKO-CD vs.
LAKO-HFrD: #P<0.05 as determined by Holm-Sidak test.
g, Immunoblots of lipogenic enzymes in livers of WT or LAKO mice fed CD or HFrD for 4 weeks.
For all panels, *P<0.05, **P<0.01, ***P<0.001.
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Figure 3.2 | Lipogenic acetyl-CoA is preferentially produced from acetate in
hepatocytes.
a, Schematic of fructolysis, glycolysis, and acetate feeding into lipogenic acetyl-CoA and de novo
lipogenesis.
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b, Total ion counts (TIC) of fructolytic intermediates in primary hepatocytes following 6 hours of
incubation with 5mM glucose + 25mM fructose + 1mM acetate, 13C-labeled substrate indicated in
bold, data are mean ± SD, n = 3.
c, % labeling of acetyl-CoA, malonyl-CoA, or HMG-CoA from [U-13C]-fructose or [1,2-13C]-acetate,
data are mean ± SD, n = 3.
d, TIC of liver labeled F1P, pyruvate, and acetyl-CoA, concentrations (µM) of portal blood labeled
acetate, and total % carbons labeled of liver 16:0 and 18:0 in WT mice gavaged with 2.0 g/kg [U13C]-fructose + 2.0 g/kg unlabeled glucose, data are mean ± SEM, n = 3/timepoint.
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Figure 3.3 | Microbiome metabolism of fructose to acetate feeds hepatic de
novo lipogenesis.
a, Area under curve (AUC 0-240 min) of labeled hepatic F1P, pyruvate, acetyl-CoA, palmitate and
portal blood acetate in saline or antibiotic-treated WT mice following a gavage of 2.0 g/kg [U-13C]fructose + 2.0 g/kg glucose.
b, % total labeled carbons in saponified serum fatty acids in saline or antibiotic-treated WT and
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LAKO mice following a gavage of 2.0 g/kg [U-13C]-fructose + 2.0 g/kg glucose, *P<0.05, **P<0.01
WT-saline vs. WT-antibiotics, #P<0.05 LAKO-saline vs. LAKO-antibiotics.
c, Heat map of hepatic triglyceride abundance in livers of mice in b.
d, Concentrations of portal and systemic blood acetate following gavage, each data point
represents an individual mouse sacrificed at indicated time. *P<0.05, ***P<0.001.
e, % total labeled carbons in saponified serum fatty acids from saline- or antibiotic-treated LAKO
mice following a gavage of 2.0 g/kg fructose + 2.0 g/kg glucose + 0.5 g/kg acetate, 13C-labeled
substrate indicated. **P<0.01, ***P<0.001 saline vs. antibiotics, #P<0.05, ##P<0.01 13C-fruc vs.
13C-acet.
f, % total labeled carbons in serum fatty acids from WT and LAKO mice 1 week after injection
with AAV-GFP or AAV-shAcss2. **P<0.01 WT + GFP vs. WT + shAcss2, #P<0.05, ##P<0.01
LAKO + GFP vs. LAKO + shACSS2.
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Figure 3.4 | Gradual fructose consumption promotes hepatic lipogenesis
from ACLY- and ACSS2-derived acetyl-CoA.
a, Experimental design for gradual fructose consumption.
b, % total labeled carbons from [U-13C]-fructose or glucose in hepatic 16:0 and 18:0, WT vs.
LAKO: *, Fruc vs. Gluc: #.
c, % total labeled hydrogens from D2O in hepatic 16:0 and 18:0.
d, % total labeled carbons from [1,2-13C]-acetate supplemented Fruc:Gluc water in saponified
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serum 16:0 and 18:0, see Extended Data Fig. 9a for experimental details, WT vs. LAKO: *, naïve
vs. conditioned: #.
e, total % labeled hydrogens from Fruc:Gluc D2O in hepatic 16:0 and 18:0 in WT and LAKO mice
following 1 week of treatment with saline or antibiotics.
f, mRNA expression of ChREBP and downstream lipogenic genes in livers of mice in (e), Abx =
antibiotics.
g, total % labeled hydrogens from Fruc:Gluc D2O in hepatic fatty acids in WT and LAKO mice 1
week after injection with AAV-GFP or AAV-shAcss2. For all panels, */#P<0.05, **/##P<0.01,
***/###P<0.001.
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Extended Data Figure 3.1 | Hepatic ACLY deficiency minimally impacts the
response to dietary fructose.
a, Body weights of WT and LAKO mice on CD or HFrD for 18 weeks (n = WT-CD:13, LAKOCD:5, WT-HFrD:14, LAKO-HFrD:5).
b, Weights of liver, subcutaneous (sWAT) and perigonadal (pgWAT) adipose tissues in WT and
LAKO mice on CD or HFrD for 18 weeks.
c, Representative images of Periodic Acid Schiff (PAS) stain for glycogen and Trichrome (TC)
histological stain for fibrosis in livers from WT or LAKO mice on HFrD. Scale bars = 100 µm.
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d, Triglyceride content in WT or LAKO mice on CD or HFrD for 18 weeks, n = (WT-CD: 4, LAKOCD: 3, WT-HFrD: 4, LAKO-HFrD: 3), **P<0.01 as determined by Welch's T test.
e, Immunohistochemistry staining against ACLY in WT or LAKO mice on H2O or Fruc:Gluc water
for 4 weeks. Yellow boxes approximate location of 20X panels. Scale bars = 100 µm for 10X, 50
µm for 20X.
For all panels, data are mean ± SD.
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Extended Data Figure 3.2 | Hepatic ACLY deficiency results in only modest
metabolic alterations on high fructose diet.
a, Volcano plot of intrahepatic metabolites in WT and LAKO mice on CD or HFrD for 4 weeks,
pink dots indicate significant hits as determined by a fold-change threshold of 2 and P-value
threshold of 0.1, assuming equal variance.
b, Principle component analysis of log-transformed data in Supplementary Table 1, each dot
represents a unique sample, 95% CI shown in corresponding color.
c, Relative metabolite abundance, normalized to WT-CD group, ***P<0.001, n = (WT-CD:5,
LAKO CD: 3, WT-HFrD: 5, LAKO-HFrD: 4).
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Extended Data Figure 3.3 | High fructose diet alters hepatic lipid
metabolism.
a, Hierarchical clustering of relative hepatic triglyceride abundance in WT or LAKO mice on CD or
HFrD for 4 weeks, clustering performed using one minus pearson correlation and average
linkage.
b, Relative abundance of hepatic triglycerides composed of 16:0 to 18:1 fatty acids, subset of
data in a.
c, Principle component analysis of log-transformed data in Supplementary Table 2, each dot
represents a unique sample, 95% CI shown in corresponding color.
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Extended Data Figure 3.4 | Sweetened drinking water consumption induces
steatosis independently of ACLY.
a, Schematic of experimental set-up of drinking water study.
b, Daily consumption of unsweetened (H2O) or 15% fructose + 15% glucose sweetened
(Fruc:Gluc) water, ***P<0.001.
c, Weight gain of WT or LAKO mice given H2O or Fruc:Gluc water for 4 weeks, **P<0.01
comparing all H2O vs. Fruc:Gluc mice.
d, H&E and Oil Red O histological stains of livers from WT or LAKO mice given H 2O or
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fructose:glucose sweetened drinking water for 4 weeks. Scale bars = 100 µm.
For all panels, data are mean ± SD.

Extended Data Figure 3.5 | Fructose carbons contribute substantially to
newly synthesized fatty acids in the liver independently of ACLY.
a, Isotopologue distribution of serum fatty acids from mice in Figure 1e, data are mean ± SD.
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Extended Figure Data 3.6 | Fructose signals the use of acetate for de novo
lipogenesis.
a, mRNA expression of lipogenic genes in livers of WT or LAKO mice given H 2O or Fruc:Gluc
water for 4 weeks (n = 4/group), statistical comparisons WT-H2O vs. WT-Fruc:Gluc: **P<0.01,
***P<0.001, LAKO-H2O vs. LAKO-Fruc:Gluc:†P<0.05, ‡P<0.01, ¥P<0.001 as determined by
Holm -Sidak test.
b, Immunoblots of lipogenic enzymes in livers of WT or LAKO mice given H 2O or Fruc:Gluc water
for 4 weeks.
c, mRNA expression of ChREBP and its target genes in livers of WT mice provided either water
for 24 hours followed by an oral gavage of saline, or Fruc:Gluc water for 24 hours, followed by an
oral gavage of 2.0 g/kg glucose and 2.0 g/kg fructose (n = 4 mice/group), livers harvested 90
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minutes after gavage, *P<0.05, as determined by Holm-Sidak test.
d, H3K27ac ChIP-qPCR under conditions used in panel c.
e, ChREBP ChIP-qPCR under conditions used in panel c, igc = intergenic control.
f, ChIP-seq tracks of Mlxipl, Pklr, Acss2 genomic loci319, red bars indicate genomic regions used
to design ChIP-qPCR primers.
For panels d-e, data are mean ± SEM.
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Extended Data Figure 3.7 | Antibiotic depletion of microbiome blocks
substrate contribution, but not signaling, of de novo lipogenesis following
fructose consumption.
a, Experimental set-up for antibiotic depletion of the microbiome followed by [U-13C]-fructose
tracing into DNL.
b, Representative images of cecums from a saline and antibiotic treated mouse.
c, Heat map of microbial metabolite abundance in the portal blood, collected 1 hour after gavage.
d-e, Abundance of portal blood [U-13C]-fructose (d), and % total labeled carbons in glucose (e),
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statistical comparisons vs. Saline.
f, mRNA expression of ChREBPβ, Acss2, and Fasn in liver, collected 1 hour after gavage,
statistical comparisons vs. Saline
g, Concentrations (µM) of portal blood labeled acetate, propionate, and butyrate, n = (WT-Saline:
8, LAKO-Saline: 4, WT-Antibiotics: 8, LAKO-Antibiotics: 4). h, Abundance of cecal labeled
acetate, propionate, and butyrate in WT mice, n = 3 mice/timepoint, except saline-180 n = 2 mice.
For all panels, data are mean ± SD, *P<0.05, **P<0.01, as determined by Holm-Sidak test.
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Extended Data Figure 3.8 | Bolus fructose-dependent DNL requires
microbial acetate and hepatic ACSS2.
a, Isotopologue distribution of serum fatty acids, collected 6 hours after gavage, data are mean ±
SD, n = (WT-Saline: 8, LAKO-Saline: 4, WT-Antibiotics: 8, LAKO-Antibiotics: 4).
b, Relative abundance of bacterial abundance in cecal contents from mice treated with saline or
antibiotics as determined by 16s RT-qPCR to a reference standard of E. coli DNA. *P<0.05 as
determined by Welch's t test.
c, Western blot of liver lysates from WT and LAKO mice 1 week following tail-vein injection with
AAV8-GFP or AAV8-shAcss2.
d, Weight gain in WT and LAKO mice 1 week following tail-vein injection with AAV8-GFP or
AAV8-shAcss2. *P<0.05 as determined by Holm-Sidak test.
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e, Liver weight as % of body weight of WT and LAKO mice 1 week following tail-vein injection
with AAV8-GFP or AAV8-shAcss2.
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Extended Data Figure 3.9 | Gradual fructose consumption promotes greater
acetate usage in LAKO mice.
a, Experimental set-up for [1,2-13C]-acetate tracing into DNL prior to and after gradual fructose
administration.
b, Western blot of ACLY, ACSS2, and S6 in liver lysates from WT and LAKO mice after 1 day or
14 days of Fruc:Gluc water.
c, Representative H&E stains of livers from WT and LAKO mice provided Fruc:Gluc water for 2
weeks. Scale bars = 100 µm
d, Relative abundance of acetate, propionate, and butyrate in the cecal contents of WT and
LAKO mice treated with saline or antibiotics for 1 week. WT: *P<0.05, **P<0.01, LAKO:
##P<0.01, ###P<0.001.
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Extended Data Figure 3.10 | Fructose provides signal and substrate to
promote hepatic de novo lipogenesis.
a, Proposed model of bolus fructose-induced hepatic DNL. Fructose catabolism in hepatocytes
acts as a signal to induce DNL genes including ACSS2, while fructose metabolism by the gut
microbiome provides acetate as a substrate to feed DNL, mediated by ACSS2.
b, Proposed model of gradual fructose-induced hepatic DNL. Like the bolus model, fructose
catabolism in hepatocytes acts as a signal to induce DNL genes. Glucose and fructose
catabolism provide citrate as a substrate to feed DNL, mediated by ACLY. Metabolism of fibers
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and other dietary components by the gut microbiome provides also acetate as a substrate to feed
DNL, mediated by ACSS2.
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CHAPTER 4: Summary and Discussion
Summary of Findings:
Prior to this work, both ACLY and ACSS2 have been shown to contribute to nuclearcytosolic acetyl-CoA pools in proliferating cells. While both enzymes have been
proposed as therapeutic targets in the treatment of cancer and other diseases70,313,344,345,
their metabolic contributions to promoting disease have largely been investigated
individually without taking the presence of the other into account. In this work, we
studied how genetic deletion of ACLY affects ACSS2 and acetate contributions to acetylCoA metabolism in the same system. By doing so, we identified a metabolic switch
between ACLY and ACSS2 upon loss of ACLY function, but not vice versa, to meet
cellular demands for acetyl-CoA production. This metabolic flexibility enables cells to
synthesize acetyl-CoA from acetate in the absence of ACLY, and maintain processes
such as DNL. Not only do we demonstrate this in proliferating cells, but also in intact
liver tissue in response to high sugar consumption, a context relevant to current public
health.

Future Directions and Outstanding Questions:
This body of work establishes that mammalian cells can compensate for the loss of
ACLY function by upregulating ACSS2 and acetate metabolism in order to meet acetylCoA demand. However, we also demonstrate that not all fates of acetyl-CoA, nor cellular
functions, are sufficiently maintained in the absence of ACLY. These results raise further
questions that warrant investigation.
First, ACLY loss in immortalized MEFs and cancer cell lines results in impaired
proliferation, consistent with previous observations173,276,279, but remain viable. This is
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despite compensation for acetyl-CoA production from acetate via ACSS2, which is able
to support lipid synthesis at physiological acetate concentrations. Although global
histone acetylation is not maintained at comparable levels to WT cells in these
conditions, supplementation of supraphysiological levels of acetate rescues global
histone acetylation levels but not proliferation. One hypothesis for this is that ACLY has
roles in other cellular functions that cannot be compensated for by ACSS2. Another
hypothesis is that although global histone acetylation can be restored with acetate,
ACLY and ACSS2 promote histone acetylation at unique sites of the genome. Indeed,
evidence that ACLY promotes histone acetylation at double-stranded breaks in response
to DNA damage to facilitate homologous recombination, and site-specific differences
between glucose- and acetate-induced histone acetylation supports both of these
theories346,347. However, the genome-wide locations of unique ACLY- and ACSS2dependent histone acetylation sites, and the functional consequences of these
differences, are still under-characterized.
Second, the molecular mechanism of ACSS2 upregulation following ACLY loss remains
to be determined. Given our findings that both genetic and chemical depletion of ACLY
activity promotes ACSS2 upregulation suggests that nuclear-cytosolic acetyl-CoA can be
sensed by cells. However, whether acetyl-CoA itself, or another downstream product of
acetyl-CoA is being sensed remains unknown. The transcription factor sterol regulatory
element binding protein 2 (SREBP2) has been reported to regulate transcription of
ACSS273. The SREBP family of proteins are activated in response to decreases in
intracellular cholesterol by its regulatory proteins INSIG and SCAP, which cleaves the
SREBP precursor to generate mature SREBP. Thus, one hypothesis is that loss of
ACLY activity depletes intracellular cholesterol abundance, thereby activating SREBP
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and upregulating ACSS2 expression. However, in conditions that ACSS2 is upregulated,
HMG-CoA, the metabolic intermediate between acetyl-CoA and cholesterol synthesis, is
being synthesized from acetate (Figure 2.3). This suggests that cholesterol can be made
in the context of ACLY-deficiency, but fails to suppress SREBP. Another possibility is
that HMG-CoA is being synthesized from ACSS2-derived acetyl-CoA, but is not being
utilized for cholesterol synthesis. In addition to cholesterol, HMG-CoA is utilized to
synthesized isoprenoids for protein prenylation, ubiquinone synthesis, and dolichol
synthesis. Whether one of these fates of HMG-CoA, or an entirely different product of
acetyl-CoA is being sensed remains an open question.
Third, we identify that fructose-dependent lipogenesis depends, at least in part, on
contributions from the gut microbiome. However, the exact specie(s) of bacteria involved
is unclear. Moreover, how fructose consumption alters diversity of the gut microbiome is
still an open question. One hypothesis is that continual fructose consumption causes a
shift in microbial diversity to favor production of SCFAs and hepatic DNL. Fecal
microbiome transplantation studies can be performed using germ-free mice to test if this
is indeed the case. Furthermore, newborns acquire a significant proportion of their gut
microbiomes from the mother348. In light of studies seeking to identify heritable risks for
obesity349, whether constant maternal fructose consumption promotes shifts to microbial
diversity that could be passed onto offspring is an important open question. Further
studies should be done to investigate 1) How fructose consumption alters the diversity of
the gut microbiome, and 2) If modulating the gut microbiome can influence hepatic DNL
to yield beneficial outcomes for treatment of diseases such as NAFLD.
Fourth, we show that DNL is largely maintained in liver, but not adipose tissue following
ACLY deletion. This is despite elevated ACSS2 levels in ACLY-null adipose tissue,
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suggesting that the extent or pattern of metabolic compensation may differ between
tissues. How this occurs is currently unclear, but may involve nutrient availability in vivo.
For instance, acetate availability to the liver from the portal vein is high relative to that
available to adipose tissue in systemic circulation. Indeed, patterns of metabolite uptake
and release between tissues is diverse350, and warrants further investigation to
understand tissue-specific responses to loss of ACLY activity.
Finally, loss of hepatic ACLY fails to suppress DNL in response to sugar consumption or
protect against development of fatty liver disease due to compensation from acetate.
Recent clinical evidence supports use of ETC-1002 to treat hypercholesterolemia in
patients, but whether targeting ACLY will be effective in treating NAFLD or cancer
remains unclear. A prediction of our findings is that targeting further downstream in the
DNL pathway would be an effective therapeutic strategy. Indeed, inhibition of ACC
prevents development of fatty liver, but promotes hypertriglyceridemia351,352. Thus,
further investigation will be required to determine the utility of therapeutically targeting
hepatic DNL for treatment of NAFLD. However, our findings that ACLY and ACSS2 can
be simultaneously suppressed with minimal toxicity in liver, at least in the short term,
provides preliminary evidence of a therapeutic window for targeting both enzymes in
cancer. Coupled to our findings that ACLY inhibition can cause dependence on ACSS2
and exogenous acetate, a therapeutic strategy using ACLY inhibitors to sensitize cancer
cells to ACSS2 inhibitors could be envisioned.
In conclusion, our data bridges current literature surrounding both ACLY and ACSS2,
and provides a model in which substrate flexibility for acetyl-CoA may underlie disease
phenotypes in the context of both cancer and metabolic diseases. This metabolic
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flexibility should be acknowledged when considering therapeutic interventions targeting
not only acetyl-CoA synthesis, but other metabolic pathways as well.
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